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ABSTRACT  
Background: Although Mtb strains have been shown to exhibit nucleotide level similarity 
of >99%, such similarity is rarely replicated in the phenotype. This phenotypic 
heterogeneity has been demonstrated by a subpopulation of cells called “persisters”. 
Persisters constitute a minority of the organisms found in clinical specimens but statistical 
modelling studies suggest that they predominate after the first few days of treatment. The 
rate of their elimination is likely the principal determinant of the length of therapy and 
likelihood of relapse. Understanding the complete biology of persistence is among the 
most important scientific barriers to shortening TB treatment. 
Methods: A total of 64 bacteriologically confirmed Mtb clinical isolates from Malawian 
patients recruited for a cohort study of determinants of treatment outcome were genotyped 
using LSP-PCR to determine the molecular epidemiology of TB in Blantyre, Malawi and 
to evaluate the possible impact of lineage on outcome. Eighteen of the 64 isolates 
including two “persister” strains defined by lipid body staining and clinical relapse were 
further subjected to whole genome sequencing using Single Molecule Real Time (SMRT)  
sequencing in order to assess differences in the methylome among these strains. Using 
bioinformatics analysis DNA methylation patterns were determined and factors leading to 
loss/ absence of methylation could then be elucidated. 
Results: The 64 isolates genotyped clustered into 4 main Mtb lineages (1-4) with lineage 
4 predominating. There was differential occurrence of methylation across the strains. 
Methylation was found to occur within three different confidently defined sequence motifs 
(CTGGAG, CACGCAG and GATN4RTAC) across all the isolates influenced by three 
different methyltransferases in a lineage specific manner. Three different methylation 
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disrupting mutations within methyltransferase genes E270A in mamA, P360L in hsdM   
the recently characterized S253L mutation in mamB were confirmed. For the first time, 
total loss of methylation in MamB was reported due to the S253L mutation. No compelling 
correlation between DNA methylation pattern and persistence during treatment was 
observed, at the level of genic or intergenic regions or within specific operons of interest 
previously associated with persistence in vitro. 
Conclusions: Four main Mtb lineages occur in Blantyre Malawi and DNA methylation in 
these isolates were lineage specific. Specific mutations are responsible for disrupting 
methylation within various Mtb strains and methylation disrupting mutations could be 
reliably used to assign Mtb lineages for some lineages. Methylation patterns did not differ 
significantly between persister and non-persister isolates, though current limitations in 
direct extraction of DNA from clinical samples and numbers of paired isolates from 
representative longitudinal studies suggest that further work is needed to definitively 
answer this question. 
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CHAPTER ONE: INTRODUCTION 
1. 1 Evolution of Mycobacterium tuberculosis 
 Tuberculosis (TB) is a debilitating human illness which mainly targets the lungs 
(pulmonary TB) but may also target other body organs (extra-pulmonary). The bacillus 
Mycobacterium tuberculosis (Mtb), which is the causative agent of TB is inhaled via 
aerosols and infects and activates macrophages and dendritic cells (DCs) in the lungs. 
After this primary  infection, only 5% of the infected population will ultimately develop 
active TB while the rest carry a lifelong latent infection (Dreher, Nicod 2002). It has been 
hypothesized that the genus Mycobacterium evolved more than 150 million years ago 
(Hayman 1984, Daniel, T. M. 2006) ultimately forming complex species. It is generally 
believed that all members of the Mtb complex shared a common African ancestor some 
35000-15000 years ago (Kapur, Whittan et al. 1994, Brosch, Gordon et al. 2002). This 
early ancestor of Mtb complex could have been present in East Africa some 3 million 
years ago (Gutierrez, Brisse et al. 2005). The M. tuberculosis complex is composed of  
several members including  M. bovis, M. africanum, M. canetti and M. microti, M. 
pinniped and M. caprae,  each one capable of causing disease in different hosts (Stead, 
Eisenach et al. 1995, Müller, Roberts et al. 2014). They are all genetically similar and only   
differ in particular nucleotide pairs. These differences may include single nucleotide 
polymorphisms (SNPs), large sequence polymorphisms (LSPs), minisatellites and 
microsatellites (Davies, P. D. O., Barnes et al. 2008). Previously the accepted hypothesis 
was that the ancestral descendant of M. tuberculosis was M. bovis which mainly causes 
disease in cattle. This hypothesis has been seriously challenged with the advent of DNA 
sequencing and other related methods (Smith 2003). Subsequently genome sequencing 
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projects have revealed that M.bovis, while maintaining 99.95% sequence identity with 
Mtb has several significant deletions (Brosch, Gordon et al. 2002). When 875 strains of 
Mtb from different parts of the world were analyzed using large sequence polymorphism 
(LSP) PCR and sequencing, six main lineages were identified (Figure 1.1).  
 
 
Figure 1. 1 Global geographical distribution of Mycobacterium tuberculosis lineages 
The Euro-American lineage is dominant in parts of Europe and America; the East 
African lineage and two West-African lineages are dominant in Africa; the East 
African-Indian lineage is dominant in the Eastern region of Africa and the Indo-Oceanic 
region; the East-Asian lineage is dominant in the Indian sub-continent; the Indo-
Oceanic lineage occurs in and around the Indian Ocean. (Figure adapted from Gagneux, 
DeRiemer et al. 2006). 
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These lineages have been associated with several factors including virulence, ability to 
cause epidemic spread and retain virulence on mutation to multidrug resistance (Davies, 
P. D. O., Barnes et al. 2008). The Indo-Oceanic lineage occurs predominantly around the 
Indian Ocean (Gagneux, DeRiemer et al. 2006) and includes a group of strains referred to 
as “ancestral”. This group has a conserved TbD1 genomic region which is lacking in 
“modern” strains (Brosch, Gordon et al. 2002, Gagneux, DeRiemer et al. 2006). The East 
Asian lineage is widespread in the Indian subcontinent  and includes strains of the Beijing 
family which is widely associated with drug resistance (Tsolaki, Gagneux et al. 2005, 
Ribeiro, Gomes et al. 2014). As expected, the East African lineage and two West African 
lineages are predominant in Africa whereas the Euro-American lineage predominates in 
different regions of America and Europe. Specific sub lineages of the Euro-American 
lineage are present in Africa and the Middle East as well.  The East African/Indian lineage 
is predominant in East Africa and the Indian Ocean (Gagneux, DeRiemer et al. 2006). 
Recently, a new lineage was characterized which appears to be  restricted to the Horn of 
Africa (Coll, McNerney et al. 2014, Firdessa, Berg et al. 2013).  This lineage has been 
proposed  to be an intermediate between the ancient and modern strains (Coll, McNerney 
et al. 2014).. 
1. 2 History of tuberculosis 
Tuberculosis is an   illness that is probably as old as man himself and has been among the 
leading historical causes of mortality in humans. In Egypt, skeletons with apparent 
tubercular deformities were frequently unearthed by modern archaeologists suggesting the 
disease had been widespread in the area for a long time.  Bones with deformations 
characteristic of TB were also uncovered in ancient sites in Italy, Denmark and part of the 
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Middle East indicating the disease was found throughout the world some 4000 years ago. 
Historians had written of patients coughing blood as early as the seventh century BC. 
Hippocrates also wrote of a disease  associated with weight loss coughing and sometimes  
with blood in sputum (the Greek word is phthisis) which he called consumption (Smith 
2003, Daniel, T. M. 2006). There is a common acceptance that Europeans of Indian origin 
brought the disease to Europe and Asia as they migrated. Europe, with population growth 
and urbanization became the epicenter of many TB epidemics starting in 16th and 17th 
centuries. At its peak, TB is believed to have killed more than 15% of the European 
population in the first half of the 19th century (Smith 2003). Recent evidence from 
archeological skeleton samples suggests that different Mtb lineages could have been 
present in Britain at the same time and even same location (Müller, Roberts et al. 2014). 
Most medical researchers in the 19th century associated TB with societal causes such as 
malnutrition, poor sanitation and overworking until Robert Koch conclusively showed  
that it was caused by a bacterium (Davies, P. D. O., Barnes et al. 2008, Smith 2003). Later, 
the tuberculin skin test (TST) was developed  and is still used today as a test for latent TB 
infection (Daniel, T. M. 2006).  
Schartz and Waksman discovered the antibiotic streptomycin in 1944 which was rapidly 
recognised as an effective treatment for TB (Woodruff 2014). Later  isoniazid (INH), 
rifampicin (RIF) and pyrazinamide (PZA) were discovered and remain the key 
components of first-line treatment for TB  (Ryan 1992). These drugs and  the widespread 
use of the bacillus Calmette- Guerin (BCG) vaccine discovered in Paris in the 1920s have 
been unable to successfully eliminate  the disease however (Andersen 2001) and  new 
approaches are clearly needed in the fight against TB 
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1. 3 Tuberculosis as a global disease  
TB remains a public health concern with 10.4 million new infections and 1.3 million 
fatalities each year. An additional 0.4 million deaths result from coinfection with human 
immunodeficiency virus (HIV) (WHO 2017b). Although the incidence of TB has been in 
decline since the early 2000s, the disease remains among the top ten leading causes of 
mortality globally (Figure 1.2). It is the 6th highest killer among  low income countries 
and it is the biggest single killer of all infectious diseases (WHO 2017a). About 1.2 million 
(11%) of the new TB infections in 2015, were co-infected with HIV and 75% of these co-
infections occurred in Africa (WHO 2016). 
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Figure 1. 2 Top 10 leading causes of death in globally 
 
TB remains among the top ten leading causes of death globally (WHO 2017a) 
 
 With 5.9 million (56%) new cases among men compared to 3.5 million (34%) among 
women  there appears to be a gender bias in new cases (WHO 2016). Although half of all 
TB infections are in the BRICS region (Brazil, Russia, India, China and South Africa), 
Africa remains the hardest hit in terms of rates of active TB per capita (Abdul-Aziz, 
Tsolaki 2013, Zumla, Raviglione et al. 2013, WHO 2017b). In addition the highest 
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proportion of TB cases co-infected with HIV were in Africa (31%) with southern Africa 
being the hardest hit (>50% of all cases) (WHO 2016) 
1. 4 Tuberculosis in sub-Saharan Africa 
 The burden of TB remains the highest in Africa in part due to high levels of poverty. 
According to the World Health Organization’s (WHO) TB report for 2017, 30 high burden 
countries (HBCs) were low and middle-income countries and accounted for over 87% of 
active TB cases in the world (WHO 2017b). Fifty percent of these countries (South Africa, 
Zimbabwe, Mozambique, DR Congo, Kenya, Ethiopia, Nigeria, Zambia, Congo, Sierra 
Leone, Namibia, Liberia, Central African Republic and Tanzania) are in Africa. TB 
incidence rates in Lesotho, Mozambique, South Africa are above 500 per 100 000 
populations compared to 150-300 cases per 100 000 populations for most HBCs (WHO 
2017b). Seven of the top 10 countries with the highest TB incidence rates per 100 000 
population in 2013 were in Africa (Figure 1.3) (Kaiser Family Foundation ). Estimates 
show that in South Africa and Swaziland at least 1 in every 100 people (1000 per 100 000 
population) become  TB infected every year (Pham, Fattal et al. 2015). TB-HIV co-
infection rates of more than 50% in all ages occurred in the Southern African countries of 
South Africa, Swaziland, Lesotho, Mozambique, Zimbabwe, Zambia and Malawi (where 
this study took place) although mortality rates among HIV positive people are on the 
decline (WHO 2016). It is estimated that in HBCs, 60% of all health expenditure is in the 
private sector and largely paid by patients out of their pockets (Lonnroth, Castro et al. 
2010). The financial difficulties experienced by TB patients in these countries are huge. 
The costs due to TB have been described as catastrophic as they amount up to 10% of a 
patient’s or household’s income. TB also contributes to poverty by reducing the patient’s 
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strength making them unable to work (Barter, Agboola et al. 2012). Care givers lose man 
hours looking after sick relatives and friends.  
 
 
 
Figure 1. 3 Top 10 countries with new TB cases per 100,000 populations 
 
Seven of these countries (Swaziland, South Africa, Namibia, Lesotho, Djibouti, 
Zimbabwe and Mozambique) are in Africa. Image adopted from (Kaiser Family 
Foundation ). 
 
1. 5 Tuberculosis pathogenesis 
Mycobacteria are organisms that appear microscopically as straight or slightly curved 
rods, 1 to 4μm in length and 0.3 to 0.6 μm wide (Sakamoto 2012). They are non-motile, 
non-spolurating, weakly Gram positive, acid fast bacilli. Mycobacteria express mycolic 
acids in their cell walls with unique characteristics for their physiological survival (Barry 
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III, Lee et al. 1998). Mtb are strictly parasitic and a member of the slow-growing 
pathogenic species of mycobacteria with a division rate of 12-24 hours and culture period 
on agar of up to 21 days (Sakamoto 2012). 
Following entry into the lungs the bacilli proceed to the alveoli, and consequently come 
in contact with and are ingested by alveolar macrophages. As a consequence of this initial 
interaction, most are destroyed but some survive within the macrophage (Abdul-Aziz, 
Tsolaki 2013). Destruction of Mtb via phagocytosis involves a variety of receptors which 
can either bind non-opsonized Mtb or recognise opsonins on the mycobacterial surface. 
Several receptors have so far been implicated including C-type lectins eg.CD 207, 
complement receptors (CR), surfactant protein (SP) receptors, scavenger receptors, and 
glycosylphostidylinositol (GPI) - anchored receptors such as CD14 (Abdul-Aziz, Tsolaki 
2013, Ehlers, Daffe 1998).  Mtb entry into macrophages is facilitated by binding their 
mannose-capped lipoarabinomannan (ManLAM) to mannose receptors (Kang, Azad et al. 
2005).  Within resting macrophages, internalized Mtb reside in phagosomes where they 
block maturation, lysosomal fusion and acidification (Sakamoto 2012, Smith 2003).  If 
normal phagosome maturation occurs, then phagosome-lysosome fusion occurs and 
bacteria encounter a hostile environment that includes acid pH, reactive oxygen 
intermediates (ROI), lysosomal enzymes and toxic peptides (Smith 2003). Additionally, 
this process produces a cytokine/chemokine response that initiates inflammation and 
attracts immune cell infiltration and tissue modification. First to be involved are 
neutrophils and monocytes which phagocytose the Mtb and secrete more cytokines and 
chemokines. Antigen presenting dendritic cells (DCs) also phagocytose bacilli  and then  
migrate to regional lymph nodes to present the Mtb antigens to lymphocytes (Sakamoto 
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2012). Lymphocytes and infected macrophages become activated in response to 
inflammatory cytokines/ chemokines and migrate to sites of infection where they help to 
form granulomas (Kapoor, Pawar et al. 2013). Macrophages, T-cells , B-cells and DCs are 
all involved in this process (Figure1. 4).Tumor Necrosis Factor-α (TNF-α) and Interferon-
γ (INF-γ) are the chief signaling cytokines for tissue infiltration although they are not 
required to initiate granuloma formation (Abdul-Aziz, Tsolaki 2013). The role of TNF-α 
in granuloma formation is partly via recruitment of  leukocytes but also TNF-α dependent 
chemokine production (Sakamoto 2012).  A granuloma will therefore consist of central 
infected macrophages; foam cells, occasional multinucleated giant cells with recruited 
lymphocytes and a fibrous capsule (Figure 1.4). Studies in non-human primates have 
shown that there are  a number of granulomas in the lungs during latent infection; either 
controlling or disseminating bacterial growth (Flynn, Capuano et al. 2003). The central 
core of the granuloma is believed to be hypoxic with little nutrient availability. Despite 
harsh conditions Mtb can persist within the granuloma for years. Reactivation of latent TB 
occurs when changes in the host immune system lead to rupture of the granuloma, 
disseminating the Mtb (Abdul-Aziz, Tsolaki 2013). 
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Figure 1. 4 Granuloma formation 
Immune cells; macrophages, dendritic cells, T cells and B cells express a variety of 
receptors that can respond to the chemokines expressed by infected cells at the point 
of initial infection (A). This culminates in migration of the cells to the site of infection 
(B). After migration, the cells remain at the site of infection, probably in response to a 
variety of signals expressed in the granuloma (C). Adapted from (Flynn 2004) 
 
1. 5. 1 The infectious process 
The primary site of Mtb implantation forms a lesion called a Ghon focus generally referred 
to as the primary complex. The bacilli may be disseminated within the lung or to other 
organs during the early stages of the disease. Intriguingly, bacillary growth tends to favour 
the upper lobes of the human lung due to higher oxygen pressure and possibly delayed 
immune responses (Park, M. K., Myers et al. 1992). Despite replication and  dissemination 
of the bacilli, it is estimated that only 5-10% of infected individuals develop clinically 
apparent and possibly life-threatening disease, while healthy individuals resolve the 
lesions without showing any symptoms (Dreher, Nicod 2002). Infected individuals may 
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remain without any symptoms for years with the bacilli in a “latent” state with only 5% 
ultimately developing active disease during their lifetime. The bacilli are presumably kept 
in check by the host immune system. Reactivation, or secondary disease, may occur as a 
consequence of any condition that may affect  immune competence (Verver, Warren et al. 
2005). The highest risk of reactivated disease occurs in HIV positive individuals with a 
rate of TB of approximately 10% per year (Corbett, Watt et al. 2003). Reactivated TB 
mainly affects the lungs forming lesions that are characterized by Bronchopneumonia and 
progress to caseous granulomas with necrosis and cavity formation following thereafter.  
Symptoms of primary TB are not easily noticeable and are often ignored. Secondary 
tuberculosis is usually associated with localized symptoms such as coughing, hemoptysis 
and pleuritic pain. Fever, anorexia, night sweats and cachexia may also be accompanying 
symptoms resulting in the patient’s health decline (Sakamoto 2012). This stage is crucial 
for disease transmission as pulmonary cavities are generated. Such cavities enable the 
bacilli to get access into sputum leading to dissemination of the pathogen  through aerosols 
of respiratory secretions (Davies, P. D. O., Barnes et al. 2008) .   
1. 6 The diagnosis of tuberculosis 
One of the major barriers to elimination of TB is the absence of fast and effective 
diagnostic tools. In most parts of the world, diagnostic methods are the same as those 
developed over a century ago, such as the acid-fast smear of the expectorated sputum 
specimen. The sensitivity of the method in some cases is low especially in areas of high 
HIV prevalence. This results in as many as half of all the tuberculosis cases remaining 
undiagnosed (Perkins, Cunningham 2007, Davies, P. D. O., Barnes et al. 2008).   
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1. 6. 1 Smear microscopy  
Microscopic sputum examination of smears for acid fast bacilli (AFB) remains the 
mainstay for TB diagnosis and is highly recommended by the WHO especially in resource 
poor settings. The technique uses Carbolfuchsin Ziehl-Neelsen (ZN) or Kinyoun acid fast 
staining. The method however, suffers from poor sensitivity for detection of pulmonary 
TB (40-60%) (Perkins, Cunningham 2007, Verma, Dhole et al. 2013). Smear microscopy 
has the advantage of being simple, rapid, inexpensive and highly specific. Yield and 
identification of AFB with ZN sputum microscopy can be improved using specific 
methods of decontamination, liquefaction and concentration of the sputum sample 
(Saxena, Mathur et al. 2001, Verma, Dhole et al. 2013). One study reported of a sputum 
sample processing technique called ReaSLR that has shown to be more sensitive than the 
conventional method with sensitivity and specificity of 90.47% and 91.60% respectively. 
It employs  ready-to-use tablets with a chaotrope and reducing agents that exert mucolytic 
activity resulting in effective release of trapped mycobacteria in sputum (Verma, Dhole et 
al. 2013). Contrastingly fluorescent microscopy (FM) uses a fluorescent stain (e.g., 
auramine O) that utilises a powerful source of light (Steingart, Henry et al. 2006) and  has 
been shown to improve the sensitivity of sputum smears by up to 10% over conventional 
microscopy (Perkins, Cunningham 2007, Steingart, Henry et al. 2006, Wallis, Pai et al. 
2010). However the cost of the florescent microscope alone ($10,000-20,000) may be 
prohibitive for resource poor settings (Perkins, Cunningham 2007). In 2009 the WHO 
recommended the use of light emitting diode (LED) FM microscopy to replace 
conventional FM (Wallis, Pai et al. 2010). LED-FM microscopes have the advantage of 
being more sensitive, are inexpensive, more robust, use less electricity and require less 
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technician time than ZN microscopes. The performance of LED-FM is said to be 
equivalent to conventional FM, with added benefits of low cost, durability and the use 
without the need for a darkroom (Wallis, Pai et al. 2010). Overall microscopy as a 
diagnostic tool for TB has limited value in children and HIV positive individuals because 
by definition it does not identify smear negative tuberculosis (Steingart, Henry et al. 
2006). Detecting HIV associated TB is extremely difficult and results in delays while 
diagnostic tests and treatment trials are being conducted. Studies show that in Malawi up 
to a third of patients with smear negative TB needed more than six visits to a health center 
before treatment was initiated (Harries, Nyirenda et al. 2003, Perkins, Cunningham 2007). 
It is therefore clear that many TB cases are missed when smear microscopy is used alone. 
1. 6. 2 Culture methods 
Mycobacterial culture on selective media remains the most sensitive diagnostic method 
and is the gold standard for Mtb detection in clinical samples and for drug susceptibility 
testing (Perkins, Cunningham 2007). A traditional egg based solid media culture known 
as Lowenstein-Jensen (LJ) takes 4-6 weeks (Cruciani, Scarparo et al. 2004, Nyendak, 
Lewinsohn et al. 2009). The long duration (4-6 weeks) of  mycobacterial detection has 
remained an area of concern. 
More sensitive and rapid alternatives to conventional solid culture are liquid culture  
systems (BACTEC and MGIT) which may detect growth in roughly half the time (1-3 
weeks) compared to LJ (Cruciani, Scarparo et al. 2004, Nyendak, Lewinsohn et al. 2009). 
In these systems growth is not directly detectable but measured using an indirect proxy 
(Asmar, Drancourt 2015) via bacterial CO2 production or O2 consumption (Williams-
Bouyer, Yorke et al. 2000). The Mycobacterial growth indicator tube (MGIT) uses a 
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fluorescent oxygen quenching sensor at the bottom of a tube embedded in silicon to detect 
bacterial growth directly. With MGIT it is possible to get results in less than eight days 
(Palomino, Juan Carlos, Martin et al. 2008). With the  addition of critical concentrations 
of streptomycin, RIF, INH and ethambutol, an automated MGIT allows for drug 
susceptibility testing (Nyendak, Lewinsohn et al. 2009). Liquid culture systems use 
expensive culture vials and require large and costly incubators/readers. These plus the 
high risk of contamination when used by inexperienced laboratory staff has caused the 
limited use of liquid culture in TB endemic developing countries (Perkins, Cunningham 
2007), although most laboratories in low income countries now make use of liquid culture 
systems. 
With advancements in standard culture procedures including improved growth conditions, 
microaerophilic environment and use of auto-fluorescence detection, researchers have 
recently demonstrated that it is possible to dramatically shorten the culture period. In the 
best case, only 72 hours may be needed to achieve both primary culture and RIF 
susceptibility testing (Ghodbane, Raoult et al. 2014). 
1. 6. 3 Nucleic acid amplification tests 
Nucleic acid amplification tests (NAAT) are molecular based diagnostic tests that provide 
fast and accurate results (Nyendak, Lewinsohn et al. 2009). These tests use 
oligonucleotide primers and enzymes that catalyze reactions to amplify a target, a probe 
or a signal and yield results within minutes or hours. Some of the widely used assays 
include polymerase chain reaction (PCR; Roche Diagnostics), transcription mediated 
amplification (GenProbe) and strand displacement amplification (Becton Dickinson) 
(Piersimoni, Scarparo 2003, Huggett, McHugh et al. 2003). In the USA the Food and Drug  
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Administration (FDA) approved some NAAT tests for direct use on smear positive 
respiratory specimens; GenProbe  Amplified Mtb Direct test (Nyendak, Lewinsohn et al. 
2009), Roche Amplicor MTB test  and BD-Probetec Direct (Becton Dickinson); second 
generation tests from GenProbe (E-AMTD) and  Roche (AMTD2) on smear negative 
samples (Greco, Girardi et al. 2006). In the past few years, several of these NAATs have 
received WHO endorsement for widespread use (Wallis, Pai et al. 2010). In 2011 the 
WHO endorsed a novel,  rapid automated NAAT called the Xpert MTB/RIF (Xpert) which 
can give results in under two hours (WHO 2011). This PCR- based test simultaneously 
detects TB and RIF resistance on the GeneXpert platform (Blakemore, Story et al. 2010, 
Helb, Jones et al. 2010). The assay PCR amplifies five overlapping probes complementary 
to the entire 81 bp RIF resistance-determining region of the Mtb, the rpoB gene and 
subsequently probes this region for mutations associated with RIF resistance (Blakemore, 
Story et al. 2010, Molicotti, Bua et al. 2014). Uniquely the Xpert, unlike conventional 
NAATs has sample processing and PCR amplification within a single self-enclosed test 
unit, the GeneXpert cartridge (Figure 1.5). Apart from sample loading, all steps are 
automated (Steingart, Schiller et al. 2014). As an initial test replacing smear microscopy, 
Xpert had shown a pooled sensitivity of 89% and pooled specificity of 99% whereas when 
used as an add-on test following a negative smear microscopy result, Xpert had a pooled 
sensitivity and specificity of 67% and 99% respectively. Further in comparison with smear 
microscopy, Xpert increased TB detection among   culture-confirmed cases by 23%. For 
rifampicin resistance, Xpert had a pooled sensitivity of 95% and pooled specificity of 99% 
(Steingart, Schiller et al. 2014). Studies in India, South Africa and Uganda show that 
introduction of Xpert increased TB case finding in all the settings; from 72%-85% to 95%-
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99% of the cohort of individuals with suspected TB compared to the base case of smear 
microscopy and clinical diagnosis of smear negative TB. These studies further suggest 
Xpert as a cost-effective method of TB diagnosis compared to the base case for low and 
middle income settings (Vassall, van Kampen et al. 2011). Despite the fact that the  cost 
of the Xpert is considerably  higher when compared with smear microscopy, roll-out 
commenced in more than  20 countries at a subsidized price of US $9.98 (US) per cartridge 
and this price will be maintained until 2022 (Steingart, Schiller et al. 2014, Molicotti, Bua 
et al. 2014) . An improved version of the most widely used NAAT for TB diagnosis the 
Xpert MTB/RIF is now available as Xpert Ultra  (Dorman, Schumacher et al. 2018) 
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Figure 1. 5 The Xpert-MTB/RIF assay 
Involves hands on (1-3) and automated steps (4-8); Sputum is liquefied and inactivated 
with sample reagent (1). Sample material is transferred into test cartridge (2). Cartridge 
is inserted into MTB-RIF test platform (3) Sample undergoes filtration and washing 
before organisms are lysed to release DNA. The DNA undergoes real-time 
amplification and detection within an integrated tube (4-8). Adapted (Boehme 2010). 
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1. 6. 4 Other diagnostic methods 
There are several TB diagnostic tests at different stages of development or 
implementation. 
In 2012 the WHO failed to proceed with policy recommendations for the replacement of 
the smear microscopy with the loop-mediated isothermal amplification (LAMP) platform 
due to insufficient evidence. Re-valuations of the TB LAMP in a multi-country setting 
have since been done (WHO 2014). In a recent evaluation in Malawi, a resource-poor 
setting where this study was conducted, TB LAMP showed sensitivity of 65% and did not 
vary by HIV status or smear status (Nliwasa, MacPherson et al. 2016). This sensitivity 
was significantly lower than that observed  in Peru, Bangladesh and Tanzania (93%) 
(Boehme, Nabeta et al. 2007). Other studies of LAMP have reported higher sensitivities 
of 87%-97% (Adhikari, Pandey et al. 2009, Iwamoto, Sonobe et al. 2003). The study in 
Malawi also found the cost of LAMP to be high making it unsuitable in these settings 
(Nliwasa, MacPherson et al. 2016). However, in  2016 WHO gave a conditional 
recommendation for TB-LAMP as a replacement test for sputum smear microscopy for 
diagnosis of TB (WHO 2016). 
New DNA probes that are capable of binding  to rRNA, and enabling quick diagnosis of 
TB have been developed.  Accuprobe (Gen-Probe, Bedford, USA) was the first and was 
able to identify the Mtb complex, Mycobacterium avium complex, Mycobacterium 
kansansii and Mycobacterium gordonae with a sensitivity and specificity of more than 
90%. Line probe assays that detect different Mycobacterial species including Mtb on 
positive cultures were subsequently introduced. These include INNO-LiPA 
MYCOBACTERA version 2 (Innogenetics NV, Ghent, Belgium) and the GenoType 
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MTBC and Genotype Mycobacterium (Hain Lifesciences, Nehren, Germany) (Molicotti, 
Bua et al. 2014). Interferon-gamma release assay (IGRA) is a new diagnostic method for 
latent TB infection based on detection of INF-γ response to TB antigens. These antigens 
include early secretory antigenic target-6 (ESAT-6), cultures filtrated protein-10 (CFP-
10) and another antigen called TB7.7. Region of difference-1 (RD1) which is present in 
Mtb complex but absent in BCG and most non-tuberculous mycobacteria encodes these 
antigens (Molicotti, Bua et al. 2014, Taki-Eddin, Monem 2011). IGRAs are less prone to 
false positives caused by non-tuberculous mycobacteria or BCG but are unable to 
discriminate between latent infection and an active disease (Metcalfe, Everett et al. 2011, 
Molicotti, Bua et al. 2014). Mycobacterial antigens are also detectable in urine of patients 
with pulmonary TB. One such antigen is the cell wall lipopolysaccharide 
lipoarabinomannan (LAM) and an enzyme linked immunosorbent assay (ELISA) that 
detects LAM has been developed. This assay could be crucial in detecting TB in HIV 
infected patients as it has shown moderate to high sensitivity in such individuals although 
its sensitivity in HIV negative individuals is poor (Molicotti, Bua et al. 2014). It was 
recently suggested that urine-LAM assays could be a key diagnostic tool for  HIV positive 
patients with advanced immune-deficiency as LAM enters urine primarily via TB 
dissemination to the kidneys in blood (Lawn, Gupta-Wright 2016). Additionally, another 
systematic review demonstrated that LAM detection in urine could be positively 
correlated with increased risk of death during HIV associated TB treatment  (Gupta-
Wright, Peters et al. 2016).   
The long culture period in Mtb remains an obstacle to quick diagnosis of TB. Researchers 
in the Gambia and UK have developed a TB diagnostic test that is able to detect and 
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characterize bacteria that cause TB from DNA obtained directly from sputum without the 
need for culture (Doughty, Sergeant et al. 2014). This approach has previously been 
applied enables useful clinical and genome-wide sequence data  to be obtained (Kay, 
Sergeant et al. 2014, Wilson, Naccache et al. 2014). This new technique called 
metagenomics although not delivering sufficient depth of coverage for sequence based 
sensitivity testing, if improved has the potential to revolutionize TB diagnosis.  
1. 7 Treatment of tuberculosis 
 The first line of treatment for TB is a multi-drug regimen consisting of rifampicin, 
isoniazid, pyrazinamide, and ethambutol (RHZE) (van den Boogaard, Kibiki et al. 2009) 
which if it is to be effective (over 85% cure rates for new cases) has to be taken for at least 
six months. The WHO recommendation is that a patient undergoes two months of RHZE 
therapy followed by  RIF and INH for a further four months (Zumla, Raviglione et al. 
2013, WHO 2014). The duration and the complexity of the treatment poses a major 
challenge for patients leading to non-adherence to treatment (van den Boogaard, Kibiki et 
al. 2009) . Non-adherence results in treatment failure and relapses and eventually 
development of drug resistance. In the 1990s, the WHO developed the directly observed 
therapy short course (DOTS) strategy to better improve response and adherence to TB 
treatment (van den Boogaard, Kibiki et al. 2009, WHO 1997). Despite being labour and 
resource intensive DOTS has been shown to produce the highest cure rates for drug 
sensitive TB (Balabanova, Drobniewski et al. 2006). As a result of this among other 
interventions, global TB mortality rates (deaths per 100 000 populations per year) and TB 
incidence rates are on the decline in most parts of the world. Through effective diagnosis 
and treatment, approximately 37 million lives were saved between 2000 and 2013. With 
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a goal of dramatically reducing the global burden of TB by 2015 and guided by 
Millennium Development Goal 6, the WHO  developed the Stop TB Strategy for the period 
2006-2015 (WHO 2014). Additionally, the World Health Assembly in 2014 approved the 
WHO End TB strategy with a call to cut TB deaths by 90% and TB incidence rates by 80% 
by the year 2030 (WHO 2016). 
However, non-adherence to treatment (irregular and low dose) can also lead to the 
emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mtb 
strains (Zhang, Ying, Yew et al. 2012). Drug resistant TB is usually managed using 
aminoglycosides and fluoroquinolones among other drugs (Flandrois, Lina et al. 2014). 
The WHO recommended regimens for MDR-TB may last up to 24 months with success 
rates of only 65% (WHO 2014). A short course of nine months (from 24 months)  using 
up to seven drugs based on experience in Bangladesh   (Aung, Van Deun et al. 2014) was 
recently  approved for treatment of MDR-TB (WHO 2016) and up to 35 countries  have 
since adopted the  this for selected patients (WHO 2017b).  
1. 7. 1 Drug resistant tuberculosis (DR-TB) 
Mtb may undergo random spontaneous  chromosomal mutations at a low frequency which 
renders them resistant to a specific drug or a drug class (Ando, H., Miyoshi-Akiyama et 
al. 2014, Flandrois, Lina et al. 2014, Zumla, Raviglione et al. 2013). Improper use of drugs 
such as low doses or poor-adherence to therapy enables selection pressures which may 
result in emergence of resistant mutants (acquired resistance). Infection with a drug 
resistant strain (primary resistance) may also result in infection and eventually disease 
(Andrews, Sarita Shah et al. 2007, Zumla, Raviglione et al. 2013). Chromosomal 
mutations in the  rpoB gene confer resistance to  RIF, while those in katG and the mabA 
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(fabG1)-inhA operon confer resistance to INH, in pncA to PZA, in rrs to amikacin (AMK) 
and in gyrA and gyrB to fluoroquinolones (FQs) (Flandrois, Lina et al. 2014, Musser, J. 
M. 1995) . 
MDR-TB is defined as resistance to at least INH and RIF while XDR- TB (reported by up 
to 100 countries) is defined as, in addition to MDR-TB, resistance to any fluoroquinolone 
and at least one second line injectable drug-amikacin, kanamycin or capreomycin 
(Andrews, Sarita Shah et al. 2007, Dheda, Shean et al. 2010, Garzelli, Rindi 2012, Günther 
2014, WHO 2014). These definitions of MDR-TB and XDR-TB are based on treatment 
outcomes (success rate compared to failure). In one  study, Falzon et al. analyzed 
outcomes from 7000 patients and reported success rates of 64% for MDR-TB patients and 
40% for XDR-TB patients (Falzon, Gandhi et al. 2013, Matteelli, Roggi et al. 2014). 
Available data from various studies in South Africa indicate that XDR-TB arises 
predominantly in HIV- infected individuals who have an increased susceptibility for TB 
(Dheda, Shean et al. 2010). In other countries, particularly the former Soviet states the 
epidemiological situation is different and the increased prevalence in XDR-TB relates to 
imprisonment and poor infections control and treatment practices (WHO 2017a).  
1. 7. 2 Rifampicin resistance 
As a semi-synthetic derivative of rifamycin with very high bactericidal activity, RIF is 
used as a first line drug for TB treatment (Ramaswamy, Musser 1998). Although the 
bactericidal activity of RIF is less than that of INH,  RIF has longer-term sterilizing 
activity and is the key drug in preventing relapses during short-course therapy 
(Paramasivan, Sulochana et al. 2005). Extensive studies on RIF activity and resistance 
have been done on Escherichia coli (McClure, Cech 1978). RIF is a lipophilic ansamysin 
24 
 
that target the β-subunit of the RNA polymerase inhibiting transcription initiation. 
Resistance to RIF occurs as a result of mutations in the RNA polymerase beta subunit 
(rpoB) gene that encodes the β-subunit of the RNA polymerase. These mutations result in 
conformational changes that lead to low affinity for the drug (Shakya, Garg et al. 2012).. 
Data from various studies has shown that 96% of RIF resistant Mtb clinical isolates have 
mutations in the 81bp ‘hot spot’ region of the rpoB gene (Shakya, Garg et al. 2012). This 
region also called the rifampicin resistance determining region (RRDR) comprises rpoB 
codons 507-533 encoding 27 amino acids. (Almeida Da Silva, Palomino 2011, Engström, 
Morcillo et al. 2012, Ramaswamy, Musser 1998). The commonest changes  however, are 
missense mutations occurring at codons 526 or 531 (Caws, Duy et al. 2006, Musser, J. M. 
1995)  and in one study 80% of resistant strains had mutations at these positions (Musser, 
J. M. 1995). Intriguingly some RIF resistant Mtb clinical isolates have resistance arising 
from mutations outside the hotspot region. A mutation, A191C in the gene, Rv2629 was 
initially associated with RIF resistance but has  been found to be related to the W-Beijing 
genotype but not resistance to RIF. Furthermore, almost all RIF resistant clinical isolates 
have shown resistance to other drugs particularly INH suggesting RIF resistance could be 
used as a surrogate molecular marker for MDR (Almeida Da Silva, Palomino 2011, Caws, 
Duy et al. 2006). 
1. 7. 3 Isoniazid resistance 
INH (isonicotinic acid hydrazide) is a synthetic bactericidal antibiotic used worldwide as 
a first line drug to treat infections caused by M. tuberculosis complex members 
(Ramaswamy, Musser 1998). INH is highly effective against TB (minimum inhibitory 
concentrations (MIC) 0.02-0.2µg/mL) but is only active against metabolically active 
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replicating bacilli (Ando, H., Miyoshi-Akiyama et al. 2014, Zhang, Y., Yew 2009). INH 
is a prodrug that is activated by the catalase-peroxidase enzyme KatG, encoded by the 
katG gene (Ando, H., Miyoshi-Akiyama et al. 2014, Zhang, Y., Heym et al. 1992). In its 
active form INH inhibits production  of essential mycolic acids by blocking  the NAD-
dependent enoyl-acyl carrier protein reductase InhA (Rawat, Whitty et al. 2003, Vilchèze, 
Av-Gay et al. 2008). Clinical isolates resistant to INH have often been shown to lose the 
catalase and peroxidase activities of KatG (Zhang, Y., Yew 2009). Some actively dividing 
Mycobacterium smegmatis cells express low levels of KatG, the enzyme that activates the 
pro-drug INH. Such cells are unable to activate INH and display classical resistance 
(Wakamoto, Dhar et al. 2013). They escape the killing effect of the drug.  The S315T 
mutation in the katG is the most common mutation conferring INH resistance. In one study 
out of  85 INH resistant strains, 49 (85%) epidemiologically unassociated isolates had 
changes in amino acid 315 (Ser)(Musser, James M., Kapur et al. 1996). Furthermore this 
mutation has been consistently associated with high level resistance (MIC>1µg/mL) to 
INH (Andres, Hillemann et al. 2014, Palomino, J. C., Anandi 2014). Mutations in the inhA 
gene (lowering InhA affinity for the gene product InhA for activated INH) and mutations 
in the mabA-inhA promoter region (causing overexpression of InhA) also confer resistance 
to INH (Seddon, Furin et al. 2012).  These are however, less frequent than katG mutations 
(Ando, H., Miyoshi-Akiyama et al. 2014, Hazbón, Brimacombe et al. 2006, Zhang, Y., 
Yew 2009). INH resistance is a rather complex process as several genes including katG, 
ahpC, inhA, kasA and ndh have all been associated with resistance (Zhang, Y., Heym et 
al. 1992).   An analysis by Hazbón et al. of 240 alleles previously associated with INH 
resistance found that mutations in katG, inhA and ahpC, but not kasA were strongly 
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associated with resistance (Hazbón, Brimacombe et al. 2006). Such conflicting evidence 
suggests that INH resistance is an area requiring further investigation. By analyzing genes 
in the laboratory strain H37Rv, Ando.et. al recently demonstrated that a silent mutation in 
the mabA also confers resistance to INH through upregulation of inhA (Ando, H., Miyoshi-
Akiyama et al. 2014, Palomino, J. C., Anandi 2014). Ethionamide (ETH) is a structural 
analog of INH used as a second line drug against TB (Ramaswamy, Musser 1998, 
Vilchèze, Av-Gay et al. 2008). INH and ETH are said to share a molecular target as low 
level INH resistance has been correlated with co-acquisition of ETH resistance 
(Ramaswamy, Musser 1998, Winder, Collins 1970). Interestingly a recent study by 
Machado et al. found that mutations in the inhA regulatory region and in the inhA coding 
region confers high level INH resistance and cross-resistance to ETH in MDR-TB 
(Machado, Perdigão et al. 2013, Palomino, J. C., Anandi 2014). 
1. 7. 4 Resistance to Fluoroquinolones 
Fluoroquinolones (FQs) are an important class of broad spectrum antibacterial agents used 
as second line treatment against TB (Fàbrega, Madurga et al. 2009). Nalidixic acid, a 
compound discovered as a byproduct of the  antimalarial drug chloroquine has been used 
to produce several generations of novel fluoroquinolones including ciprofloxacin, 
ofloxacin, moxifloxacin and levofloxacin (GOSS, DEITZ et al. 1965). Studies of 
quinolone activity in bacterial species have found that these antimicrobial agents inhibit 
topoisomerase II (DNA gyrase) and topoisomerase IV, two enzymes critical for bacterial 
viability (Fàbrega, Madurga et al. 2009, Palomino, J. C., Anandi 2014). In Mtb only 
topoisomerase II is present and is therefore the only target for fluoroquinolone activity 
(Aubry, Pan et al. 2004). DNA gyrase is composed of two A and two B subunits   encoded 
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by gyrA and gyrB respectively (Musser, J. M. 1995) and its function is to catalyze DNA 
supercoiling (Takiff, Salazar et al. 1994). It uses energy from ATP to introduce negative 
supercoils into DNA. Introduction of negative supercoils in DNA is essential for RNA 
polymerase to introduce the transcription process (Fàbrega, Madurga et al. 2009). 
Resistance to fluoroquinolones in Mtb develops as a result of mutations in the Quionolone-
resistance determining region (QRDR) of gyrA or gyrB (Palomino, J. C., Anandi 2014). 
Positions 90 and 94 of gyrA have the most frequent mutations but other studies have also 
reported mutations at positions 74, 88 and 91. Mutations in gyrA result in high level 
resistance against Mtb (Cheng, Yew et al. 2004).  Contrastingly, mutations in gyrB are 
responsible for lower level resistance to Mtb (Takiff, Salazar et al. 1994, Maruri, Sterling 
et al. 2012). Although efflux determinants of FQ resistance in bacteria have previously 
been described (Pasca, Guglierame et al. 2004, Poole 2005), Lui et al. recently used 
expression profile analysis to demonstrate that high level FQ resistance may also be 
conferred by efflux pump mechanisms in Mtb (Lu, Liu et al. 2014). 
1. 7. 5 Resistance to Kanamycin, Amikacin, Capreomycin and Viomycin 
These four antibiotics are second-line drugs used in the management of MDR-TB. All 
four have the same mechanism of inhibiting protein synthesis by blocking normal function 
of ribosomes (Ramaswamy, Musser 1998). Kanamycin and amikacin bind to the 16S 
rRNA. Mutations at position 1400 and 1401 of the rrs gene are the most common in 
kanamycin resistant strains, conferring high level resistance to both kanamycin and 
amikacin (Palomino, J. C., Anandi 2014). Some studies have however reported mutations 
at position 1483 (Alangaden, Kreiswirth et al. 1998, Suzuki, Katsukawa et al. 1998). Up 
to 80% of clinical isolates in other studies have mutations showing low level resistance to 
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kanamycin but not amikacin. Such mutations occur at positions -10 and -35 of the ies 
promoter leading to overexpression of the protein (Campbell, Morlock et al. 2011, 
Palomino, J. C., Anandi 2014, Zaunbrecher, Sikes et al. 2009). The ies gene encodes an 
aminoglycoside acetyltransferase, ies (Zaunbrecher, Sikes et al. 2009). These data suggest 
that there is no complete cross-resistance between kanamycin and amikacin. Some 
resistant strains have not shown  known mutations suggesting resistance to kanamycin and 
amikacin which could also be a result of as yet undetermined mechanisms 
(Sowajassatakul, Prammananan et al. 2014). 
Capreomycin and viomycin share a similar structure and target the same site on the 
ribosome, causing  interface of the small and large subunits (Palomino, J. C., Anandi 
2014). They belong to the tuberactinomycin family of antibiotics, regarded among the 
most effective class of antibiotics against MDR-TB (Stanley, Blaha et al. 2010). Mutations 
in the tylA gene inhibit methylation of rRNA consequently conferring resistance to both  
capreomycin and viomycin. Full cross resistance between capreomycin and viomycin has 
also been previously reported (Palomino, J. C., Anandi 2014). 
1. 8 The Mycobacterium tuberculosis genome 
Sequencing of the entire Mtb genome was based on a reference strain, H37Rv which 
revealed that the genome contains 4 411 329 base pairs (Cole, S. T., Brosch et al. 1998) 
and around 4000 genes (Behr, Wilson et al. 1999, Davies, P. D. O., Barnes et al. 2008). 
In comparison to other bacteria, Mtb has a larger genome although it is smaller   than that 
of Escherichia coli (E. coli). It has a uniformly high content of guanine + cytosine (65.6%) 
indicating there has been minimal incorporation of foreign DNA during its evolution. A 
large number of genes in Mtb, (250 compared to 50 in E.coli) code for lipid metabolism 
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enzymes. Studies have detected all known lipid biosynthetic pathways encountered 
elsewhere in nature within Mtb. The enzymes are largely involved in the synthesis of 
complex lipid-rich mycobacterial cell walls (Davies, P. D. O., Barnes et al. 2008). One 
unique feature of the Mtb genome is the large number of the genes it contains, up to 10% 
of the total coding potential containing polymorphic guanine-cytosine repetitive 
sequences (PGRS).Two unrelated families proline-glutamic acid (PE) and proline-proline 
glutamic acid (PPE) of the acidic glycine-rich proteins are coded for by these genes. 
Specific functions of the genes and their proteins remain unclear (Cole, S. T., Brosch et 
al. 1998, Cole, Stewart T. 2002) although they have recently been implicated in immune 
evasion and virulence (Fishbein, van Wyk et al. 2015). Consistent evidence has previously 
suggested that proteins located in the cell wall and cell membranes are responsible for 
diversity in antigenic structure and virulence. This greatly contributes to Mtb evolution 
and adaptation of its various members to different hosts (Brennan, Delogu 2002, Filliol, 
Motiwala et al. 2006). 
1. 8. 1 Genotyping of Mycobacterium tuberculosis 
In order to effectively control the transmission of Mtb there is a need to identify and treat 
individuals with active disease. Most transmission however may occur before such 
individuals are identified. It becomes crucial to track specific strains of Mtb as they are 
transmitted in a community and understand their transmission dynamics and how they 
may impact on TB control activities.  Several methods are currently in use which can help 
to identify the source of infection including route of transmission and dissemination. 
Genotyping allows distinction between different strains of Mtb. Additionally, genomics 
has been critical in many areas including Mtb evolution (Gagneux 2012) drug discovery  
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(Lechartier, Rybniker et al. 2014) and more recently prediction of resistance (Helb, Jones 
et al. 2010). A project that seeks to use WGS to identify all drug resistance genes and 
correlate them with laboratory phenotype and clinical outcomes has been established at 
University of Oxford (University of Oxford 2016). Once completed the project will ensure 
not only quick TB diagnosis and treatment but also the right treatment  for patients with 
drug resistant strains.  
1. 8. 2 Genotyping methods 
Some of the common  methods that clinical researchers use to classify the Mtb complex 
into groups of related strains are IS6110 restriction fragment length polymorphism 
(IS6110 RFLP), mycobacterial interspersed repetitive unit-variable number tandem repeat 
(MIRU-VNTR) typing, spacer oligonucleotide typing (spoligotyping), targeting of large 
sequence polymorphisms (LSPs) and use of single nucleotide polymorphisms (SNPs) 
(Müller, Roberts et al. 2014). 
1. 8. 3 IS6110-based restriction fragment length polymorphisms  
The method uses restriction enzymes to cut mycobacterial DNA at sites of the common  
IS6110 insertion sequence once, resulting in DNA restriction fragments of varying lengths 
that can be separated by gel electrophoresis (van Soolingen, Hermans et al. 1991). 
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Figure 1. 6 Chromosome of Mycobacterium tuberculosis strain 
 
IS6110 Insertion Sequences and Mycobacterial Interspersed Repetitive Units (MIRUs) 
typing of (BCG), the M. tuberculosis Reference organism H37Rv, and Strain X. 
Chromosome of Strain X (top left). Results of IS6110 genotyping (top right); 
Mycobacterial DNA is digested with the restriction enzyme PvuII. The IS6110 probe 
hybridizes to IS6110 DNA to the right of the PvuII site in IS6110. The size of each 
hybridizing fragment depends on the distance from this site to the next PvuII site in 
adjacent DNA (fragments a through f). Results are shown by gel electrophoresis of the 
DNA fragments of BCG, H37Rv, and X. Results of MIRU- based typing (bottom three 
panels). Sizes of molecular-weight markers (M) and PCR products for the loci A, B, C, 
and D in BCG, H37Rv, and X are shown. Adapted from (Barnes, Cave 2003) 
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IS6110 complementary probes hybridize to IS6110 DNA and these DNA complexes form 
a particular band pattern on the gel. The insertion sequence IS6110 is unique to Mtb and 
is dispersed randomly throughout the genome although areas of common insertion of 
IS6110 have been reported (Thierry, Cave et al. 1990). The method is highly 
discriminatory, reproducible and has historically  been the gold standard for genotyping 
Mtb strains. One limitation of the method is that it requires large amounts of high quality 
DNA (2µg). Furthermore there is need for expensive computer software and experienced 
technical personnel. In addition the discriminatory power of this method is inadequate for  
strains with an IS6110 copy number of 6 or less (Jagielski, van Ingen et al. 2014).  
1. 8. 4 Mycobacterial Interspersed Repetitive Unit-Variable Number Tandem Repeat 
(MIRU/VNTR) 
MIRU/VNTR is a very accurate PCR-based method. It describes the number and size of 
the variable number tandem repeats (VNTR) in each of the 12 independent genetic loci 
termed mycobacterial independent repetitive units (MIRU) (Supply, P., Lesjean et al. 
2001). Specific MIRU loci are PCR amplified and followed by determination of amplicon 
sizes by gel electrophoresis (Jagielski, van Ingen et al. 2014). The method can be used on 
strains regardless of their IS6110 RFLP copy number as MIRUs are more conserved. It is 
automation friendly and so can be used for genotyping large number of samples and is 
amenable to quick comparison of results between laboratories. MIRU-VNTR has lower 
discriminatory power than IS6110 based RFLP when using 12 loci but when analyzing 
strains with lower copy number of the IS6110 sequence the power is higher (Davies, P. 
D. O., Barnes et al. 2008). 
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1. 8. 5 Spacer oligonucleotide typing (Spoligotyping) 
Spacer oligonucleotide (spoligotyping) is a PCR- based method based on a particular 
genomic region called the Direct Repeat (DR) locus which comprises a series of well 
conserved 36bp direct repeats. DRs are interspersed with unique non-repetitive spacer 
sequences of 34-41bp. Following PCR amplification, products of different sizes are 
hybridized to a membrane with 43 covalently bound synthetic oligonucleotides 
representing the polymorphic spacers identified in Mtb H37Rv  (spacers 1-19,22-32,and 
37-43) and in M.bovis BCG (spacer  20-22 and 33-36) (Kamerbeek, Schouls et al. 1997). 
Spoligotyping is simple, cheap, quick and easily reproducible. Although the method can 
identify Mtb complex isolates up to the (sub) species level (Jagielski, van Ingen et al. 
2014), it  is less discriminatory than IS6110 typing and is usually applied as a secondary 
or  a primary method parallel with a more powerful genotyping method (Davies, P. D. O., 
Barnes et al. 2008). The reason for an inferior discriminatory power of spoligotyping is 
that it targets only a single genetic locus of less than 0.1% of the Mtb complex genome 
(Jagielski, van Ingen et al. 2014). 
1. 8. 6 Other genotyping methods 
Polymorphic GC-rich repetitive sequences (PGRS) occur abundantly and at multiple sites 
within the Mtb complex genome. Several repeats of a 9bp consensus sequence (5’-
CGGCGGCAA-3’) are arranged in segments of up to 1.5kb (Ross, Raios et al. 1992). The 
number and distribution of the PGRS is used to distinguish Mtb strains (Jagielski, van 
Ingen et al. 2014). Repetitive Sequence - Based-(rep-) PCR uses primers to generate 
amplified fragments that produce a fingerprint pattern upon gel electrophoresis (Sechi, 
Zanetti et al. 1998, Wojtasik, Majchrzak et al. 2011). Single Nucleotide Polymorphisms, 
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SNPs are a reliable marker for Mtb complex lineage classification. Non-synonymous 
SNPs (ns-SNPS) when present introduce amino acid changes to proteins and influence 
phenotype and selection pressures (drug resistance in Mtb is associated with ns-SNPs) 
while synonymous SNPs (s-SNPs) do not alter amino acid profiles (Ramaswamy, Musser 
1998). The only major limitation of SNP typing is the large number of genes required to 
achieve satisfactory resolution (Homolka, Projahn et al. 2012). Genomic deletions within 
Mtb lead to large sequence polymorphisms (LSPs). Through sequencing, Mtb strains can 
be distinguished based on genomic deletions (Fleischmann, Alland et al. 2002). While 
LSP analysis targets  only a small section of the genome usually <1%, sequencing covers  
the entire genome. 
1. 9 Bacterial persistence 
 The problem with antibiotic resistance in TB is that it  has placed pressure on scientists 
in the pursuit of novel antimicrobials to tackle the issue. One major challenge however, is 
that there has not been attention paid to  persister cells during TB therapy. Persisters have 
been described as cells that survive prolonged bacterial antibiotic exposure despite being 
genetically susceptible (Balaban, Gerdes et al. 2013). Persisters have largely been ignored 
in part due to the presumption that all pathogens that evade antibiotics eventually get 
eliminated by host immunity (Gefen, Balaban 2009). Furthermore, persisters have been 
difficult to study because of their low frequencies in a naïve bacterial population (10-4 to 
10-6 in Escherichia coli) and the persister phenotype is not genetically inherited in passage 
(Dhar, McKinney 2007).  As early as 1942 it was observed that Staphylococcus aureus 
infections could recur even following high doses of penicillin. Further penicillin could kill 
99% of streptococcal culture leaving 1% intact (Hobby, Meyer et al. 1942). Joseph Bigger 
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later noted that within a clonal population of Staphylococcus aureus, there was phenotypic 
variation, with a subpopulation that remains tolerant to antibiotics (Bigger 1944). He 
termed this population of rare bacterial cells “persisters’’ and evaluated them at about one 
per million (Gefen, Balaban 2009).This phenotypic variation is not unique to bacteria as 
it has also been observed in fungi (Dhar, McKinney 2007). Unlike bacterial resistance 
which is attributable to heritable genetic mutations, bacterial persistence is a transient 
phenotype observed following exposure to antibiotics (Lewis 2010).When a bacterial 
population is exposed to a bactericidal antibiotic, quantification of viable bacteria at 
different time points can be achieved. The resulting killing curves are generally biphasic, 
with a majority of the cells rapidly killed before the killing rate decreases dramatically. 
The tail of the killing curve has a subpopulation of rare cells that survive antibiotic 
exposure (Lewis 2010). Persister cells do not proliferate in the  presence of antibiotics but 
removal of the bactericidal agent leads to a random switch back to the growing state. 
Consequently removal of the antibiotic gives rise to a population that is as sensitive as the 
original and produces a small proportion of persisters (Maisonneuve, Etienne, Gerdes 
2014). Persisters therefore possess non-heritable phenotypic antibiotic tolerance  and 
produce progeny that are fully susceptible to antibiotics upon regrowth (Zhang, Ying, Yew 
et al. 2012). This suggests that persistence is an epigenetic rather than a genetic trait 
(Korch, S. B., Hill 2006, Lewis 2010).  Evidence from other studies however suggests that  
persisters are present in a population prior to antibiotic exposure. In one study phenotypic 
switching occurred between normally growing Escherichia coli cells and persisters with 
reduced growth rates (Balaban, Merrin et al. 2004).   It has now become clear that 
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persistence make treatment of chronic infections such as tuberculosis more difficult to 
manage and may be  responsible for disease relapses (Gefen, Balaban 2009). 
1. 9. 1 Mechanisms generating persister cells 
Specific mechanisms responsible for persistence remain largely unknown. There have 
been questions as to whether persistence is indeed only as a result of antibiotic exposure 
or whether there may be other drug independent stochastic mechanisms. Balaban 
classified persisters into two groups: type I persisters (non-growing) that require an 
external trigger to differentiate into an antibiotic tolerant state and type II persisters 
(slowly growing) that are continuously generated in the absence of an external trigger 
(Balaban, Gerdes et al. 2013, Balaban, Merrin et al. 2004).Type II persisters are capable 
of regaining the non-persister  phenotype and increase their population in the log phase 
(Zhang, Y. 2014). In type I persisters the suggestion is that unfavorable environmental 
conditions may be sensed by a small fraction of the cells which then shuts down into a 
dormant state. This is used as a bet-hedging strategy where one group of cells continues 
to proliferate and risk deaths while others shut down to avoid the unfavorable conditions 
(Balaban, Gerdes et al. 2013). Antibiotic exposure is just one of those stressful external 
triggers for type I persister formation. Zhang however suggests that type I and type II 
persisters are not easy to classify as both types contain heterogeneous persisters cells 
themselves. Furthermore both type I and type II persisters may interconvert (Zhang, Y. 
2014) 
1. 9. 2 Genetic basis of persistence 
 Moyed’s pioneer study first suggested that persistence could have a genetic basis (Moyed, 
Bertrand 1983).  Stable hip (high persister) mutants were generated by exposing a 
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population of chemically mutagenized bacteria to high doses of antibiotic (Moyed, 
Bertrand 1983, Wolfson, Hooper et al. 1990). A gain of function hipA7 allele which 
enhanced persistence 1000 fold was identified. This demonstrated that a heritable 
mutation could increase the level of persistence (Maisonneuve, Etienne, Gerdes 2014). 
The hipA7 allele carries two point mutations in hipA, a gene of 440 codons (Black, Kelly 
et al. 1991, Moyed, Broderick 1986). The hipA gene is upstream of hipB which is a 
transcription regulator of the hipBA operon (Black, Kelly et al. 1991). In E.coli, high 
production of HipA inhibited DNA replication, transcription and translation, consequently 
inhibiting cell growth and increasing tolerance to antibiotics (Korch, S. B., Hill 2006). 
Consistently HipB directly inhibited HipA activity suggesting hipBA constitutes a toxin-
antitoxin (TA) locus (Korch, Shaleen B., Henderson et al. 2003). In addition to hipA,   
mutagenesis has been used to identify and   isolate several other persistence related genes 
such as relA , phoU, sucB and ubiF (Zhang, Y. 2014). Mutations in persister related genes 
have caused either increased or decreased persistence. Mutations mapping to hipA, metG, 
tktA, and glpD cause increased persistence while those  in relA , phoU, sucB and ubiF  
cause decreased persistence (Zhang, Y. 2014). A more recent study has demonstrated that 
tolerance mutations pave a way for rapid evolution of resistance (Levin-Reisman, Ronin 
et al. 2017). In the Levin-Reisman study, intermittent exposure of E.coli  cultures to 
ampicillin led to development of genotypic resistance which was preceded by an increase 
in MIC, extended lag times and emergence of tolerance mutations. 
1. 9. 3 Toxin and Antitoxin (TA) module 
Several studies have demonstrated that persistence in bacteria may be based on the TA 
module (Dorr, Vulic et al. 2010, Maisonneuve, E., Shakespeare et al. 2011). TA modules 
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consist of gene pairs where one gene acts as a “toxin” by increasing the frequency of 
persisters while the other cancels out its effect (Rotem, Loinger et al. 2010). In a previous 
study, Keren et al. demonstrated that the frequency of persistence in E.coli was greatly 
increased due to expression of relE toxin in excess of antitoxin relB, suggesting that TA 
modules could be mediators of persistence (Keren, Shah et al. 2004). Additionally the 
number of TA systems in an organism directly determines the frequency of persisters in a 
population (Maisonneuve, E., Shakespeare et al. 2011). The HipA toxin and the HipB 
antitoxin form a tight complex and these two gene products are regulated by the HipBA 
module. Overproduction of the toxin inhibits cell growth and this is counteracted by 
activity of the antitoxin (Korch, S. B., Hill 2006, Keren, Shah et al. 2004, Gerdes, 
Maisonneuve 2012). Studies have shown that HipA is a serine/threonine kinase having 
the kinase activity necessary for enhancement of both cell growth arrest and persister cell 
formation(Correia, D'Onofrio et al. 2006). HipA phosphorylates elongation factor-thermal 
unstable (EF-TU) leading to growth arrest (Correia, D'Onofrio et al. 2006, Keren, Shah et 
al. 2004).  It was previously discovered that HipA attenuated glutamyl tRNA synthetase 
(GltX) via phosphorylation (Germain, Castro-Roa et al. 2013). Inhibition of Gltx triggers 
synthesis of guanosine tetra-phosphate (p)ppGpp, a signaling nucleotide. In turn 
overproduction of (p)ppGpp dramatically enhanced persistence (Germain, Castro-Roa et 
al. 2013). (p)ppGpp induces slow growth in rare cells by activation of TA loci through a 
regulatory cascade that depends  on inorganic polyphosphate (PolyP) and Lon protease 
(Kåhrström 2013, Maisonneuve, E., Castro-Camargo et al. 2013). Consistent with this 
finding another study has demonstrated that the stringent response is activated due to 
attenuation of GltX by its phosphorylation. Inactivation of GltX leads to overexpression 
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of RelA and increases (p)ppGpp levels. Notably, expression of GltX reverses effects of 
HipA and prevents persister formation (Kaspy, Rotem et al. 2013). Others have suggested 
that (p)ppGpp synthesis may be triggered by  a micro-starvation environment created in 
exponentially growing cells (Maisonneuve, Etienne, Gerdes 2014). TAs have been 
classified into types I to V based on nature of TA activity regulation and genetic 
architecture (Masuda, Tan et al. 2012). Of  particular interest is the role of a type II TA 
locus which has been highly associated with persister cell formation. Type II loci encode 
an antitoxin that interacts with and attenuates the toxin (Masuda, Tan et al. 2012). Several 
studies have demonstrated that high production of type II toxins very efficiently lead to 
growth arrest in cells which could again be rapidly resuscitated by activation of related 
antitoxin genes (Christensen-Dalsgaard, Gerdes 2006, Pedersen, Christensen et al. 2002). 
Evidently the most up-regulated transcripts in the persister fraction obtained from the 
hipA7 locus were TA mRNAs, further supporting the finding that TA genes regulate 
persistence (Keren, Shah et al. 2004). Interestingly TA modules have also been associated 
with tolerance by lag (tbl) genes. Notably tbl genes have  been implicated in the extended 
lag time of bacteria before regrowth following exposure to antibiotics (Fridman, Goldberg 
et al. 2014).  
1. 10 Mycobacterium tuberculosis persistence 
Current TB therapy takes a minimum of six months. Some patients are unable or unwilling 
to complete treatment due to the prolonged duration (Sahbazian, Weis 2005). Poor 
adherence increases the risk of emergence of multi-drug resistant TB (MDR-TB) and 
extensively drug resistant TB (XDR-TB) (Zhang, Ying, Yew et al. 2012).  In order to 
prevent emergence of resistance, this treatment must combine at least three drugs (Davies, 
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G. R. 2013). The prolonged treatment is however, necessitated in part because of 
Mycobacterial persistence (Zhang, Ying, Yew et al. 2012). Current TB drugs do not 
possess sufficient sterilizing ability against persister cells. Clearly new approaches are 
needed to develop ultra-short drug regimens to combat TB.  
1.  10. 1 The special populations hypothesis and Mtb metabolic activity 
Early work by Dennis Mitchinson proposed that an Mtb lesion may constitute four 
bacterial  sub-populations at varying metabolic states (Mitchison, D. A. 2004, Mitchison, 
D. A. 1979). These distinct populations are targeted individually by different drugs based 
on their physiological states resulting in a biphasic bacillary elimination. A metabolically 
active replicating population are rapidly killed by isoniazid during an ‘early bactericidal 
phase’. The surviving bacilli are in different states of non-replicating persistence (NRP) 
and isoniazid is ineffective against these (Mitchison, D. A. 1985, BLOCH, SEGAL 1956). 
During this phase, up to 2 months, NRPs with intermittent spurts of metabolism are 
targeted by pyrazinamide (Mitchison, D. A. 1985). Metabolically quiescent bacilli are 
targeted by rifampicin in a slow prolonged ‘sterilization phase’ suggesting a shorter 
regimen is achievable with an improved activity against NRP bacilli. Further studies 
revealed a  synergy between pyrazinamide and rifampicin and that while pyrazinamide 
could be used only during the initial bacterial sterilizing phase, rifampicin was effective 
throughout the treatment period (Mitchison, D., Davies 2012). The modern short course 
chemotherapy is therefore credited to a series of British Medical Research Council 
(BMRC) clinical trials in East Africa, Hong Kong and Singapore (Fox, Ellard et al. 1999). 
A few more clinical trials have since been conducted in attempts to further shorten the 
treatment duration to four months.  
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Moxifloxacin and gatifloxacin are two antibiotics that have shown high sterilizing 
potential against mycobacteria in vitro (Johnson, Hadad et al. 2006).  However, a recent 
clinical trial was abandoned prematurely as the two drugs failed  to demonstrate non 
inferiority to the standard 6 month treatment (Jawahar, Banurekha et al. 2013). Similarly  
4-month phase three clinical trials of two Moxifloxacin containing regimens failed to 
demonstrate non-inferiority with  the standard 6-month regimen (Gillespie, Crook et al. 
2014). Merle et al. compared the standard 6-month regimen to a four-month regimen in 
which gatifloxacin was substituted for ethambutol (Merle, Fielding et al. 2014). In this 
trial non-inferiority of the 4-month regimen to the standard regimen could not be 
demonstrated as it was characterized by higher recurrences as compared to the standard 
regimen. Development of shorter and more effective drugs against TB therefore, hinges 
on understanding mechanisms and pathways that underlie persister Mtb cells. 
1. 10. 2 Laboratory investigations into Mycobacterium tuberculosis persistence 
Well known animal or in vitro models to study Mtb persistence are not in abundance, 
making study of persistence more challenging. Models are however available that may 
simulate one or two aspects of persistence (Wang, Wang et al. 2011). McDermott 
demonstrated using the Cornell mouse model that persisters were responsible for the 
failure of drugs to completely kill supposedly in vitro drug susceptible Mtb in the body. 
This murine model has since been used  in several other studies to demonstrate Mtb 
persistence (MCCUNE, R. M.,Jr, TOMPSETT 1956, MCCUNE, R. M.,Jr, 
MCDERMOTT et al. 1956, McCune, Robert M., Feldmann et al. 1966, McDermott 1958). 
Studies with guinea pigs demonstrate disease arrest during the initial acute phase of 
bacterial replication in Mtb infection. Notwithstanding the fact that guinea pigs display 
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pathological features of the disease seen in humans, they have extremely quick disease 
progression (McMurray 2001). Persistent infections have also been demonstrated in the 
cynomolgus monkey a non-human primate model (Flynn, Capuano et al. 2003, Walsh, 
Tan et al. 1996). Although infections closely mimic those of humans, use is limited by 
high costs (Monack, Mueller et al. 2004). 
 The hypoxic “Wayne model” is a well-recognised in vitro model that demonstrates entry 
into a non-replicating persistent state (NRP) under anaerobic conditions for an Mtb 
culture. The model is based on generating non-replicating bacilli by putting a low-
inoculum culture in a sealed tube and  stirred until all the oxygen is consumed (Wayne, 
Hayes 1996). Subsequently when such cultures are re-exposed to aerobic conditions, they 
resume synchronous replication, suggesting they could have been arrested at various 
stages of the cell cycle (Wayne, Sohaskey 2001). Several studies have attempted to 
demonstrate an in vitro model of the human granuloma, the hallmark of Mtb persistence 
(Marino, El-Kebir et al. 2011, Puissegur, Botanch et al. 2004, Segovia-Juarez, Ganguli et 
al. 2004). Others have used the Zebrafish-Mycobacterium marinum model to mimic the 
human granuloma (Clay, Davis et al. 2007). Infected zebrafish develop caseating 
granulomas with striking similarities in pathology to the human granuloma. These studies 
were however, unable to demonstrate resuscitation of Mtb (Kapoor, Pawar et al. 2013). 
Later an in vitro model in which Mtb goes into dormancy and subsequent resuscitation as 
observed in human TB was reported. Additionally the study demonstrated loss of acid 
fastness, lipid body accumulation, RIF resistance and gene expression changes for 
dormant bacilli (Kapoor, Pawar et al. 2013). A true in vitro model that fully demonstrates 
43 
 
the persistence phenotype requires multiple stress conditions similar to those encountered 
in the host (Deb, C., Lee et al. 2009). 
Recent studies have however challenged the view that persisters are in a state of growth 
arrest. It has been suggested that some persisters are in an  actively growing state but that 
efflux pumps detoxify the bacterial cells or lower antibiotic intake (Helaine, Kugelberg 
2014). In another study low level production of KatG in replicating INH susceptible Mtb 
cells led to drug tolerance akin to persistence (Wakamoto, Dhar et al. 2013). This form of 
drug tolerance was however found to be drug specific and it is yet to be established if such 
cells could exhibit multi-drug tolerance. 
1. 10. 3 Mechanisms of persister formation in Mycobacterium tuberculosis 
Studies have identified several mechanisms and pathways believed to be responsible for 
persister formation and maintenance in Mtb (Zhang, Ying, Yew et al. 2012) .  
It is now widely accepted that persistent Mtb use fatty acids as the major source of carbon 
and energy (McKinney, Honer zu Bentrup et al. 2000). During period of insufficient 
supply of pyruvate from glycolysis, β-oxidation of fatty acids becomes the major carbon 
source (Zahrt 2003). The glyoxylate shunt is necessary for carbon anaplerosis in the Krebs 
cycle, essential for survival of bacteria (Gomez, McKinney 2004, Gould, Van De 
Langemheen et al. 2006, Russell 2003).  Isocitrate lyse (ICL) is an initial enzyme of the 
glyoxylate shunt essential for fatty acid metabolism (McKinney, Honer zu Bentrup et al. 
2000). In Mtb, ICL is encoded by the icl gene and is responsible for catalytic conversion 
of isocitrate to glyoxylate and succinate (Zahrt 2003). There is up regulation of ICL during 
infection of macrophages by Mtb species, suggesting it could have a role in  persistence 
(Parish, Smith et al. 2003, Zahrt, Deretic 2001). Furthermore, mouse studies demonstrated 
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a marked reduction in persistence and virulence when icl was disrupted while bacterial 
growth remained unaffected (Kumar, Bhakuni 2008).  
However, other studies have disputed the fact that ICL plays a role in persistence and that 
fatty acids are not the sole carbon source (Wang, Wang et al. 2011). In vitro studies have 
shown that high expression of the gcvB gene was correlated with Mtb entry into 
persistence. Reductive amination of glyoxylate is catalyzed by glycine dehydrogenase, an 
enzyme encoded by the gcvB gene (Wayne, Lin 1982). It also proved not to be a drug 
target because there are two isoforms of the enzyme which cannot be completely 
simultaneously inhibited. A plethora of energy related pathways and genes associated with 
Mtb persistence have been identified. They include cydC, essential for energy production 
under anaerobic conditions and in vivo infection and encoding a transporter for 
cytochrome bd assembly (Dhar, McKinney 2010) and  tgs1 (triacylglycerol synthase 1) 
responsible for fatty acid storage in triglycerides (Deb, C., Lee et al. 2009) among others. 
Tgs1 is the most active of enzymes encoded by a set of genes (tgs1-tgs15) that have been 
characterized in Mtb  Induction of tgs1 resulted in both increased triacylglycerol and lipid 
body content (Garton, Waddell et al. 2008), phenotypes associated with persistence. The 
gene tgs1 is a member of the dosR regulon which is discussed in  more detail below. 
 In vitro  studies using conditions of hypoxia have identified a set of at least 48 co-
regulated genes, the dosR (dormancy survival regulator) regulon. The dosR regulon is 
activated by   hypoxia and by pulmonary “poisons” including nitric oxide (Voskuil, Martin 
I., Schnappinger et al. 2003) and carbon monoxide (Shiloh, Manzanillo et al. 2008). DosR 
is a two-component transcription regulator encoded by Rv3331c and is  necessary for 
induction of dosR regulon genes (Park, H. D., Guinn et al. 2003). Induction of  dosR is via 
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phosphorylation by two sensor histidine kinases dosS and dosT (Roberts, D. M., Liao et 
al. 2004). Induced  dosR genes are important for entry and maintenance of dormancy 
(Leistikow, Morton et al. 2010, Wang, Wang et al. 2011). One such gene which encodes 
a 16-kDa α-crystallin protein (also called HspX for heat shock protein X, Acr, and 
Rv2031c) is called the hspX gene (Yuan, Crane et al. 1996). HspX is the dominant antigen 
produced by stationary phase cultures in vitro (Yuan, Crane et al. 1996) and in vivo 
recognised by most TB patient sera (Park, H. D., Guinn et al. 2003). An acr mutant 
displayed increased growth in mice (in vivo) and both in activated and resting 
macrophages (in vitro). Consequently, when acr was constitutively expressed, Mtb growth 
slowed suggesting hspX plays an active role in slowing growth in Mtb. This evidence 
though remains rather controversial as no difference was observed in lung damage 
between a hspX deletion mutant and the wildtype. (Hu, Movahedzadeh et al. 2006).  In 
other studies dosR has been associated with increased expression of tgs1 and subsequent 
accumulation of intra cytoplasmic triacylglycerol (TAG) droplets (Daniel, Jaiyanth, Deb 
et al. 2004, Deb, C., Lee et al. 2009). Conversely deletion of tgs1 led to a mutant’s 
impaired ability to accumulate TAG (Kapoor, Pawar et al. 2013). Prolonged starvation 
induces expression of lipY, a gene encoding an enzyme responsible for hydrolysis of 
accumulated TAG stores back into Acetyl CoA for energy production (Deb, Chirajyoti, 
Daniel et al. 2006). Consistently, deletion mutants  of lipY displayed compromised ability 
to mobilize stored TAG (Kapoor, Pawar et al. 2013). Interestingly, others have suggested 
that the dosR regulon is not involved in persister cell formation in Mtb as only eight of the 
~48 genes were overexpressed in persisters (Keren, Minami et al. 2011). 
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Table 1. 1 Genes implicated in Mtb persistence.  
 
Reference Gene Name  Function  Knockout/ 
expression 
studies 
(McKinney, Honer 
zu Bentrup et al. 
2000) 
Rv0476 Icl Isocitrate lyase Reduced 
persistence in 
mice 
(Wayne, Lin 1982) Rv1832 gcvB Glycine de 
carboxylase 
Increased 
expression 
during hypoxia 
(Fritz, Maass et al. 
2002) 
Rv1161-4 narGHJI Nitrate reductase Reduced pers 
istence in mice 
(Fritz, Maass et al. 
2002) 
Rv1736c narX Fused nitrate 
reductase 
Increased 
expression 
during hypoxia 
and in human 
granulomas 
(Hutter, Dick 2000) Rv1737c narK2 Nitrate/nitrite 
transport 
Increased 
expression 
during hypoxia 
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(Glickman, Cox et 
al. 2000) 
Rv0470c pcaA Cyclopropane 
synthase 
Reduced 
persistence in 
mice 
 (Murphy, Stewart 
et al. 2005) 
Rv0126 treS Trehalose 
synthase 
Prolonged time-
to-death in mice 
(Zahrt, Deretic 
2001) 
Rv0981 mprA Two-component 
regulator 
Reduced 
persistence in 
mice 
(Parish, Smith et al. 
2003) 
Rv3132c dosR Two-component 
regulator 
Increased 
lethality in mice 
(Parish, Smith et al. 
2003) 
Rv3764/5c tcrY Two-component 
regulator 
Increased 
lethality in mice 
(Parish, Smith et al. 
2003) 
Rv1032c trcS Two-component 
regulator 
Increased 
lethality in mice 
(Parish, Smith et al. 
2003) 
Rv1027/8c kdpDE Two-component 
regulator 
Increased 
lethality in mice 
(Chen, Ping, Ruiz 
et al. 2000) 
Rv3286c sigF RNA polymerase 
σ factor 
Prolonged time-
to-death in mice 
(Kaushal, 
Schroeder et al. 
2002) 
Rv3223c sigH RNA polymerase 
σ factor 
Reduced 
pathology, 
prolonged time-
to-death in mice 
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(Ando, M., 
Yoshimatsu et al. 
2003) 
Rv1221 sigE RNA polymerase 
σ factor 
Prolonged time-
to-death in mice 
(Steyn, Collins et 
al. 2002) 
Rv3416 whiB3 Transcriptional 
regulator 
Reduced 
pathology, 
prolonged time-
to-death in mice 
(Primm, Andersen 
et al. 2000) 
Rv2583c relA (p)ppGpp 
synthase 
Reduced 
persistence in 
mice 
(Hu, 
Movahedzadeh et 
al. 2006) 
Rv2031c hspX α-crystallin Increased 
expression 
during hypoxia 
and in mice 
(Stewart, Snewin et 
al. 2001) 
Rv0353 hspR HspR repressor Reduced 
persistence in 
mice 
(Stewart, Snewin et 
al. 2001) 
Rv0350 hsp70 Heat shock 
protein 70 
 
(Li, Kelley et al. 
1998) 
Rv1908c KatG Catalase-
peroxidase 
Reduced 
persistence in 
mice 
Adapted from (Wang, Wang et al. 2011) 
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The stringent response is a microorganism’s overall alteration in metabolism when 
subjected   to a nutrient-limited environment (Dahl, Kraus et al. 2003). The response is 
characterized by dramatic reduction in growth rate emanating from reduced levels of 
rRNA, tRNA and translation. This is often associated with reduction in metabolism of 
carbohydrates, amino acids and phospholipids. Dramatic increases in guanine nucleotides 
(p)ppGp, mediate the stringent response while low levels reverse it (Dahl, Kraus et al. 
2003). (p)ppGpp production  is regulated by RelA (ppGpp synthase) which has been 
implicated in  Mtb persistence as relA mutant bacteria could not survive in vitro or in mice 
(Dahl, Kraus et al. 2003, Zhang, Ying, Yew et al. 2012).  
TA modules are the most extensively studied persister related mechanism in E.coli 
(Zhang, Ying, Yew et al. 2012). Notably, over 30 TA modules have been identified in the 
Mtb genome (Pandey, Gerdes 2005). TA modules are highly redundant and others have 
suggested there could be over 80 in Mtb (Arcus, Rainey et al. 2005, Ramage, Connolly et 
al. 2009). Ten  of these were overexpressed in persisters and in vitro one of the most 
overexpressed modules was Rv2866 a homologue of RelE (Keren, Minami et al. 2011). 
Toxin RelE is the most well studied in Mtb and its high expression was shown to cause 
persistence and drug tolerance (Singh, R., Barry et al. 2010). The role of other TA modules 
in Mtb remains poorly described (Zhang, Ying, Yew et al. 2012). 
A recent study has reported novel genes unique to Mtb persistence notably lipid 
biosynthesis and feast or famine regulation (Torrey, Keren et al. 2016). In this study hip 
Mtb mutants were generated via mutagenesis and used to identify Mtb specific persister 
genes. Genes associated with synthesis of lipids, metabolism of carbon, toxin-antitoxin 
modules and regulation of transcription were identified. 
50 
 
1. 10. 4 Persistent Mycobacterium tuberculosis in sputum 
The primary host cells for pulmonary Mtb are pulmonary macrophages (Russell 2001). 
The eventual formation of the granuloma is characterized by the presence of a specific 
population of macrophages enriched in lipid droplets (LD) known as foamy macrophages 
(Neyrolles 2014). Caire-Brändli and co-workers (Caire-Brändli, Papadopoulos et al. 
2014) have described a model in which mycobacteria within foamy macrophages undergo 
reversible cell growth arrest. The mycobacterial phagosome fuses with the host cell LD 
and accumulates the TAG content of the LD to the phagosome. In vitro, Mtb in hypoxic 
macrophages were shown to accumulate lipid bodies and lose acid fastness (Daniel, J., 
Maamar et al. 2011). Loss of acid fastness is suggestive of organisms in dormant state. 
Furthermore non-replicating Mtb in vitro were previously shown to contain LD levels 
comparable to those found in sputum (Garton, Waddell et al. 2008), suggesting LD could 
be a putative marker of persistent Mtb. Interestingly LD accumulation in macrophages has 
also been associated with ESAT-6, the Mtb virulence factor (Singh, V., Jamwal et al. 
2012). 
 Transcriptomic studies have shown that Mtb organisms are present  in sputum which have  
gene expression signatures comparable to slow growing or non-replicating organisms. 
This sputum phenotype was also correlated with upregulation of the dosR regulon. Lipid 
body populations in sputum were negatively  correlated with time to positivity (Garton, 
Waddell et al. 2008). Both lipid body formation and increased time to positivity are highly 
correlated with poor treatment outcomes in Mtb (Sloan, D. J., Mwandumba et al. 2015). 
Furthermore, transcription signatures of Mtb early in treatment can be used to predict 
efficacy of treatment later. This was demonstrated in a recent study where mRNA profiles 
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of bacilli at days 7 and 14 of treatment were consistent with pre-chemotherapy signatures 
(Honeyborne, McHugh et al. 2016). This suggests presence of a drug tolerant sub-
population in sputum prior to treatment. Accumulating evidence suggests that drug 
tolerant Mtb cells while having low metabolic activity are still transcriptionally active 
(Walter, Dolganov et al. 2015). Taken together, these data suggest that drug tolerance or 
persistence plays a key role in Mtb treatment failure and disease relapse.  
1. 11 Epigenetics in Mycobacterium tuberculosis 
Conrad Waddington coined the term epigenetics in reference to factors above or in 
addition to genetics to explain the formation of tissues and organs during development 
(Waddington 1956). Currently epigenetic mechanisms are defined as stable and heritable 
changes in gene function with no associated change in genome sequence. These changes 
are characterized by modifications in the DNA and its associated histones. They include 
methylation, acetylation, phosphylation, and ubiquitination (Yadav, Dwived et al. 2015). 
In humans epigenetic mechanisms have been shown to play a role in development of 
cancer via repression of tumor suppressor genes (Yadav, Dwived et al. 2015). In bacteria 
epigenetics works to aid the organism in adapting to varying environmental conditions 
(Chen, Poyin, Jeannotte et al. 2014). The most common and well characterized epigenetic 
mechanism in prokaryotes is DNA methylation (Clark, T. A., Murray et al. 2011, Sánchez-
Romero, Cota et al. 2015). During DNA methylation a methyl group is transferred from 
S-adenosyl-methionine (SAM) to DNA by enzymes called methyltransferases (Jeltsch 
2002, Clark, T. A., Murray et al. 2011). Methyltransferases (Mtases) recognise specific 
DNA sequences (motifs) methylating adenine and cytosine bases. The result is formation 
of N-6methyladenine (m6A), N-4methylcytosine (m4C) and N-5methylcytosine (m5C) 
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(Figure 1.7). Bacterial DNA may also undergo modification to the atoms between 
nucleotides, a phenomenon called phosphorothioation (Figure 1.7)  (Chen, Poyin, 
Jeannotte et al. 2014). 
  New DNA methylation types such as 5-hydroxymethylcytosine (5hmC), 5-
formylcytosine (5fC) and 5-carboxylcytosine (5caC) have recently been discovered in 
eukaryotes although their biological functions remain unknown (Murray, Clark et al. 
2012). 
 
 
.                           
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Figure 1. 7 Chemical structure of some methylated  bases 
Chemical structure of commonly methylated adenine and cytosine bases in Mtb. 
6methyladenine(m6A), N-4methylcytosine(m4C), N-5methylcytosine(m5C) and 
phosphorothioation. Figure adapted from(Chen, Poyin, Jeannotte et al. 2014) 
1. 11. 1 Role of DNA methylation 
Bacterial Mtases form part of the restriction-modification (RM) system which also 
includes a restriction endonucleases (REs). Pairs of Mtases and REs target the same 
sequence motifs (Davis, Chao et al. 2013). Evolutionarily RM systems are believed to 
have offered protection to bacterial DNA against viruses. REs will cleave unmethylated 
viral DNA whereas methylation will protect host DNA from digestion (Wion, Casadesus 
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2006). This notwithstanding, ‘orphan’ Mtases with missing cognate REs have been 
described. These perform many other cellular functions. For example orphan Mtases may 
be involved in DNA mismatch repair and initiation of the  cell cycle process (van der 
Woude, Hale et al. 1998). Interestingly REs that cleave methylated DNA have recently 
been described (Sánchez-Romero, Cota et al. 2015). In eukaryotes DNA methylation plays 
key roles in regulation of genes, chromatin remodeling, genomic integrity, parental 
imprinting and has been implicated in human disease (Wion, Casadesus 2006). 
Three different types of RM systems have previously been described (types I, II and III). 
Types I and III have the R and M systems as part of a single polypeptide while in type II 
they are in separate polypeptides. In types II and III, the RE cleaves the DNA in proximity 
to the methylation target site whereas in type I it cleaves further from the site (Casadesus, 
Low 2006). A RM system was later discovered that recognises methylated DNA and 
phosphothioated DNA and was classed as a type IV system (Liu, Ou et al. 2010). The best 
evidence of the role of DNA methylation in gene expression comes from GATCs in Ecoli 
(Casadesus, Low 2006). Expression of pyelonephritis associated pilus (Pap) is under the 
control of a phase variation. Individual cells may be in the phase-on or phase-off state. 
When the GATC1028 is methylated the pap gene is in off state and the GATC1130 is 
unmethylated. Methylation of the GATC1130 means that the pap gene is on and the 
GATC1128 is unmethylated. 
1. 11. 2 Detection of modified bases 
Until recently, it has been challenging to detect modified DNA bases. It is possible to 
detect base modifications such as DNA methylation using Sanger sequencing although 
the method does not have enough throughput for this purpose (Clark, T. A., Murray et al. 
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2011). DNA amplification erases epigenetic modifications. To this end  high throughput 
second generation sequencing (SGS) such as Illumina HiSeq that incorporate an 
amplification step cannot be used on native DNA for base modification detection (Davis, 
Chao et al. 2013). It has been possible to detect m5C methylation via bisulfite DNA 
sequencing. The method involves conversion of unmodified cytosine to uracil followed 
by sequencing using various platforms (Clark, S. J., Statham et al. 2006). Sample 
preparation is labour intensive   and costly and bisulfite treatment causes degradation of 
DNA (Korlach, Turner 2012, Rhoads, Au 2015). Additionally bisulfite sequencing is 
unable to discriminate between C, mC, and hmC (Flusberg, Webster et al. 2010)  although 
new methods can now circumvent  this problem (Korlach, Turner 2012). It has also been 
possible to detect DNA methylation in Mtb using technologies such as chromatography 
and mass spectrometry (Zhu, Zhong et al. 2015). These methods are however unable to 
offer genome wide detection of epigenetic modifications (Korlach, Turner 2012). 
Single Molecule Real Time (SMRT) Sequencing developed by Pacific Biosciences is 
capable of determining the nucleic acid sequence together with the methylation status at 
single base resolution (Flusberg, Webster et al. 2010). Sequence information is captured 
in real time during incorporation of nucleotides which are conjugated with distinct 
fluorophores (Davis, Chao et al. 2013). When a sample of DNA template termed 
SMRTbell is loaded into a cell, it diffuses into a sequencing unit called the Zero Mode 
Waveguide (ZMW). The DNA polymerase attached to the bottom of ZMW initiates 
replication. A light pulse identifies the incorporated base and a ‘movie’ of light pulses 
records the replication process (Rhoads, Au 2015). Additionally, kinetic data regarding 
the time and width of nucleotide incorporation, inter pulse duration (IPD) and pulse width 
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(PW) respectively are obtained (Figure 1. 8). There are changes in kinetic signatures when 
a DNA polymerase encounters a modified base. This allows for identification of the type 
and position of the modified base (Clark, T. A., Murray et al. 2011, Flusberg, Webster et 
al. 2010). PacBio sequencing has the advantage of having longer read lengths than other 
second-generation sequencing (SGS) platforms. Typically the PacBio RS II machine with 
sixth generation of polymerase and fourth generation chemistry (P6/C4) offers average 
read lengths of over 10kb and is much faster (Rhoads, Au 2015). Contrastingly the 
Illumina Hiseq 2500 offers minimum read lengths of 250 bp (Illumina ). The weaknesses 
of PacBio are less throughput and higher single pass error rate compared to other SGS 
techniques. Increasing the number of passes aids in increasing the accuracy. As an 
example sequencing coverage of 15 passes yields greater than 99% accuracy. 
Additionally, PacBio sequencing is costlier. Since strengths and weaknesses of PacBio 
and SGS are complementary, hybrid sequencing has been used as the best approach that 
integrates both methods (Rhoads, Au 2015). 
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Figure 1. 8 Detection of methylated DNA bases using Single Molecule Real Time 
Sequencing 
(a) Addition of a nucleotide to a DNA strand containing a methylated (mA) and 
unmethylated (A) base (b) Kinetic variations during sequencing. Nucleotides being 
incorporated are identified using florescent pulses. When a nucleotide is incorporated 
opposite a modified base, the duration (IPD) taken is characteristically longer. In this 
case the IPD is ∼5x for mA than for A. Adapted from (Flusberg, Webster et al. 2010). 
 
Circumstantial evidence points to the fact that epigenetic mechanisms could be 
responsible for the persistence phenotype in bacteria (Balaban, Gerdes et al. 2013, Korch, 
S. B., Hill 2006, Lewis 2010). DNA Methylation in host cells has been vigorously 
pursued.  Methylation and gene expression profiles of dendritic cells (DCs) in individual 
patients were found to undergo differential changes following Mtb infection (Barreiro, 
Pacis et al. 2013). Additionally a recent study found striking differences in DNA 
methylation of granulocytes and monocytes between TB patients and health individuals 
(Esterhuyse, Weiner et al. 2015).These changes were all in host immune cells. However, 
within the pathogen DNA methylation has also been linked to survival of Mtb under 
58 
 
hypoxic conditions. This association was however found to be strain specific as 
methylation mediated by a mycobacterium adenine methyltransferase A (MamA) was 
shown to offer fitness to a Euro-American strain during hypoxia associated with infection. 
Such fitness could not be demonstrated in the Beijing lineage strain owing to point 
mutation within the Mtase (Shell, Prestwich et al. 2013). Since DNA methylation is the 
best characterized form of epigenetic gene regulation in prokaryotes (Shell, Prestwich et 
al. 2013) and that the persister phenotype is not genetically inherited, the hypothesis in 
this study is that methylation is  responsible for the persistence phenotype in Mtb. 
Consistently, inactivation of SAM was associated with reduced DNA methylation in Mtb 
and rapid death of Mtb infected mice (Berney, Berney-Meyer et al. 2015) suggesting DNA 
methylation has a role  in Mtb survival. To date, the role of DNA methylation in Mtb 
epigenetic inheritance and its association with the persister phenotype in Mtb remains to 
be evaluated.  
1. 12 Aims of this thesis  
A large body of evidence in part implicates persister Mtb in the need for prolonged 
chemotherapy for the effective treatment of TB. New ultra-short and effective drug 
regimens against TB that target persistent Mtb cells need to be developed. Such drug 
regimens should be able to eliminate Mtb in both replicating and non-replicating state. 
Additionally, they should be able to eliminate Mtb from tissues and granulomas. This will 
only possible if scientists thoroughly understand mechanisms that underlie persistence in 
vitro and in clinically relevant in vivo conditions. 
This thesis will report on a laboratory based investigation aimed at identifying genetic and 
epigenetic mechanisms responsible for Mtb persistence. Specific objectives include: 
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i. To validate genomic DNA extraction methods compatible with DNA 
methylation analysis in Mtb 
ii. To analyze DNA methylation patterns in persistent Mtb 
iii. To assess stability of DNA methylation patterns in passage/strains 
iv. To evaluate occurrence of methylation within different Mtb strains and factors 
that lead to loss of  methylation  
1.13 Study hypothesis  
  The main hypothesis in this study was that persister Mtb cells would demonstrate a 
differential   methylation profile compared to metabolically active mycobacteria and 
that specifically persister related genes would largely be unmethylated especially in 
their promoter regions. 
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CHAPTER TWO: MATERIALS AND METHODS 
2. 1 Experimental procedures 
 All experiments involving Mycobacterium tuberculosis were performed in a Biosafety 
Level (BSL) 2 or  3 Laboratory as appropriate at University of Malawi-College of 
Medicine/ Malawi Liverpool Welcome Trust (CoM/MLW) TB Laboratory or at the  
Liverpool School of Tropical Medicine following local Standard Operating Procedures 
(SOPs). All reagents used were purchased from Sigma-Aldrich unless otherwise stated. 
2. 1. 1 Mycobacterial strains and growth conditions 
Mycobacterium tuberculosis strains used were clinical isolates from frozen stocks derived 
from a previously completed clinical  study: Studying Persistence and Understanding 
Tuberculosis in Malawi (SPUTUM) or Monitoring and Evaluation (M & E) samples 
processed in the CoM/MLW TB laboratory. Samples were selected from a total of 133 
stored strains derived from bacteriologically confirmed drug susceptible Mtb patients. 
Fifteen  of these patients had poor treatment outcomes in the SPUTUM study (defined as 
confirmed culture positivity for Mtb positive at end of treatment, death attributable to TB 
or relapse within one year of finishing treatment). 
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Table 2. 1 Patient characteristics from whom bacterial isolates used in the study were 
obtained 
Patient ID Sex HIV status Age Treatment End of 
treatment 
outcome 
S520R F Non-
infected 
27 2HRZE/4RH Cured 
S571T M Non-
infected 
43 2HRZE/4RH Cured 
S524R M Non-
infected 
61 2HRZE/4RH Cured 
S545R M Non-
infected 
28 2HRZE/4RH Cured 
S519T F Non-
infected 
36 2HRZE/4RH Cured 
S530Y F Non-
infected 
42 2HRZE/4RH Cured 
S528S M Infected 45 2HRZE/4RH Cured 
S555L M Infected 43 2HRZE/4RH Cured 
S621S F Non-
infected 
23 2HRZE/4RH Cured 
S610T M Non-
infected 
39 2HRZE/4RH Cured 
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S616T M Infected 27 2HRZE/4RH Cured 
S625D M Non-
infected 
29 2HRZE/4RH Cured 
S657S M Non-
infected 
29 2HRZE/4RH Cured 
S714Y F Non-
infected 
37 2HRZE/4RH Cured 
S696E M Infected 38 2HRZE/4RH Cured 
S699W M Infected 45 2HRZE/4RH Cured 
S406T F Infected 28 2HRZE/4RH Cured 
S020Q F Infected 39 2HRZE/4RH Cured 
S07U F Non-
infected 
40 2HRZE/4RH Cured 
S533U M Non-
infected 
44 2HRZE/4RH Cured 
S616M M Non-
infected 
30 2HRZE/4RH Cured 
S677J M Non-
infected 
34 2HRZE/4RH Cured 
S566A M Non-
infected 
56 2HRZE/4RH Cured 
S634U M Non-
infected 
49 2HRZE/4RH Cured 
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S532S M Non-
infected 
38 2HRZE/4RH Cured 
S010X M Non-
infected 
27 2HRZE/4RH Cured 
S334A F Non-
infected 
25 2HRZE/4RH Cured 
S060A M Infected 28 2HRZE/4RH Cured 
S137U M Infected 29 2HRZE/4RH Cured 
S181R M Infected 46 2HRZE/4RH Cured 
S005G M Infected 22 2HRZE/4RH Not cured 
S29R M Non-
infected 
28 2HRZE/4RH Not cured 
S180P M Infected 45 2HRZE/4RH Cured 
R730C F Infected 43 2HRZE/4RH Not cured 
S990F F Infected 52 2HRZE/4RH Cured 
S037Q F Non-
infected 
41 2HRZE/4RH Cured 
S004F M Non-
infected 
27 2HRZE/4RH Cured 
S147Q F Non-
infected 
29 2HRZE/4RH Cured 
S1025H M Non-
infected 
46 2HRZE/4RH Cured 
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S994K M Non-
infected 
28 2HRZE/4RH Not cured 
S1027K M Non-
infected 
30 2HRZE/4RH Cured 
S006K F Non-
infected 
39 2HRZE/4RH Cured 
S081T M Infected 34 2HRZE/4RH Cured 
S003H F Non-
infected 
36 2HRZE/4RH Cured 
S249F F Non-
infected 
35 2HRZE/4RH Cured 
S300Q F Infected 47 2HRZE/4RH Cured 
S306H M Infected 45 2HRZE/4RH Cured 
S357K F Infected 41 2HRZE/4RH Cured 
S370M M Non-
infected 
43 2HRZE/4RH Cured 
S383Z M Non-
Infected 
29 2HRZE/4RH Cured 
S379J M Non-
infected 
45 2HRZE/4RH Cured 
S416M F Non-
infected 
22 2HRZE/4RH Cured 
S494T F Infected 28 2HRZE/4RH Cured 
65 
 
S479A M Non-
infected 
35 2HRZE/4RH Cured 
S478B M Infected 37 2HRZE/4RH Cured 
S486T M Non-
infected 
53 2HRZE/4RH Cured 
S481L M Non-
infected 
36 2HRZE/4RH Cured 
S507T F Non-
infected 
27 2HRZE/4RH Cured 
S549Y F Non-
infected 
38 2HRZE/4RH Cured 
S510J F Infected 28 2HRZE/4RH Cured 
S539K F Infected 28 2HRZE/4RH Cured 
S511L M Non-
infected 
38 2HRZE/4RH Cured 
S589U M Infected 21 2HRZE/4RH Cured 
S662Y M Non-
infected 
51 2HRZE/4RH Cured 
 
 
 Mtb strains were revived after storage in glycerol using liquid culture (MGIT) and later 
transferred to solid culture (LJ). Putative persister strains  were selected based on their 
lipid body profile and treatment outcomes. Those with high lipid  body droplet as assessed 
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during the SPUTUM study using LipTOX Red microscopy and poor treatment outcomes 
were classified as “persisters” while those with lower lipid body content and treatment 
success were classified as “non-persisters”. All samples with LipTOX Red microscopy 
counts of ≥50% were classified as being high lipid body. Two putative “persister” and 
“non-persister” isolates respectively were cultured and sequenced. A further 14 isolates 
were cultured under varying conditions and sequenced. 
2 .1. 2 Decontamination of sputum samples 
It is obvious that in addition to Mtb cells sputum may contain non-tuberculous 
mycobacteria and fungi/bacterial contaminants. In view of this, it was imperative to 
decontaminate the sputum samples in order to rid it of contaminants. Frozen sputum 
samples were left to thaw before being processed. Samples were decontaminated using 
3% NaOH following standard laboratory operating procedures. 
2. 1. 3 The saline wash procedure 
The major challenge of extracting genomic  DNA directly from sputum is that of host 
DNA contamination and current methods do not effectively discriminate between host and 
bacterial DNA. A saline wash step was therefore employed to remove host cells before  
direct extraction from sputum  as previously described (Votintseva, Pankhurst et al. 2015). 
A 1mL aliquot of sputum Mtb was  heat-killed at 80 at for 40 minutes and  centrifuged at 
3000xg for 15 minutes. Supernatant was carefully removed by pipetting before addition 
of 1mL of sterile saline. The pellet was re-suspended by pipetting up and down. This was 
followed by further centrifugation at 3000xg for 15 minutes. The final pellet was 
recovered by pipetting out the supernatant. A 700mL aliquot of distilled water was added 
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to the pellet followed by re-suspension by pipetting up and down. This was then used for 
extraction of total genomic DNA in the sample. 
2. 1. 4 Solid plate preparation and determination of colony counts 
Solid plates for determination of colony forming units (CFU) were prepared according to 
the manufacturer’s instructions. Twenty-one grams of 7H11 medium powder (Becton 
Dickinson Difco, 212240) was suspended in 900mL of distilled water containing 5mL of 
glycerol. Following heating with frequent agitation, the mixture was boiled for a minute 
to dissolve the powder. A 2.5mL aliquot comprised of 2% suspension of carbendazim in 
70% alcohol was added to the media before autoclaving at 121 °C for 15 minutes. After 
cooling to 45°C the media was supplemented with 100mL oleic acid-albumin, dextrose 
and catalase (OADC, Becton Dickinson). Antibiotics in the form of two selectatabs 
(MAST24) with a final concentration of  polymyxin B, amphotericin B, nalidixic acid, 
trimetho prim and azlocillin (PANTA) were added. As the media was cooling 8mL was 
added to a tri-segment of each 100mm diameter petri dishes. Plates were dried overnight 
in an inverted position at 4°C until use. Sputum samples were homogenized by vortexing 
with glass beads to ensure even distribution of Mtb cells. The volume to be used for solid 
plates for CFU determination was incubated in an equal volume of dithiothreitol 1g/l 
(Oxoid) for one hour to liquefy the sample. 
Phosphate buffered saline (PBS) was used to prepare three 10-fold dilutions of the 
concentrated homogenized sputum. A 50 µl aliquot of neat sputum and the three 10-fold 
dilutions from each sample were inoculated using fresh sterile loop onto tri-segmented 
plates. Culture plates were placed in Ziploc polythene bags and incubated at 37°C. 
Contamination was checked weekly and plate reading was done at 21 days. Any growth 
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in a segment preventing plate reading was regarded as contaminated and was excluded 
from the count. The optimum dilution for reading the count was selected by choosing the 
plate segment with between 10 and 100 colonies. Colony counts per mL were expressed 
as follows: 
CFU/mL = number of colonies counted X 2 (dithiothreitol dilution) X 20 (50 µl was 
inoculated per segment) X dilution factor. 
2. 1. 5 Liquid culture 
Frozen clinical isolates were left to thaw and immediately after liquefaction of the sample 
a 0.5mL aliquot was added to a commercially available BBL MGIT™ 7ml tube. The tube 
contained Middlebrook 7H9 broth base supplemented with oleic acid-albumin, dextrose 
and catalase (OADC) and an antibiotic mixture of polymyxin B, amphotericin B, nalidixic 
acid, trimethoprim and azlocillin (PANTA). Tubes were incubated in a BACTEC MGIT 
960 instrument at 37°C and automatically monitored with additional manual inspection 
for possible growth once a week for up to eight weeks. 
2. 1. 6 Solid culture inoculation  
After four weeks of growth 2mL of confirmed Mtb sample from each MGIT tube was 
inoculated into each of 3 Lowenstein-Jensen (LJ) slopes following laboratory SOP. LJ 
slopes were prepared by addition of each of the following: 1.2g Potassium dihydrogen 
phosphate anhydrous (KH2PO4), 0.12g Magnesium sulphate (MgSO4. 7h2O), 0.3g 
Magnesium citrate, 1.8g Asparagine, 6mL Glycerol, 0.3g Malachite green to 300mL 
distilled water in a sterile reagent bottle. This was autoclaved at 121°C and 15lbs pressure 
for 15 minutes in order to make the mixture sterile and then left to cool to room 
temperature. Ten clean fresh eggs previously washed with a hand brush and  plain alkaline 
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soap before being rinsed thoroughly in running water and soaked in ethanol for 15 minutes 
were used. The eggs were cracked with a sharp knife and beaten with a sterile glass rod 
for five  minutes until  watery. The salt solution was then poured into the egg solution and 
mixed to homogenize. While maintaining the pH at (6.8 – 7.2) 4mL of the solution was 
dispensed into 14mL McCartney bottles. Within 15 minutes, the medium was inspissated 
in a slanting position for six minutes at 85°C. The bottles were labeled and the media was 
stored at 2-8°C until use. Following inoculation of Mtb LJ slopes were incubated at 37°C 
and checked weekly for possible growth for up to eight weeks. 
 Mtb identification/confirmation was done using both the BD MGIT TBC ID test device 
(Becton Dickinson, Maryland U.S.A) following manufacturer’s   instructions and by ZN 
staining. 
2. 1. 7 Ziehl Neelsen (ZN) staining 
ZN staining was done according to laboratory SOP. Sputum smear were spread over the 
center of the slide using circular rotational movements. Slides were air dried for 30 
minutes before being heat fixed by a flame. The smear was then covered with carbol 
fuchsin stain followed by further heating. The heated stain was allowed to stand on the 
slide for five minutes. The stain was then washed off with clean water and the smear 
covered with 3% v/v acid alcohol for three minutes or until the smear was sufficiently 
decolorized to a pale pink colour. The slide was washed with clean water followed by 
staining with methylene blue for up to 30 seconds and then further washed with clean 
water. The slide was air dried in a rack and then examined microscopically using the 100X 
oil immersion. 
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2. 1. 8 Nitric Oxide (NO) induction of H37Rv isolates 
H37Rv isolates were grown onto solid plates of Middlebrook 7H11 (Diffico) agar 
supplemented with 10% v/v OADC. Following 28 days of growth cells were harvested 
and homogenized in pre-warmed Middlebrook 7H9 (Diffico) media supplemented with 
10% v/v OADC and 0.05% v/v tween 80. The density of the  homogenate was normalized 
to OD580 =0.25. The media temperature was maintained at 35-37°C to avoid cold shocking 
the cells. A 5ml aliquot of the suspension was exposed to 500 µM Spermine NONOate 
(Santa Cruz Biotechnology)  and 500 µM Spermine-4HCL (XYZ) respectively for four 
hours at 37°C with shaking at 100rpm.Spermine NONOate is a rapid nitric oxide donor 
known to cause dose dependent bacteriastasis in Mtb with minimal apparent killing 
(Voskuil, M. I., Bartek et al. 2011). Spermine NONOate has a short half-life in aqueous 
solution and to avoid degradation weighing was done under nitrogen and the powder 
diluted in pre-warmed 7H9 immediately before use. After four hours, a 500 µl aliquot was 
drawn and used for genomic DNA extraction. 
2. 1. 9 Drug susceptibility testing 
Determination of MICs of the Mtb isolates was done using UKMYC3 sensititre custom 
made plates (Thermo Scientific) following manufacturer’s instructions. Briefly, a loopful 
of colonies were scraped from LJ slants and emulsified in a McFarland tube containing 
saline, 0.2% tween and glass beads. The tube was vortexed for 30 seconds and turbidity 
adjusted to 0.5 McFarland standard. A 100µl aliquot was transferred into a tube of 10ml 
of 7H9 broth supplemented with 10% OADC to give an inoculum of ~1X105 cfu/mL. 
Suspension was briefly vortexed and allowed to settle for 15 minutes. Another 100 µl 
aliquot was transferred into each well of the microtitre plate for inoculation. Wells were 
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covered with an  adhesive seal and wiped with 5% Surfanios and 70% ethanol before 
being placed into a sealed plastic bag.  
Plates were incubated at 37°C for 10 days after which visual inspection of growth was 
done. Plates with poor growth were re-checked using the positive control as a guide at 
days 14 and 21. Plate reading was done manually by visual inspection when growth was 
clearly visible in the positive control. If results of two plate readers differed a sample was 
re-tested using a fresh inoculum. 
2. 1. 10 DNA extraction -from culture 
To extract genomic DNA mycobacterial cultures, two in house methods both of which use 
a Cetyltrimethylammonium bromide (CTAB) step were employed; the 
Phenol/Chloroform/Isoamyl alcohol method and the Chloroform/Isoamyl alcohol method. 
2. 1. 11 Phenol/Chloroform/Isoamyl alcohol 
An adaptation of the previously described  CTAB based method (Warren, de Kock et al. 
2006) was used. In brief growth was scraped from LJ slants or pellet obtained from spun 
MGIT tubes and re-suspended in a sterile 50mL polypropylene Falcon tube containing 
2mL TE buffer (0.01 M Tris-HCl, 0.001 M EDTA [pH 8.0]) with or without 20x4mm 
glass beads. The sample was heat killed at 80°C for 40 minutes. A 2mL aliquot of 2X 
extraction buffer was added followed by gentle inversion to mix the suspension. The 
sample was vigorously vortexed for two minutes and then a 500µl freshly prepared 
lysozyme (50mg/mL, Roche, USA) was added. Ten microliters of RNAse, concentration 
at a concentration of 10mg/mL (Ambion, USA) was then added to the suspension followed 
by gentle inversion. A two-hour incubation in a 37°C preheated oven was followed by 
addition of 450 µl (1 x volume) of 10X Proteinase K buffer and 150 µl Proteinase K, at a 
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concentration of 10mg/mL (Qiagen, U.S.A). This was mixed by gentle inversion and then 
incubated at 45°C for 16 hours (overnight) in a preheated oven. An 820 µl aliquot of 5M 
NaCl and  710 µl of 10% CTAB (Amresco, USA) preheated to 65°C were added. The 
suspension was then incubated for 10 minutes at 65°C. After cooling to room temperature, 
an equal volume of phenol/chloroform/isoamyl alcohol (25:24:1, Sigma-Aldrich, USA) 
was added (about 5 mL). This was followed by gentle mixing repeated every 30 minutes 
for two hours.  The suspension was centrifuged at 3000xg for 20 minutes at room 
temperature. The top phase was carefully aspirated and transferred to a new labeled 15mL 
tube. This was followed by addition of an equal volume of chloroform/isoamyl alcohol 
solution  (24:1, v/v, Sigma-Aldrich, USA). The suspension was gently mixed before being 
centrifuged at 3000xg for 20 minutes. The top phase was carefully aspirated to a new 
15mL tube.  A 0.1 volume of 3M sodium acetate, pH 5.2 final concentrations was  then 
added followed by gentle inversion. To precipitate the DNA a 7mL aliquot of ice cold 
isopropanol was added followed by gentle inversion. DNA was pelleted by centrifugation 
at 3000xg for 20 minutes at 4°C. The supernatant was discarded and the DNA pellet 
washed in 1mL cold 70% ethanol for 10 minutes. The pellet was then air dried for 2-3 
hours before being re-suspended in 50 µl x1 TE buffer. The DNA was re-dissolved by 
incubating at 4°C overnight. All DNA was stored at 4°C until use.  
2. 1. 12 The Chloroform/ Isoamyl alcohol method 
Genomic DNA was isolated using the traditional CTAB method as previously described  
(Somerville, Thibert et al. 2005). Growth was scraped from LJ slants and dispensed into 
600µl of TE buffer. Growth from H37Rv was processed in a similar way as a positive 
control. The concentrated culture was heated to 80°C for 40 minutes to kill the 
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mycobacterial cells. Fifty microliters of 10mg/mL lysozyme (Roche, USA) was added to 
each tube which was vortexed and incubated at 37°C overnight. Ten microliters of 
10mg/ml proteinase K  (Qiagen, USA) and 35 µl of 20% (w/v) sodium dodecyl sulfate 
(SDS) were added and following vortexing incubated at 55°C for 30 minutes. One hundred 
microliters of pre-warmed (55°C) 5M NaCl and 100 µl pre-warmed (55°C) CTAB 
solution was added, vortexed and the tube incubated at 65°C for 15 minutes.  After 
cooling, 700µl of chloroform: isoamyl alcohol (24:1, v/v) was added to the tube  which 
vortexed for 10 seconds followed by centrifugation at 13000xg for 5 minutes. The top 
aqueous layer was pipetted out using a P200 pipette and a 0.6 volume of isopropanol  
added to precipitate the DNA. Tubes were kept at -20°C for a minimum of 30 minutes or 
overnight. After centrifugation at 13000xg for 15 minutes, the supernatant was discarded 
using one single motion. About 20 µl was left in the tube to which 1.0ml of 70% ethanol 
(stored at -20°C) was added. Following centrifugation at 13000xg for 7 minutes liquid 
was removed using a 1.0mL tip. After centrifugation at 13000xg for 2 minutes, the 
remaining liquid was removed using a 200 µl tip. The tube was left with the lid open at 
37°C until the last traces of liquid had evaporated. A fifty microliter volume of TE buffer 
(0.01 M Tris-HCl, 0.001 M EDTA [pH 8.0]) was added and the tube left at 4°C - overnight 
for the pellet to dissolve. Extracted DNA was quantified using a Qubit 3.0 fluorometer 
(Life Technologies, USA) according to manufacturer’s instructions. DNA purity was 
determined on a NanoDrop ND-1000 Spectrophotometer V3.7 (Thermo Scientific, 
Wilmington U.S.A) following manufacturer’s instructions. DNA purity was checked at 
absorbance 260nm and 280nm by calculating a ratio of A260/A280. An A260/A280 ratio 
ranging 1.8 to 2.0 was considered a pure DNA preparation. For additional confirmation 
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of DNA quality, samples were also  analyzed on 1.5% Agarose Gel electrophoresis 
following standard operating procedures. The gel was prepared by addition of 1.5g of 
agarose powder (Thermo Fisher Scientific, UK) to 200mL of TBE buffer. The mixture 
was heated in a microwave for not more than three minutes until the agarose had dissolved. 
After cooling to approximately 50°C, 10µl of ethidium bromide was added with 
continuous swirling. This was poured into casting dams and used for electrophoresis of 
the DNA.  All extracted DNA was stored at 4°C until use. 
2. 1. 13 DNA extraction -from sputum 
Genomic DNA was extracted directly from sputum using the commercially available 
Primextract kit (Longhorn Vaccines and Diagnostics, USA) and an in house DNA 
extraction method as previously described (Amita, Vandana et al. 2002). All sputum 
samples used in this extraction were of bacteriologically confirmed   3+ smear status. For 
the Primextract kit 200 µL of the sputum sample was mixed with equal volumes of 100% 
ethanol and Primextract lysis buffer. The mixture was homogenized by a brief vortex 
followed by a quick spin. Following incubation at ambient temperatures for 5 minutes, 
entire contents of the sample were pipetted into an extraction column/collection tube. This 
was centrifuged at 7500xg for 60 seconds. The eluate was discarded and the collection 
tube reused. Following two buffer washes each of which preceded centrifugation at  for 
7500xg for 60 seconds a third centrifugation removed the remaining traces of wash buffer. 
The extraction column was placed into a clean 1.5mL micro centrifuge tube. Elution 
solution equal to 50 µl (preheated to 70°C) was pipetted directly onto the silica filter 
followed by incubation for 60 seconds. After a final centrifugation 7500xg for 60 seconds 
the column was discarded and the eluted DNA was stored at 4°C until use. Similarly, as a 
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positive control, H37Rv growth re-suspended in 200 µl of molecular biology grade water 
was processed.  For the CTAB direct extraction of  Mtb DNA from sputum sample was 
conducted as in section 2.1.12 
2. 1. 14 Sample preparation 
Sputum samples were prepared following laboratory standard operating procedures 
(SOPs) as follows; A 2mL aliquot of sputum sample was decontaminated by addition of 
3% Sodium Hydroxide (NaOH) for 15 minutes. This was neutralized using an equal 
volume of phosphate buffer. The suspension was centrifuged at 16000xg for 20 minutes 
and the pellet re-suspended in 500 µL of phosphate buffered saline (PBS). The sample 
was incubated with an equal volume of dithiothreitol 1g/l (Oxoid) for one hour for the 
purpose of breaking sulfide bonds in mucoid sputum. Following vigorous vortexing for 
five minutes, 200 µL aliquots were drawn and used for DNA extraction using two different 
extraction methods. An aliquot of 50 µL and three tenfold dilutions were plated on 7H11 
agar medium supplemented with oleic albumin dextrose complex (OADC, Becton and 
Dickinson, UK) with antibiotics and was used to determine cell counts. 
2. 1. 15 Genotyping of Mycobacterium tuberculosis isolates using large sequence 
polymorphisms 
Mtb strains used for genotyping were collected from patients presenting with sputum 
smear positive pulmonary TB at QECH in Blantyre during a period of 18 months (June 
2010-December 2011). A singleplex PCR based method using specific primers targeting 
the occurrence of each of regions of difference RD239, RD105 and RD 750 was 
employed. These were selected based on Mtb molecular epidemiology studies in and 
around Malawi within the last 15 years.  RD239 is a marker of Lineage 1(Indo-Oceanic), 
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RD105 is a marker of the Lineage 2 (East Asian/W-Beijing) and RD750 is a marker of 
Lineage 3 (East African Indian). All isolates not falling within these two lineages were 
considered Lineage 4 (Euro-American) based on the occurrence of these lineages within 
the region. PCR reactions were performed in a micro centrifuge tube in a final reaction 
volume of 15 µL. For an RD239 reaction mixture,  15ng of DNA was added a PCR master-
mix containing 1X buffer (Bioline, UK), 0.2mM dNTPs, 0.5µM of each primer (forward 
and reverse), 1.50mM MgCl2, double distilled water and 0.5µM Taq polymerase (Bioline, 
UK). PCR reactions were performed using a denaturation step at 95°C /180 seconds, 
followed by five cycles of 95°C /30 seconds, 64°C/30 seconds ,72°C/30 seconds, and 
72°C/360 seconds. 
For the RD105 LSP the reaction mixture contained 15ng of DNA and a PCR master mix 
of 1X buffer without MgCl2 (EHF), 0.2mM dNTPs, 1.5mM MgCl2, 0.3µM each primer 
(forward and reverse) and 1 U EHF Taq polymerase. PCR reactions were performed using 
a denaturation step at 95°C/180 seconds, followed by 25 cycles at 95°C/15 seconds and 
64°C/240 seconds and finally 72°C/360 seconds. The RD 750 PCR assay was run as 
previously described (Reed, Pichler et al. 2009) with modifications. In brief the reaction 
mixture composed of a 15µl volume containing  15ng of genomic DNA,0.4µM of 
oligonucleotide, 200µM of dNTPs, 1.5mM of MgCl2, 1X Eurofins Taq buffer (+KCl) and 
Taq Polymerase (Eurofins). A denaturation step at 95°C /120 seconds was followed by 25 
cycles of 95 °C /15 seconds, 56°C /15 seconds, 72°C /240 seconds and a cycle of 72°C/360 
seconds. Oligonucleotide primers used for RD239 were forward 5’-GGC CAA CAT CGA 
CCA CCT ACC C-3’ and reverse 5’-ATC CTC GCT ACC GGC ACC TCA T-3’. For 
RD105 forward 5’-GGA GTC GTT GAG GGT GTT CAT CAG CTC AGT C-3’ and 
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reverse 5’-CGC CAA GGC CGC ATA GTC ACG GTC G-3’were used. For RD750 
forward 5’-GTC AAC TGC CGA TGG CTG AC-3’ and reverse 5’- CGT CAG CGA TGA 
TCA CCT CG-3’ were used. 
2. 1. 16 Agarose gel electrophoresis 
 Five microliters of the extracted DNA solution were separated on 1.5% agarose gel at 
120 volts for 40 minutes and visualized by staining with ethidium bromide. Gel DocTM 
EZ Gel Documentation System (Bio-Rad) was used to capture gel images. Image LabTM 
Software bundled in the Gel Doc System was used in image analysis. 
2. 2 DNA sequencing 
DNA sequencing was performed by the staff  at the Centre for Genomic Research (CGR), 
Institute of Integrative Biology, University of Liverpool, United Kingdom. Extracted 
DNA was purified with 1x cleaned AMPure beads (Agencourt) and the quantity and 
quality was assessed using the Qubit and NanoDrop assays respectively. In addition, the 
Fragment Analyzer (using a high sensitivity genomic kit) was used to determine the 
average size of the DNA and the extent of degradation. This procedure was also used at 
the steps indicated below to determine average fragment size of the DNA. DNA was used 
in the protocol without further shearing. DNA was treated with Exonuclease VII at 37 °C 
for 15 minutes. The ends of the DNA were repaired as described by the manufacturer 
(Pacific Biosciences, Menlo Park, CA, USA). Sample were incubated for 20 minutes at 
37 °C with DNA damage repair mix supplied in the SMRTbell library kit (Pac Bio). This 
was followed by a five minute incubation at 25 °C with end repair mix. DNA was cleaned 
using 0.5x AMPure and 70% ethanol washes. DNA was ligated to adapter overnight at 25 
°C. Ligation was terminated by incubation at 65°C for 10 minutes followed by 
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exonuclease treatment for one hour at 37°C. The SMRTbell library was purified with 0.5x 
AMPure beads. The library was size selected with 0.75% blue pippin cassettes in the range 
7000-20000 bp. The recovered fragments were damage repaired again. The quantity of 
library and therefore the recovery was determined by a Qubit assay and the average 
fragment size determined by Fragment Analyzer. SMRTbell library was annealed to 
sequencing primer at values predetermined by the Binding Calculator (PacBio) and a 
complex made with the DNA polymerase (P6/C4 chemistry). The complex was bound to 
Magbeads and this was used to set up the required number of SMRT cells for the project 
(two for each sample). Sequencing was performed on Pacific Biosciences RSII sequencing 
system (Pacific Biosciences, Menlo Park, CA, USA) using 360-minute movie times per 
cell, yielding ~ 350x average genome coverage. 
 2. 2. 1 Bioinformatics analyses of SMRT sequence data 
Analysis of Bioinformatic data was conducted using the 
RS_Modification_and_Motif_Analysis.1 protocol in SMRT Portal software (version 
2.2.0). Sequence reads were assembled using Hierarchical Genome Assembly Process 2 
(HGAP2) and mapped using the Basic Local Alignment with Successive Refinement 
(BLASR)  (Chaisson, Tesler 2012) algorithm within the SMRT portal. The BLASR 
pipeline is specifically designed for long reads. Annotations were done by comparing with 
the well annotated reference genome H37Rv (GenBank accession NC_00962). Standard 
settings (QV of modified motifs >40) in SMRT Portal were used to detect base 
modifications in the genome. A modification QV is a score that gives the confidence to 
which a modified site is correctly predicted as being modified (Naidu 2014). A score of 
20 represents a 99% chance that the site is indeed modified with a p value of 0.01. 
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Following identification of methylation sites downstream analysis was done to determine 
methylation patterns. The inter-pulse duration (IPD) ratio which is the difference between 
the observed and the expected IPD for an unmethylated position was measured. An IPD 
ratio of one represents no methylation while an IPD ratio of greater than one denotes 
methylation (Berney, Berney-Meyer et al. 2015). The methylated motif site ratio which is 
the proportion of modified motifs of all the motifs (modified + unmodified) was also 
determined. This was calculated automatically by SMRT portal (Zhu, Zhong et al. 2015) 
2. 2. 2 Analysis of DNA methylation patterns using SMRT sequencing 
To analyze methylation patterns in Mtb  the reference file for H37Rv (GenBank accession 
NC_00962) containing all genomic annotations in general features format (gff) was 
downloaded. All rows in the genome containing m6A modifications were extracted using 
a custom script run in Python software.  
The genomic ranges for the genes were obtained from ProteinTable166_159857.txt 
(http://www.ncbi.nlm.nih.gov/genome/proteins/166?genome_assembly_id=159857). If 
the gene was on the positive strand, the start site was reduced by 100 nucleotides while if 
the gene was on the negative strand, the start site was extended by 100 nucleotides. Any 
m6A modification found within the gene’s genomic range was reported.  
2. 2. 3 Prediction of promoter regions 
Genes of prokaryotes occur in clusters called operons. Genes in an operon are co-
transcribed  as a single mRNA under the control of the promoter of the head gene (Lim, 
Lee et al. 2011). Operon gene organization is capable of altering gene expression in the 
presence of specific regulatory mechanisms (Lim, Lee et al. 2011). A promoter is a region 
between two genes and is usually found between 10 and 35 bases upstream of the 
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transcription start site. A promoter is the binding site of the RNA polymerase during 
transcription (Newton-Foot, Gey van Pittius 2013).  
To predict the operons and promoter regions of Mtb a gff file of H37Rv (GenBank 
accession NC_00962) was uploaded and analyzed using a BPROM tool using soft berry 
software: 
www.softberry.com/berry.phtml?topic=bprom&group=programs&subgroup=gfindb 
 A tab separated values (tsv) file was generated with positions of  start and end coordinates 
of operons. It was possible to identify the coordinates of promoter regions by subtracting 
100 nucleotides upstream of the start codon of the first gene in the operon. Any 
methylation site occurring within greater than or equal to the promoter start site and less 
than or equal to the promoter end site was considered to be within the promoter region. 
The largest single operon consisted of eleven genes.  
2. 2. 4 Comparative analysis of methylated sites within persisters and non-persisters  
Methylation patterns including by strand were compared within persister and non-
persister Mtb isolates. Methylated sites within genic, intergenic and promoter regions were 
determined. Having identified the methylated genes, a gene ontology (GO) enrichment 
analysis of these genes was conducted  using a functional enrichment analysis tool  
(Panther 2018) to determine which gene categories were over-represented in persisters. 
2. 2. 5 SNP calling and identification of mutations causing loss of methylation 
MAFFT software (version 7) run in unix as previously described (Katoh, Standley 2013) 
was used in multiple sequence alignment of  consensus fasta files against the H37Rv 
reference genome  to identify SNPs and indels. MAFFT software was also used to identify 
large genomic deletions. The software was also used in multiple sequence alignment of 
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methyltransferase genes using specific reference sequences to identify possible mutations 
responsible for loss of methylation. A 7 bp deletion in the pks15/1 gene characteristic of 
all lineage 4 Mtb isolates (Constant, Perez et al. 2002) was also identified in the same 
manner. A phylogenetic tree was constructed for the 18 sequences using  RAxML 
(Randomized Accelerated Maximum Likelihood) a program for phylogenetic analysis in 
GTRCAT model (Stamatakis 2014) based on all polymorphic sites. M. cannetti was used 
as an outlier. The branch support values were determined using  1000 bootstrap replicates. 
To identify SNPs within genes implicated in persistence, gene sequences were extracted 
from the each of the four sequences (two failures and two successes). Gene ranges 
included were equal or less than the start site of the gene and  equal to or greater than the 
gene end site. These sequences were aligned with the reference sequence to determine 
SNPs and indels. All data and analysis are freely available online at: http 
s://github.com/codemeleon/MtbMethylationProfile. 
2. 2. 6 Comparison of Malawian isolates against a global sample 
In order to compare Malawian isolates against a global sample, 26  SMRT sequenced 
genomes were downloaded from https://www.ebi.ac.uk/ena/data/view/PRJEB21888  and 
analyzed using SMRT portal version 5.1.0. After running SMRT analysis all genomes 
with analysis steps<60 were considered to have low quality reads and were excluded from 
downstream analysis and therefore only 16 genomes were used. For the base modification 
analysis the reference file for H37Rv (GenBank accession NC_00962) containing all 
genomic annotations in general features format (gff) was downloaded and the genomes 
analyzed as detailed in sections 2.2.3 and 2.3.4. For the phylogenetic analysis, a fasta file 
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of the reference file for H37Rv (GenBank accession NC_00962) was used and analysis 
conducted as detailed in section  
2. 2. 7  Ethical approval 
The study from which these isolates were obtained had ethical approval previously granted 
by the College of medicine research ethics committee, University of Malawi 
(P.01/10/855) and LSTM ethics committee (09.67). 
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CHAPTER THREE:OPTIMIZATION OF A DNA EXTRACTION 
METHOD FOR SINGLE MOLECULE REAL TIME (SMRT) 
SEQUENCING 
3. 1 Introduction 
The arrival of high throughput sequencing platforms such as Pacific Biosciences Single 
Molecule Real Time (SMRT) Sequencing has led to unprecedented use of whole genome 
sequencing to better understand the genome and epigenome of Mycobacterium 
tuberculosis (Somerville, Thibert et al. 2005). Other whole genome sequencing platforms 
such as Illumina Hiseq are unable to completely sequence genomes with high GC content 
and repetitive sequences (Doughty, Sergeant et al. 2014). The Mtb genome is 
characterized by high GC content (∼65%) and numerous repetitive PE/PPE regions (Cole, 
S. T., Brosch et al. 1998). While PCR based analyses are amenable to fragmented or 
heterogeneous DNA (Caws, Duy et al. 2006, Fresquet-Wolf, Haas et al. 1998, van 
Vollenhoven, Heyns et al. 1996), preparation of sequencing libraries requires good yields 
of high quality, pure DNA (Cole, S. T., Brosch et al. 1998). To obtain good yields of high 
molecular weight DNA from Mtb, a long culturing step is deemed necessary (Merker, 
Kohl et al. 2013, Witney, Gould et al. 2015). The detergent CTAB is useful in the chemical 
lysis of cells from organisms with large quantities of polysaccharides (Tan, Yiap 2009). 
The method that utilizes CTAB has been applied in several studies (Honore-Bouakline, 
Vincensini et al. 2003, van Soolingen, Hermans et al. 1991). This method has been shown 
to yield considerably higher amounts of pure DNA compared to other techniques (Ali, Al-
Thwani et al. 2014). Mycobacterial DNA may be recovered from a number of sources 
including solid or liquid cultures and biological specimens such as sputum, urine, biopsies 
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and in vitro cultures (van Helden 2001). Recovery of pure Mtb DNA from liquid cultures 
such as MGIT is particularly problematic however  due to human and bacterial DNA 
contamination (Votintseva, Pankhurst et al. 2015). Unlike other whole genome 
sequencing platforms SMRT sequencing does not incorporate an amplification step. This 
necessitates use of high molecular weight double stranded native DNA (Davis, Chao et 
al. 2013). Furthermore to prepare a 10kb SMRTbell library DNA should be a minimum 
of 5µg and free from RNA and insoluble materials (Pacific Biosciences 2015). Long read 
lengths and high sequencing coverage are critical due to the high GC content and the 
repetitive PE/PPE regions of the Mtb genome. Such stringent DNA requirements in SMRT 
sequencing mean that the extraction method should be harsh enough to lyse the tough 
mycobacteria cell wall and at the same time gentle enough  so as not to shear the DNA. 
Sheared DNA will create problems during PacBio library preparation. Previous studies to 
sequence Mtb DNA using SMRT technology have largely used commercial kits (Naidu 
2014, Zhu, Zhong et al. 2015). To date no published study has employed an in-house DNA 
extraction method for SMRT sequencing of Mtb.  
3. 2 Aims 
This chapter discusses optimization of a suitable DNA extraction method compatible with 
SMRT sequencing technology. 
3. 3 Results  
To optimize a method that would extract DNA compatible with SMRT sequencing, an 
evaluation of two DNA extraction techniques that incorporate a CTAB step; the phenol/ 
chloroform/isoamyl alcohol and a chloroform/ isoamyl alcohol method was conducted.  
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3. 3. 1 The Chloroform/Phenol/Isoamyl alcohol method 
Mycobacterium tuberculosis is made up of a tough cell wall consisting of various  lipids 
and polysaccharides. To lyse this tough cell wall, enzymes and chemicals are usually used 
sometimes in combination with bead beating. In order to obtain sufficient DNA yield, an 
enzymatic chemical lysis method that utilizes chloroform: phenol/isoamyl alcohol in the 
purification step (Total time 11± hours) was employed. In this study the DNA extraction 
method was evaluated with bead beating/ homogenization at cell optical density (OD) =1 
at 540nm. Bead beating has been reported to be   an efficient method of DNA isolation in 
Mtb (Amaro, Duarte et al. 2008). Therefore, the enzymatic/chemical lysis method with 
bead beating was evaluated at durations of one and five minutes (Materials and Methods 
2.2.1.1).  DNA was extracted using the same CTAB method at two different bead beating 
durations of one minute and five minutes. An equal loopful amount of sample was used 
for each extraction. Each extraction was done in duplicate. Extracted DNA was quantified 
using a qubit fluorometer and concentration expressed as µg/mL. The results were as 
follows: ( Mean+SEM) 1 minute; 162.5 ± 114.6, (n=3), five minutes; 181.1 ± 123.5, (n=3), 
(P=0.92,95%CI -450.3 to 487.5 t-test with Welch’s correction).The duration of bead 
beating did not significantly affect the DNA yield (Figure 3.1). It was therefore decided 
the shortest bead beating duration of one minute be adopted. The bead beating method 
was thereupon compared with the homogenization method in subsequent experiments. To 
ensure reproducibility each extraction of six samples was done in triplicate. Mean DNA 
concentrations (µg/mL) of 121.2 ± 55.81 (mean± SEM) and 81.32 ± 27.29 (mean± SEM) 
were obtained for bead beating and homogenization methods respectively (n=6) (Figure 
3.1). The highest concentration obtained using the bead beating method was 389.2 µg/mL 
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with the lowest being 24.7 µg/mL. Comparatively the homogenization method had 201.5 
µg/mL and 21.7 µg/mL being the highest and lowest concentrations respectively. 
Although the mean concentration for the  bead beating method was higher, no statistically 
significant difference in concentration between the two methods was observed (P= 0.54, 
95% CI -185.7.3 to 105.9, t-test with Welch’s correction). An assessment of the DNA 
purity using the A260/A280 ratio on a Spectrophotometer ND-1000 was done. Values of 
1.518 ± 0.08616 (mean± SEM) and 1.532 ± 0.1258 (mean± SEM) for bead beating and 
homogenization respectively were obtained (Figure 3.3). Both these results were lower 
and outside the purity requirements for PacBio SMRT sequencing of 1.8-2.0. Analysis 
using gel electrophoresis revealed that most of the DNA obtained bead beating was 
degraded (Figure 3.2) 
 
   
  Figure 3. 1 Comparison of bead beating duration on DNA concentration 
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Figure 3.2 Gel electrophoresis image of genomic DNA obtained using the bead 
beating method 
Lanes 1 and 10 Lambda HindIII DNA Ladder. Lanes 2-8 Mtb DNA from cultured 
clinical isolates showing mostly highly degraded DNA and lane 9 was blank (nuclease-
free wáter) as a negative control. Lanes 4 and 7 were insufficiently loaded with sample. 
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Figure 3. 3 Comparison of DNA concentration by extraction method. 
Mtb culture was scrapped off from late exponential phase LJ slants and extracted using 
the chloroform; phenol; isoamyl alcohol method. Cells were heat killed at 80C for 40 
minutes. Disruption of cells was done by chemical/enzymatic method with bead beating 
or homogenization. Error bars represent Mean+SEM. Results (µg/mL), bead beating: 
121.2 ± 55.8 (n=6) and homogenization:81.3 ± 27.3 (n=6) (P=0.5, CI, -185.7 to 105.9 t-
test with Welchs’s correction). 
3. 3. 2 The Chloroform/Isoamyl alcohol method 
A decision was made to evaluate a faster and less complex method which would give 
fairly pure and sufficiently high yields of DNA. A chemolysis/enzymatic method without 
the use of phenol; (Materials and Methods 2.1.13) was evaluated. This method is less 
complicated and considerably shorter (Total time 7± hours). The aim was to compare the 
yield and purity of DNA obtained from LJ slants with those from MGIT tubes. This 
comparison was necessary as a MGIT culture would offer a quicker alternative to 
conventional solid culture. Extraction of 11 samples in triplicate was conducted in order 
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to ensure reproducibility of the technique.  Concentrations of (µg/ml) of 228.6 ± 54.1, 
n=11 and 28.73 ± 10.83, n=11 (Mean ± SEM) for LJ and MGIT respectively were obtained 
(Figure 3.4).  The results from LJ slants were significantly higher than those from MGIT 
(P=0.004, 95% CI -321.6 to -78.2). Purity values A260/A280 were 1.695 ± 0.1896, n=11 
(Mean ± SEM) for LJ and 2.739 ± 0.4512, n=11(Mean ± SEM) for MGIT. A 260/280 
ratio of 1.8-2.0 was considered as a pure DNA preparation. These results were outside the 
purity range of 1.8-2.0 required for SMRT sequencing although LJ results were closer to 
the required purity value. 
  
Figure 3. 4 Comparison of DNA yields from LJ slants and MGIT culture 
Mtb cells were grown under two different growth conditions: LJ slants and MGIT tubes 
respectively. Cells were harvested at 6 and 8 weeks and DNA was extracted using the 
chloroform;isoamyl alcohol (CTAB) method. Extracted DNA was quantified using a qubit 
fluorometer and concentration expressed as µg /mL. Error bars represent Mean±SEM. 
Results, LJ: 228.6±54.1 (n=11) and homogenization:28.7±10.8 (n=11) (P=0.004, CI, -
321.6 to -78.2, t-test with Welchs’s correction). 
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Table 3. 1 General Summary of DNA extraction methods and yield/purity  
Extraction Method  Procedure/Source Concentration (µg/mL) Purity 260/230 
  Mean ± SEM Mean ± SEM 
 Bead beating 121.2 ± 55.8  1.518 ± 0.08616  
CTAB (Phenol)    
 Homogenization 81.3 ± 27.3  1.532 ± 0.1258  
    
 LJ 228.6 ± 54.1 1.695 ± 0.1896 
CTAB (Without Phenol)    
 MGIT 28.73 ± 10.83 2.739 ± 0.4512 
            
  
3. 4 Discussion 
The success of downstream molecular applications is highly  dependent on the quality and 
quantity of the DNA available. Choice of a DNA extraction method is therefore critical to  
success. One published study that has sequenced Mtb on the PacBio SMRT sequencing 
platform has used a TIANamp Bacteria Genomic DNA kit (Zhu, Zhong et al. 2015) while 
a more recent study used the CTAB method (Phelan, de Sessions et al. 2018).The amount 
of DNA obtained from a commercial kit is however limited by  its design.This is due to 
the fact that most kits use 1.5-2.0 mL tubes or spin columns that take samples not 
exceeding  500 µl.The starting material is therefore usually low limiting the maximum 
amount of DNA that can be extracted.This study sought to find an extraction method that 
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would allow us to increase the input material while giving pure high molecular weight 
double stranded DNA.The use of CTAB in the extraction procedure  helps to improve the 
purification process.CTAB has been recommended for extraction from  solid cultures 
(Amaro, Duarte et al. 2008). Although the combined enzymatic/chemolysis bead beating 
method has been previously demonstrated to yield higher DNA quantities (Amaro, Duarte 
et al. 2008), in this study this  was not the case. It was discovered that this was due to low 
starting cell density.The method was also found to be time and labour intensive (Total 
time 11± hours). Mechanical disruption such as bead beating is one method used to lyse 
the tough cell wall of Mtb. Gel electrophoresis visibly showed highly sheared DNA 
produced with the bead beating method.This result was consistent with previous studies 
(Amaro, Duarte et al. 2008) where it was demonstrated that bead beating leads to 
massively degraded DNA.This notwithstanding, for downstream applications such as real-
time PCR where DNA integrity and quality may be less critical, bead beating has been 
demonstrated to be the most efficient and reproducible method(Pan, Gu et al. 2013). 
However, sheared DNA is incompatible with SMRT sequencing and consequently this 
method was deemed unsuitable. A low purity value for this method of 1.518 ± 0.08616 
(mean± SD) demonstrates RNA contamination. Although the method utilizes RNAse to 
remove RNA, it is likely that it did not work efficiently. A longer incubation period than 
the two hours may have helped to improve the purity of the extracted yield. 
The homogenization method has the advantage of not using mechanical disruption to lyse 
the cell thereby avoiding shearing of the DNA. Low DNA yield from the homogenization 
method could have resulted from failure to effectively weaken the hard cell wall of Mtb 
as there was no use of harsh physical treatment. Harsh pre-treatment such as freezing at -
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20 °C for 20 minutes and boiling for 10 minutes help to weaken lipid linkages of the cell 
wall, freeing chromosomal DNA (Amita, Vandana et al. 2002). 
Since both yield and purity of DNA obtained using the homogenization (CTAB-phenol) 
method did not significantly differ from that obtained using the bead beating method it 
was also deemed incompatible with SMRT sequencing. The two methods therefore, were 
not adopted for SMRT sequencing. 
The enzymatic/chemolysis method without the use of phenol was adopted. The study 
compared yields and purity of DNA from LJs and MGIT tubes using 
enzymatic/chemolysis without phenol.  Mean DNA yield for LJ was significantly higher 
than that from MGIT (Figure 3.2). This method was adopted for use as it was able to 
consistently recover >5µg of DNA from an LJ culture which is required to prepare a 10Kb 
insert SMRT library  and up to 2 µg from a MGIT culture which is required to prepare  a 
5Kb insert  library.  LJ medium is selective to Mtb and efficiently inhibits growth of other 
bacteria and fungi. On the other hand, MGIT medium is more prone to contamination and 
may  allow proliferation of various other bacterial and fungal organisms. It was therefore 
appropriate to infer that the DNA yield obtained from MGIT could also  have contained 
fungal and other non-Mtb DNA. In addition, purification of DNA from a MGIT culture 
proved to be challenging as evidenced by both low yield and purity obtained by the method 
compared to LJ. An additional purification step was used to improve the purity of the 
DNA. Ultimately the chloroform:isoamylalcohol (CTAB) method was adopted and used 
for DNA extraction  from solid cultures for SMRT sequencing. 
It has been demonstrated in this chapter that the CTAB method remains the gold standard 
for the extraction of Mtb DNA from solid culture. Additionally, the CTAB 
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chloroform/isoamylalcohol method without phenol has been found to be faster and easier 
to use than the phenol method. The method is feasible for SMRT sequencing. 
Furthermore, the method can be applied to SMRT sequencing from a MGIT culture. The 
study has further demonstrated that the use of bead beating is insignificant to the final 
DNA yield. 
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CHAPTER FOUR: COMPARISON OF PRIMEXTRACT DNA 
EXTRACTION KIT AND AN IN- HOUSE CTAB METHOD 
4. 1 Introduction 
The purpose of this chapter was to evaluate two DNA extraction methods for direct 
extraction of DNA from Mtb sputum. This comparison would potentially aid in identifying 
an extraction method that is fast and efficient in isolating DNA directly from sputum and 
also compatible with SMRT sequencing.  
Mtb is an agonizingly slow growing organism and conventional culture typically takes 
between two to eight weeks (Nolte, Metchock et al. 1993). However, WGS from a positive 
mycobacterial growth indicator tube (MGIT) culture is achievable in a mean time of two 
weeks (Fadzilah, Ng et al. 2009, Pfyffer, Welscher et al. 1997) although a later study was 
able to reduce it to three days (Koser, Bryant et al. 2013). As a consequence of the period 
required for culture, relevant genotyping results for molecular epidemiology can usually 
only be obtained in retrospect during outbreaks (Walker, Ip et al. 2013). 
The long culture period has also hampered efforts to use WGS as a diagnostic tool for TB 
(Doughty, Sergeant et al. 2014).The ideal situation would be to efficiently sequence 
directly from clinical specimens such as sputum. However attempts to sequence directly 
from Mtb clinical samples have achieved very low coverage (less than 0.7X) due to high 
rates of human DNA contamination (Doughty, Sergeant et al. 2014). 
Two published studies sequenced Mtb DNA extracted using commercial kits for SMRT 
sequencing but samples were from culture and not the primary sputum samples (Zhu, 
Zhong et al. 2015).To date, and to the best of our knowledge, no study has attempted 
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SMRT sequencing directly from clinical samples either through a commercial kit or an 
in-house DNA extraction method.  
The CTAB method has been used extensively in the extraction of Mtb DNA from a variety 
of samples (Honore-Bouakline, Vincensini et al. 2003, van Soolingen, Hermans et al. 
1991), one study demonstrated recovery of high yields of pure DNA directly from sputum 
(Amita, Vandana et al. 2002). In this study, the CTAB method was demonstrated to be 
superior to other in-house methods including some commercial kits.  The Primextract 
DNA extraction kit has been claimed to recover high yields of Mtb DNA directly from 
sputum (Longhorn Vaccines 2017). No published study has evaluated the efficacy of this 
kit against the traditional CTAB method or any other DNA extraction method. 
The purpose of this chapter is therefore to compare the efficiency of a commercially 
available DNA extraction kit (Primextract kit, Longhorn Vaccines and Diagnostics, USA) 
and an in-house CTAB based method for the extraction of DNA directly from confirmed 
Mtb positive sputum samples. The two methods were evaluated on the quantity and purity 
of the DNA and thus suitability of each method for SMRT sequencing. The aim of this 
chapter was to identify a DNA extraction method for Mtb compartible with SMRT 
sequencing. 
4. 2 Results  
Forty sputum samples collected from the M&E study were used for the comparison.  To 
evaluate the DNA extraction efficiency of the PrimeXtract kit against the CTAB method, 
an equal aliquot (200µl) of decontaminated sputum was simultaneously used for 
extraction. Cell density was determined by plating a sample on solid media to determine 
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CFU/mL.Since frozen sputum samples were used, those samples which were positive for 
DNA yield but yielded zero colony counts were recorded as <10CFU/mL 
The two direct extraction methods were quantitatively and qualitatively evaluated. The 
efficiency of a method was evaluated based on the runtime, DNA yield, purity and labour 
intensity. Cell densities were obtained from colony counts using the formula: Number of 
colonies x 20 (50 µl was inoculated into each segment) x dilution factor. DNA 
concentrations were determined using a qubit fluorometer and the yield was calculated 
from the concentration in 50 µl of DNA sample with results  presented as Mean ± SEM 
for each method. DNA purity was determined on a Nanodrop and results were also 
presented as Mean ± SEM. Significant differences were observed in the both the 
concentration and the yield of the different methods. The PrimeXtract kit produced both 
higher yield and concentration (Figure 4.1 and 4.2). Extraction with PrimeXtract resulted 
in a mean concentration (µg/mL) of 5.93 ± 0.94 (n=40) and DNA yield (µg) of 0.2975 ± 
0.04723, (n=40). By comparison the CTAB method produced a mean concentration 
(µg/mL) of 1.88 ± 0.38 ( n=40) and DNA yield (µg) of 0.09 ± 0.02 (n=40). Both 
concentration (P=0.0002) and yield (P=0.0002) from PrimeXtract were significantly 
higher than those obtained using the CTAB method. The PrimeXtract kit had a DNA 
purity (260/280) ratio of 1.69 ± 0.09  compared to the CTAB’s 1.73 ± 0.14, (n=40). 
PrimeXtract’s purity was lower than CTAB’s, although this result was not statistically 
significant (P=0.76). Purity values for the CTAB method however, were closer to the 
target purity range of 1.8-20.  
 
97 
 
 
Figure 4. 1 Concentrations of DNA extracted using two different methods 
DNA concentrations from two different extraction methods; the PrimeXtract kit 
(Longhorn Vaccines, USA) and an in- house CTAB method (n=40). Concentration was 
measured using a qubit fluorometer (ug/mL) 
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Figure 4. 2 Yields of DNA extracted using two different methods. 
Yields of DNA obtained using two different extraction methods: The PrimeXtract kit 
(Longhorn vaccines, USA) and an in-house method CTAB (n=40). Yields were calculated 
from concentrations (ug) 
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Figure 4. 3 Purity of DNA extracted using two different methods 
Purity of DNA obtained using two different extraction method: The PrimeXtract kit 
(Longhorn Vaccines, USA) and an in-house CTAB method (n=40). Purity was obtained 
using an ND-1000 Spectrophotometer Nanodrop. A 260/280 value of 1.8-2.0 was 
considered a pure preparation. Error bars represent standard error of the mean (SEM) 
 
Table 4. 1 Summary of results of DNA extraction using PrimeXtract and CTAB method  
 n=40 
Method  
  
 
Concentration(µg/ml)   Yield (µg)  
 
Purity 
260/280 
Cost 
/Sample 
Total 
Time 
     Mean ± SEM Mean ± SEM Mean ± SEM   $ Hours 
PrimeXtract           5.93± 0.94  0.29± 0.047 1.69± 0.09   5.76                  0.5 
CTAB      1.88± 0.38 0.09± 0.02 1.73± 0.14  0.39 7 
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One published study demonstrated that by employing a saline wash step in the 
extraction of Mtb  DNA from sputum, it is possible to significantly remove host 
contamination from the bacterial DNA and improve the overall purity of the output 
(Votintseva, Pankhurst et al. 2015). Since it was found in this study that increasing the 
starting cell density in the CTAB method resulted in corresponding increase in DNA 
output, an attempt was made to increase the cell density but apply the saline wash step 
to improve the DNA purity. By extracting DNA from 500 µl aliquots of 18 sputum 
samples it was revealed that the saline wash step significantly decreased the DNA 
output (Figure 4.4). Without the saline wash a mean concentration of  23.21 ± 6.154, 
(n=18) was obtained whereas with the saline wash it was 2.002 ± 0.5754, (n=18). There 
was a statistically significant difference (P=0.0016,unpaired t-test) between the 
concentrations of DNA obtained using the two methods. The mean DNA purity values 
(260/280) obtained by the two methods were 4.08 ± 0.985 (n=18) with the saline wash 
and 1.566 ± 0.1618 (n=18) with saline ( Figure 4.5). Again there was a statistically 
significant difference between the two methods (P=0.02, unpaired t-test). The saline 
wash step was consequently abandoned. 
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Figure 4. 4 Comparison of DNA concentrations obtained by CTAB method with and 
without a saline wash step 
 
 
   
 
 
 Figure 4. 5 Comparison of DNA purity obtained by CTAB method with and without a   
saline wash step 
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4. 3 Discussion 
In order to efficiently extract DNA for the purpose of sequencing choosing a suitable DNA 
extraction method is a critical step. With Mtb recovery of high molecular weight DNA is 
challenging even with relatively large volumes of cultured isolates.  
Furthermore, unlike other WGS technologies, SMRT sequencing uses native DNA 
without an amplification step. In order  to prepare a 10Kb insert library a minimum of 5µg 
of genomic DNA is typically required (Centre for Genomic Research, University of 
Liverpool ). This amount cannot be easily recovered from Mtb without a culture step. 
The PrimeXtract kit has been highly recommended for recovery of high molecular weight 
quality DNA directly from Mycobacterium tuberculosis clinical specimens(Longhorn 
Vaccines 2017). To date, no published study has evaluated the efficiency of the kit, either 
against other kits or an in-house extraction method.  
In the present work, it has been demonstrated that the PrimeXtract DNA extraction kit is 
superior to the CTAB method for the isolation of Mtb genomic DNA directly from 
sputum. PrimeXtract was capable of recovering both higher quantities and better purity 
DNA than the comparator in the 200µl sample under consideration. The superiority of 
PrimeXtract is demonstrated in almost all the samples evaluated  (Figures 4. 1-4. 3) where 
despite an equal amount of input material, it has consistently higher DNA yield and purity 
output. PrimeXtract uses a specialized lysis solution and wash buffers and aid to release 
the DNA and wash off any cell impurities. These are critical in release and clean-up of 
DNA. The sensitivity of the kit is enhanced by a silica-based spin column that traps the 
DNA during centrifugation though this format limits the amount of input material. The 
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other advantage of the kit is that it is easy to use with short centrifugation times (60 
seconds each) and the total time to complete the extraction procedure is only ± one hour . 
In the present study however, the kit was deemed unsuitable for SMRT sequencing. It 
could only recover less than the 5µg of extracted DNA which is the minimum the 
requirement for a 10Kb insert library preparation.  
The CTAB method has been shown to recover higher yields of DNA with good purity 
from clinical samples compared to other in house methods (Amita, Vandana et al. 2002). 
In this study this was not the case. Some studies have suggested that the CTAB method is 
efficient for DNA extraction from solid Mtb cultures (Amaro, Duarte et al. 2008). 
Successful isolation of Mtb DNA, especially from clinical samples, requires harsh 
treatment to weaken the cell wall. In this study the use of heating and immediate freezing 
to disrupt connections holding lipid contents of the cell wall together was employed. It is 
obvious that this did not work very well or that the reagents used by the kit were just 
superior. Other studies propose heating at 100°C in an appropriate buffer to achieve better 
results (Cormican, Barry et al. 1992). It has further been suggested that phenol and 
chloroform aids in improving the yield (Sjobring, Mecklenburg et al. 1990). The study 
avoided using phenol as residual phenol is incompatible with PacBio library preparation. 
Chloroform aids in denaturation of proteins and formation of a separating layer between 
aqueous and organic phases (Amita, Vandana et al. 2002). From experience the protein 
removal and DNA precipitation steps were appropriate as these have previously been 
successfully applied. Isopropanol was used to selectively remove DNA leaving RNA and 
other impurities. The remaining impurities were washed off from the DNA then using 
100% ethanol.  
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There were significant  variations among the samples on the purity obtained using the two 
methods (Figure 4. 3). These variations are expected as these samples were likely to have 
had different levels of impurities/contaminations. The CTAB method however had better 
mean purity value of 1.73, which is closer to the required range of 1.8-2.0 compared to 
the kit’s 1.69 which is lower. Since there was no use of phenol, the lower 260/280 ratio 
would most likely indicate protein contamination. This is suggestive of the fact that the 
chloroform step did not work properly.  
The CTAB method however has the advantage of being flexible with regard to volume of 
material and capacity for further optimization. It is possible to increase the cell density 
and successfully recover higher amounts of DNA. To improve purity however a 
eukaryotic DNA, clean up step may be necessary. Another point to consider in the choice 
of an extraction method would be the cost. The PrimeXtract kit costs $5.76 per extraction 
(Longhorn Vaccines 2017). Compared to other DNA extraction kits, $2.30 for Qiagen and 
$1.05 for Prepman (Aldous, Pounder et al. 2005) the PrimeXtract is much more expensive. 
Comparatively the CTAB method costs ~$0.39 per extraction (Lickfeldt, Hofmann et al. 
2002). Evidently the PrimeXtract despite being more efficient in terms of time, labour and 
quantity of DNA, is much more expensive that the CTAB method. It was observed that 
all samples had positive DNA concentrations despite some having zero CFUs. Though 
this discrepancy could simply be caused by release of mycobacterial DNA into the sample 
after cell death. It could also be as the result of a presence of persisters or resuscitation 
promotion factor (rpf) dependent cells which do not easily grow on solid media. Another 
challenge with the recovery of DNA using this approach is the use of a decontamination 
step during routine processing of the sputum samples. While decontamination greatly 
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reduces the risk of contamination from non-tuberculous bacterial and fungal organisms it 
is known to  greatly compromise recovery of Mtb, reducing the load of organisms by 1-2 
orders of magnitude (Sloan, D. 2013). 
The results from this study suggest that the PrimeXtract kit is superior to the CTAB 
method for direct extraction of Mtb DNA from sputum samples. With proper optimization, 
the PrimeXtract kit holds the potential to be used in direct DNA extraction from sputum 
for the purpose of SMRT sequencing. However, the technique is proprietary and relatively 
expensive. This study has previously sequenced cultured isolates using the CTAB method 
on the SMRT platform. For resource-poor settings where kits are not readily available 
CTAB will likely remain the method of choice.Current data however suggests it is 
possible to recover adequate amounts of DNA from direct CTAB extraction by increasing 
the amount of input material but a clean-up step will necessarily be required in order to 
achieve the required DNA purity.The saline wash step that was tested in this study was 
found to significantly negatively affect the DNA yield. More studies will be required to 
develop a DNA clean-up method for Mtb which while improving the purity of the DNA 
also maintains the required yield. 
The comparison of the two methods as presented here has some limitations. It is not 
possible to say with certainty that all the DNA recovered in this study was Mtb DNA as 
sputum will contain high levels of human and non-tuberculous DNA. The optimal clean-
up method for SMRT sequencing is an area requiring further research. 
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CHAPTER FIVE: GENETIC DIVERSITY OF MYCOBACTERIUM 
TUBERCULOSIS ISOLATES IN BLANTYRE, MALAWI 
5. 1 Introduction 
Despite the high burden of TB worldwide, specific factors responsible for disease 
transmission remain elusive. Long term epidemiological studies provide evidence of 
relative fitness of Mtb strains but few such studies are available (Cowley, Govender et al. 
2008).  Several methods are currently in use for molecular typing and lineage assignment 
of Mtb strains. Some studies have used insertion sequence 6110 restriction fragment 
length polymorphism (IS6110 RFLP) typing in Mtb epidemiology and the method was 
once regarded as the gold standard (Stavrum, Mphahlele et al. 2009). The validity of  data 
from IS6110 RFLP typing  has however  been hampered by the fast molecular clock with 
a short half-life of this method ~3.5 years (Glynn, JR, Alghamdi et al. 2010). Additionally, 
the method is labour intensive and suffers from poor inter-laboratory reproducibility. 
Mycobacterial interspersed repetitive units- variable number tandem repeats (MIRU-
VNTR) is a PCR based method which is faster than IS6110  RFLP and offers 
comparatively  higher discriminatory power (Supply, Philip, Mazars et al. 2000). For long 
term molecular trends, MIRU-VNTR in combination with spoligotyping has been 
efficiently used in the study of transmission and phylogenetic changes in Mtb.  
Spoligotyping is a hybridization assay that relies on absence or presence of unique spacer 
sequences separating copies of conserved 36 bp sequences (Gagneux, Small 2007). 
However with spoligotyping, homoplasy (convergent evolution of phylogenetically 
unrelated strains)  has been reported (Flores, Van et al. 2007, Rindi, Medici et al. 2014). . 
Additionally, it has been possible to describe Mtb lineages based on deletions and single 
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nucleotide polymorphisms (SNPs). Lineage classification from such studies has been 
closely consistent with families described from use of spoligotyping (Jagielski, van Ingen 
et al. 2014) 
Genomic deletions and rearrangements result in large sequence polymorphisms (LSPs) 
and in Mtb these are irreversible owing to non-existence of horizontal gene transfer 
between strains (Mathema, Kurepina et al. 2006,Coscolla, Gagneux 2014). LSPs are a 
robust molecular marker and are feasible as an epidemiological investigative tool. IS 
transposition has been associated with some deletions and such deletions are termed 
regions of difference (RD). A genomic deletion analysis of 875 global samples from 80 
countries revealed six Mtb phylogenetic lineages and 15 sub lineages. There was an 
association between each of the six lineages and a particular geographic region (Gagneux, 
DeRiemer et al. 2006, Reed, Pichler et al. 2009). A novel lineage restricted to the horn of 
Africa has been characterized in Ethiopia and is classified as  lineage 7 (Coll, McNerney 
et al. 2014). These lineages were comprehensively discussed in section 1.1.  Important 
RD loci  described in Mtb include RD9, RD105, RD207, RD239 and RD750 among others 
(Flores, Van et al. 2007). These deleted fragments can be used to discriminate between 
Mtb strains by  use of a simple PCR  method (Desikan, Narayanan 2015). The advantage 
of LSP or RD-PCR is that it can be used to screen large  numbers of strains in a high-
throughput manner (Gagneux, DeRiemer et al. 2006). Although all the above genotyping 
methods are useful, whole genome sequencing (WGS) has proved to be superior for many 
purposes (Brown, Bryant et al. 2015). WGS is the only tool capable of definitively 
assigning lineages to all Mtb strains as well as analyzing genomic diversity at all levels 
(RW.ERROR - Unable to find reference:644). Additionally, it can be used to track the 
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source of disease outbreaks and monitor transmission patterns (Brown, Bryant et al. 2015, 
Roetzer, Diel et al. 2013). 
 Genotyping Mtb strains is also important in  discriminating between disease relapses and 
new episodes, particularly in clinical trials (Stucki, Malla et al. 2012). In Malawi a few 
Mtb molecular epidemiological studies have been reported but these have mostly  been 
from the Northern Region of the country under the Karonga Prevention Study (KPS) 
(Glynn, JR, Alghamdi et al. 2010, Glynn, J. R., Crampin et al. 2005). Lack of laboratories 
with molecular tools has hampered efforts to conduct Mtb molecular epidemiology studies 
in Malawi and in most other low resource settings. Mtb molecular epidemiological data 
for the rest of the country is therefore currently lacking. The currently prevailing Mtb 
lineages for Malawi as a whole remain to be established and the impact of transmission 
patterns over time elucidated. 
 This chapter of the thesis aimed at performing a preliminary characterization of the 
genetic diversity of Mtb clinical isolates amongst patients presenting at Queen Elizabeth 
Central Hospital, Blantyre, Malawi the largest referral hospital in the country. 
Additionally, the study sought to correlate the identified lineages to clinical phenotypes 
observed in Mtb patients including phenotypic   drug tolerance.  
5. 2 Results  
5. 2. 1 Large sequence polymorphism (LSP)-PCR 
 Following a literature search of Mtb molecular epidemiological studies conducted in 
Malawi and the surrounding countries of Tanzania, Mozambique and South Africa over 
the last 15 years, primers were designed targeting the RDs of circulating lineages within 
the region (Geurra-Assuncao, Crampin et al. 2015, Cowley, Govender et al. 2008, 
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Mulenga, Shamputa et al. 2010, Viegas, Machado et al. 2013). These were RD239 for the 
Indo-Oceanic lineage, RD105 for the W-Beijing lineage and RD 750 for the East 
African/Indian lineage. Sixty-four bacteriologically culture confirmed Mtb positive 
samples were selected from a total of 133 isolates based on the ones to be successfully 
resuscitated from frozen state and subjected to genomic deletion analysis, as outlined in 
Chapter 2. The analysis revealed that six strains (9%) were of the Beijing lineage (RD 105 
deleted) generating a deleted product ~785bp on gel electrophoresis (Figure 5. 1), ten 
strains (16%) were of the Indo-Oceanic lineage (RD 239 deleted) with a deleted fragment 
of ~888bp (Figure 5. 2), two strains (3%) were of the East African/Indian lineage (RD750 
deleted) producing a deleted product of ~743bp and forty six strains (72%) were of the 
Euro-American lineage (Figure 5. 3).  
 It was not possible to design lineage specific primers for the Euro-American lineage, a 
common previously reported lineage in Malawi. Twelve out of the 46 isolates were 
therefore confirmed as Euro-American using whole genome sequencing. All other strains 
lacking deletions stated above were hence assumed to belong to the Euro-American 
lineage owing to the fact that this lineage was reported to be the most predominant in the 
region and has previously been reported at a high prevalence in Karonga (Geurra-
Assuncao, Crampin et al. 2015). Drug sensitivity testing of all the 64 isolates revealed that 
one sample had INH resistance while one another lineage was multi-drug resistant.  
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 Figure 5. 1 Gel electrophoresis of RD-105 deletion PCR 
Lanes 1 and 16, 2-Log DNA ladder (New England Biolabs). Lane 2 Blank (nuclease free water) as 
a negative control. Lanes 3-13, Clinical Mycobacterium tuberculosis DNA samples. Lanes 14-15 
H37Rv DNA as a positive control.  A deletion ~785bp observed in sample in lane 3 with a strong 
band. Samples in lane 5,8,10 and 11 were re-run to confirm that there was no deletion. 
 
 
Figure 5. 2 Gel electrophoresis of RD-239 deletion PCR 
Lanes 1 and 16, 2-Log DNA ladder (New England Biolabs). Lanes 2 and 3   H37Rv DNA as a 
positive control. Lanes 4-13 clinical Mycobacterium tuberculosis DNA samples. Lanes 14 and 15 
blank (nuclease free water). A deletion ~888bp was observed in lane 11 with a strong band. Lanes 
2,4, 10 and 13 were re-run to confirm there was no deletion as the bands were either faint or 
missing. 
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Figure 5. 3 Diversity of Mycobacterium tuberculosis in Blantyre, Malawi 
Proportions of Mtb lineages occurring in Blantyre.10 (16%) lineage 1(Indo-Oceanic), 6 (9%) 
lineage 2 (Beijing), 2 (3%) lineage 3 (East African/Indian) and 46 (72%) lineage 4 (Euro-
American). 
 
 5. 2. 2 Whole genome sequence analysis 
In this study, 18/64 Mtb clinical isolate genomes were completed using  SMRT sequencing 
and it was therefore possible to compare and confirm the results of genomic deletion 
analysis in this subset of the strains.The average sequencing coverage was ~x174 (range 
x35-460) with a mean read length of ~8kb (range 3.5-12kb) and a N50 read length of 
~12kb (range 5-24kb). In comparison with the Mtb H37Rv reference genome 
(NC_000962)  (Cole, S. T., Brosch et al. 1998) the 18 genomes showed >99.8% identity 
at the nucleotide level. In the phylogenetic analysis a total of 14353 SNPs were found in 
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the non-repetitive regions with one sample having 6909 SNPs not present in any other 
sample. These SNPs were   used to construct a genome-wide maximum likelihood tree 
(Figure 5.3). The tree comprised of three of the four Mtb lineages known to be present in 
Malawi (L1, L2 and L4). Three of the 18 strains belonged to lineage 1 (Indo-oceanic), 
3/18 to lineage 2 (East-Asian-Beijing) and 12/18 belonged to lineage 4 (Euro-American). 
No lineage 3 strain was found among the 18 sequenced strains. All lineage 4 Mtb strains 
have been reported to possess a 7 bp deletion in the pks15/1 gene (Gagneux, DeRiemer et 
al. 2006). Screening for this deletion in the 18 strains confirmed that indeed 12 of the 18 
strains belonged to lineage 4 (Figure 5. 4). Additionally, membership of lineages 1 and 2 
was confirmed by the presence of lineage specific mutations causing loss of 
methyltransferase activity (C758T and A809C respectively) as previously reported 
(Phelan, de Sessions et al. 2018). This analysis has been comprehensively described in 
section 6. 2. 8 
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Figure 5. 4 Phylogenetic analysis of the 18 sequenced Mycobacterium tuberculosis 
strains   from Blantyre Malawi.  
Strains clustered into 3 lineages (L1,2 and 4). Green indicates that strains belong to lineage 
1(Indo-Oceanic). Red indicates that strains belong to lineage 2 (East Asian-Beijing). Black 
indicates strains belong to lineage 4 (Euro-American). M.canettii was used as an outlier 
and the branch support values determined by 1000 bootstrap replicates. There are large 
deletions in all samples except L1 samples 12366_1,12366_9 and 12 (18501-13222 and 
18605-18877) 
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Figure 5. 5 Presence of a 7 bp deletion in the polyketide synthase (pks15/1) gene 
Six out of 18 samples 12366_1, 10,11,15460_8,12 and 12366_9 have an intact pks15/1 gene 
responsible for production of phenol glycolipids. Twelve out of 18 samples have a 7 base pair 
deletion at position 1461-1467 in the pks15/1 gene characteristic of lineage 4 (Euro-American 
lineage). Sample that has been identified as pks15 in the diagram was the reference obtained 
from an Indo-Oceanic lineage sample known to have an intact pks15/1 gene. 
 
5. 3 Discussion 
In this chapter 64/133 clinical isolates from patients presenting at a referral facility in 
Blantyre, Malawi were genotyped using genomic deletion analysis and 18 of these 
compared with classification according to whole genome sequencing. Four of the seven 
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known Mtb lineages were detected as circulating in Blantyre. The Euro-American lineage 
(lineage 4) is the most predominant of the Mtb lineages in Europe and America but has 
specific sub-lineages dominating in Africa (Rindi, Medici et al. 2014, Gagneux, DeRiemer 
et al. 2006). Results in this study and those done previously in Malawi (Glynn, JR, 
Alghamdi et al. 2010, Geurra-Assuncao, Crampin et al. 2015) demonstrate complete 
concordance with those done  in this region of Africa (Stucki, Malla et al. 2012). In the 
present study the lineage was identified as a default based on the absence of deletions RD 
105, 239 and 750 representing the East-Asian, Indo-Oceanic and East African/Indian 
lineages respectively which were previously identified in Malawi. The fact that no 
deletion analysis was done to confirm the number of isolates belonging to lineage 4 does 
not exclude the possibility that a novel lineage not previously reported in Malawi could 
be present. The probability of such a lineage being detected however appears low as 
Malawi is not presently a high burden TB country.  In addition membership of lineage 4 
can be confirmed by the presence of a short 7bp deletion (GCCGCGG) in the polyketide 
synthase (pks 15/1) gene and a CTG to CGG substitution in katG gene at position/codon  
463 (Gagneux, DeRiemer et al. 2006, Rindi, Medici et al. 2014, Marmiesse, Brodin et al. 
2004, Constant, Perez et al. 2002). The  deletion in the pks15/1 gene results in a frameshift 
mutation in the gene inactivating production of phenol glycolipids in a large group of 
Mycobacterium tuberculosis strains (Constant, Perez et al. 2002). Bioinformatic analysis 
of the 18 sequenced isolates in this study revealed the presence of this deletion in only 12 
of the 18 sequences further confirming the findings from the LSP assay. However, results 
from the study being reported here are largely in  agreement with previous studies done 
in Karonga (Glynn, JR, Alghamdi et al. 2010, Glynn, J. R., Crampin et al. 2005). In one 
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particular study from this region, out of 781 patients with a first episode of TB, 76% were 
Euro-American lineage (Glynn, JR, Alghamdi et al. 2010) while in another the lineage 
was found to occur at 68% (Geurra-Assuncao, Crampin et al. 2015). A proportion of 
lineage 4 isolates could not be definitively confirmed using pks15/1 deletion as these were 
not sequenced but they are very unlikely to be any other lineage. The Euro-American 
lineage appears to be the predominant lineage in Malawi based on data from these few 
studies although more studies are necessary to increase the power of these data.  
Lineage 1 (Indo-Oceanic) was found to be present in 16% of patients in this study, 
consistent with reports from Karonga (Geurra-Assuncao, Crampin et al. 2015). Similarly, 
phylogenetic analysis (SNPs and indels) confirmed that three of the isolates that were 
identified as belonging to lineage 1 (Indo-Oceanic) using LSP-PCR were indeed of this 
lineage. These isolates also possessed less deleted sequences characteristic of ancient Mtb 
strains compared to the other sequences as previously documented (Brosch, Gordon et al. 
2002). Again, membership of this lineage could further be confirmed by loss of a 
methyltransferase mamB attributed to a missense mutation in the Rv2024c gene (Zhu, 
Zhong et al. 2015) as discussed in section 6.2.8. Although lineage 1 has global prevalence, 
it is more common in East Africa and the Indian sub-continent (Duarte, Nery et al. 2017). 
Karonga is easily accessible from the East African country of Tanzania which has a higher 
prevalence of this lineage and so the expectation might have been that a higher prevalence 
of this lineage would have been observed than in Blantyre. However, the relatively small 
number of isolates available means that significant uncertainty about the prevalence and 
transmission of lineage 1 within Malawi remains.  
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The Beijing strain (East Asian lineage) has been reported to be widespread globally and 
may be associated with increasing  drug resistance in some regions (Stavrum, Mphahlele 
et al. 2009). The RD 105 LSP is the universally accepted marker of the Beijing lineage 
although this deletion has also been reported in some isolates with non-Beijing 
spoligoprofiles (Flores, Van et al. 2007).This lineage was previously specifically 
associated with an intact pks15/1 sequence and production of phenolic glycolipid, which 
has been proposed as an important virulence factor, until an intact sequence was reported 
in non-Beijing Mtb clinical isolates  in Thailand(Alonso, Borrell et al. 2008). A later study 
suggested that the intact pks15/1 sequence could be a marker of isolates originating from 
Asia rather than a general marker of the Beijing lineage (RW.ERROR - Unable to find 
reference:639). The study being reported here did not use the pks15/1 marker to 
specifically discriminate isolates belonging to the Beijing lineage. Rather, RD105 which 
is believed to be a more robust marker of the Beijing lineage was used. In WGS analysis, 
the phylogenetic tree constructed from SNPs and indels confirmed that 3/18 isolates 
belonged to lineage 2. Additionally, methylation analysis revealed that these three samples 
lacked the mamA methyltransferase owing to a point mutation in the Rv3263c gene (see 
section 6.2.8). This mutation is known to be present only  in lineage 2 clinical isolates 
(Shell, Prestwich et al. 2013).   
In Malawi, the Beijing genotype has previously been reported with proportions of patients 
at ~2% and no association with drug resistance has been reported (Glynn, JR, Alghamdi 
et al. 2010). All the Beijing strains from the current  study were drug sensitive which is 
consistent with the study from Karonga (Geurra-Assuncao, Crampin et al. 2015). While 
the Beijing strain has been associated with increasing drug resistance in South Africa 
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(Cowley, Govender et al. 2008), such an association is yet to be established in Malawi, 
possibly because the overall prevalence of drug resistance is low by regional standards 
and lineage 2 remains relatively rare to date. The Beijing lineage was also found to be 
more prevalent among HIV positive individuals in South Africa and Mozambique 
(Middelkoop, Bekker et al. 2009, Viegas, Machado et al. 2013). The results of the 
published data in Malawi have differed in that no association with HIV could be 
established (Geurra-Assuncao, Crampin et al. 2015). The results presented in the current 
study may appear to suggest a higher prevalence of the Beijing genotype at 9% in Blantyre 
compared to 4% in Karonga (Geurra-Assuncao, Crampin et al. 2015)  however it should 
be recognised  that the sample size in this study was quite small. A larger sample size 
would be necessary to definitively confirm these findings. However, the apparently higher 
prevalence of the Beijing lineage in Blantyre compared to Karonga could be attributed to 
the fact that Blantyre is an urban setting where transmission rates are likely to be higher. 
Furthermore Blantyre has a higher geographical accessibility to South Africa and 
Mozambique where the Beijing lineage has been reported at a higher prevalence  
(Middelkoop, Bekker et al. 2009, Viegas, Machado et al. 2013).  
A study of strains from histological samples from a 76-year period in South Africa 
demonstrated that the Beijing strain was a recent arrival in the country. The Beijing strain 
was found to be absent in samples from 1930-1965 and more common in samples from 
1996-2005 (Cowley, Govender et al. 2008). From these data, it would be reasonable to 
infer that a similar trend could ocuuring in Malawi as there is significant of regional 
migration between Malawi and South Africa. A study from Karonga suggests that the  
Beijing lineage may  have only recently arrived in Malawi compared to other 
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Mycobacterium tuberculosis lineages (Glynn, JR, Alghamdi et al. 2010). The spread of 
Beijing in Malawi could also be attributed to recent influx of people of Eastern-Asian 
ethnic background involved in road construction and trade. Additionally, there has been 
an increase of Malawian business people travelling to China over the past few years. A 
country-wide study on the diversity of Beijing strain in Malawi will be needed to fully 
confirm the current prevalence of this lineage and its drug sensitivity profile and to 
monitor trends in its representation among cases of tuberculosis in Malawi in the future. 
(Zhu, Zhong et al. 2015)(Zhu, Zhong et al. 2015)(Zhu, Zhong et al. 2015)(Zhu, Zhong et 
al. 2015) 
Overall the data presented in this chapter reveal that results from lineage assignment using 
WGS of the 18 sequences were in complete concordance with those obtained from LSP-
PCR. It could therefore be reasonably inferred that the rest of the lineage assignment from 
LSP-PCR was reliable.  
Although Mtb lineages are associated with a specific geographical location, Africa is the 
only region where all the lineages are represented consistent with the evolutionary theory 
that the pathogen Mtb  originated from  Africa (Gagneux, DeRiemer et al. 2006).  
Although LSP-PCR analysis appears to be consistent with WGS analysis, the method has 
a number of limitations and newer methods are needed. The power of WGS in TB 
transmission surveillance and control has previously been documented (Roetzer, Diel et 
al. 2013). With increasingly widespread use of WGS sequencing, it is only proper that 
definitive molecular characterization of Mtb make use of WGS in all areas where such 
tools exist. 
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CHAPTER SIX: CHARACTERIZATION OF DNA METHYLATION 
IN CULTURED MTB ISOLATES USING SMRT SEQUENCING 
6. 1 Introduction 
The aim of this chapter of the thesis was to investigate whether epigenetic mechanisms 
specifically, DNA methylation could play a role in Mtb persistence. Although Mtb strains 
have been shown to exhibit nucleotide level similarity of >99% (Hershberg, Lipatov et al. 
2008) such similarity is rarely replicated in the phenotype. This phenotypic heterogeneity 
has been seen in the virulence of the Beijing strain which has been associated with 
increasing MDR-TB (van der Spuy, Kremer et al. 2009) whereas the  East African Indian 
(EAI) lineage has been associated with lower rates of transmission compared to other 
lineages (Albanna, Reed et al. 2011). Similarly, the  Euro-American lineage is the most 
geographically successful strain (Coscolla, Gagneux 2014) but specific reasons for this 
phenotype remain unknown. Phenotypic heterogeneity in Mtb has been associated with 
epigenetic inheritance (Balaban, Merrin et al. 2004) and the most common epigenetic 
mechanism in Mtb is DNA methylation (Shell, Prestwich et al. 2013). This chapter 
therefore sought to characterize DNA methylation patterns within the Mtb genome. This 
characterization is important as some studies have demonstrated that DNA methylation 
plays a critical role in gene expression and long term survival of Mtb under hypoxic 
conditions (Shell, Prestwich et al. 2013). Furthermore, the link between DNA methylation 
and Mtb persistence has not yet been explored  (Shell, Prestwich et al. 2013). The persister 
phenotype is not genetically inherited (Balaban, Gerdes et al. 2013) suggesting that here 
could be some other as yet unknown mechanisms responsible for this phenotype. The 
characterization of the Mtb methylome in the current study was specifically done on 
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clinical isolates, this enabled selection of strains and samples most closely related to a 
clinical definition of persistence and also because if DNA methylation indeed a has a role 
in Mtb persistence, this could have important implications for treatment outcomes. 
Understanding the biology of persisters remains among the most important barriers to 
shortening of Mtb treatment regimen. 
DNA methylation in prokaryotes is  widespread and is identified by diverse modification 
types such as 6methyladenine(m6A), N-4methylcytosine(m4C), N-
5methylcytosine(m5C) among others. DNA methylation is regulated by 
methyltransferases which target specific sequence motifs (Sater, Lamelas et al. 2015). 
DNA methylation has been associated with pathogenicity and virulence in Salmonella 
enterica (Wion, Casadesus 2006). In Mtb it was previously proposed that DNA 
methylation had a role in virulence as cytosine methylation was found to be present in the 
virulent strain H37Rv but absent in the avirulent H37Ra (Srivastava, Gopinathan et al. 
1981). However later reports seem to be inconsistent with this finding (Naidu 2014) as no 
compelling evidence was found to associate methylation to virulence in Mtb. A recent 
study has established a possible role of DNA methylation in the long term survival of Mtb 
under anaerobic conditions (Shell, Prestwich et al. 2013) and this link requires further 
investigation. The advent of SMRT sequencing has made it possible to determine novel 
DNA modifications in prokaryotes and more importantly to study it globally across the 
genome and not just in specific genes. In resequencing of six bacteria using SMRT 
sequencing, new DNA methylation sites were discovered and their cognate methyl 
transferases assigned (Murray, Clark et al. 2012). Although the study of DNA methylation 
in Mtb using SMRT sequencing is becoming an area of active research (Zhu, Zhong et al. 
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2015), to date no  published study has so far investigated its association with persistence 
in Mtb. 
In this chapter, the aim was to characterize the complete DNA methylome of Mtb using 
Pacific Biosciences SMRT sequencing with the specific objectives: 
 
 To identify and characterize the different types of DNA base modification (DNA 
methylation) in Mtb 
 To identify the DNA sequence motifs in Mtb and their cognate methyltransferases 
 To compare DNA methylation patterns in genic and intergenic regions between 
treatment failures  and successes (“persisters” and “non-persisters”). 
 To compare DNA methylation patterns between promoter regions of “persisters” 
and “non-persisters” and stability of methylation under different growth conditions 
including within different lineages. 
6. 2 Results  
In order to perform a preliminary characterization of Mtb methylation patterns four 
confirmed drug susceptible Mtb clinical isolates from a previous  study (Sloan, 
Mwandumba et al. 2015)  were selected. Two of the isolates had an outcome of treatment 
failure and were  rich in lipid body content (putative “persisters”), while the other two had 
treatment success with lipid poor in body content (non-persisters). Phenotypic drug 
tolerance and accumulation of lipid body content are putative markers of Mtb persistence. 
The aim was to conduct a global comparative analysis of the methylation patterns between 
treatment failures (“persisters”) and successes (“non-persisters”) and try to establish a 
possible role of DNA methylation in the persistence phenotype. It was not possible to 
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resuscitate the targeted number of failures (“persisters”) from frozen samples and 
therefore comparison of “persisters” and “non-persisters” was only limited to four clinical 
isolates. Strains were resuscitated from a frozen state in liquid culture media before 
transferring to solid culture media. All the data and the analysis from this study are 
available online at https://github.com/codemeleon/MtbMethylationProfile. 
6. 2. 1 Comparative bioinformatics analysis of “persister” and “non-persister” Mtb 
isolates  
Four clinical isolates were sequenced using SMRT sequencing technology at the Centre 
for Genomic Research (CGR), University of Liverpool. The average sequencing genome 
coverage for the four isolates was ~ 352X. All genomes were analyzed using the SMRT 
portal software provided by the manufacturer (version 2.2.0). Through sequence 
alignment with the reference genome H37Rv and kinetic data analysis, it was possible to 
accurately detect m6A methylated DNA sequence motifs in the genomes of the four 
isolates (Table 6. 1). Some weak m4C signals could be detected but with very low IPD 
ratio and no specific pattern. No m5C could be detected. Some bases could only be 
reported as “modified” without a specific methylation pattern. The bases reported as only 
“modified” could not be experimentally verified, but previous studies have confirmed 
using WGS based on multiple displacement amplification that such modifications are in 
actual fact false positives (Zhu, Zhong et al. 2015). Additionally, such modified bases had 
low IPD ratios (average <5).This might  indicate that they could have been as a result of 
sequencing errors (Naidu 2014). All modifications with bases reported only as “modified” 
or with low IPD ratios (<5) were therefore excluded from further downstream analysis. 
Two 6mA motifs (CTCCAG and CACGCAG) 5’ to 3’ direction; (a base with methylation 
124 
 
was indicated by A) were detected using SMRT portal analysis in all the four isolates 
(Table 6. 1). The motif CTGGAG is a partner motif for CTCCAG. The modifications in 
these motifs had apparently higher IPD ratios (average >5) compared to those reported 
only as “modified” at <5. Additionally, they had high motif site ratios of ~0.80-0.98 (Table 
6. 1). There were some exceptions to this and have are discussed below (Section 6.2.2). 
 
 
 
Table 6. 1  Motifs and Modifications within “persisters” and “non-persisters” 
Motif Modification        Motif site ratio* Mean IPD ratio 
  “persisters” 
“non-
persisters”  
          
CTCCAG 6mA 0.97  0.98 6.5 
CACGCAG 6mA 0.97  0.98 6.2 
CTCCAGB 6mA 0  0.69 2.9 
CTCCAGA 6mA 0  0.31 2.1 
AGGCMGYA Modified 0.43  0.38 1.9 
GARVDTKGV Modified 0.19  0.9 1.9 
TNNNNNNH Modified 0.4  0.5 1.7 
TVNVNNNG Modified 0.2  0.2 1.7 
*Motif site ratios were computed as the average of two isolates 
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6. 2. 2 Occurrence of methylated motifs within persister and non-persister isolates 
 The occurrence of methylated motifs within “persisters” and “non-persisters” was first 
investigated. The two “persister” isolates (9909_1 and 9909_2) were sequenced at a mean 
motif coverage of ~145X and 225X respectively. Two predicted m6A motifs were 
detected at a similar proportion of ~97% and an IPD ratio of ~6-7 (CTCCAG, and 
CACGCAG) 5’ to 3’ direction. Motif CTGGAG (5’ to 3’ direction) a palindrome of 
CTCCAG, was detected at an average proportion of 95% and a lower IPD ratio of ~5 only 
(Table 6.1 and 6.2). This suggests that some sites with this motif remained unmethylated. 
A search for genes homologous to known methyltransferases in the database of 
prokaryotic enzymes REBASE (Roberts, Vincze et al. 2015) was conducted. This search 
led to identification of the gene Rv3263 which encodes the enzyme Mycobacterium 
Adenine Methyltransferase A (MamA) termed M. MtuHIII (according to standard 
nomenclature) which target the motif CTCCAG. This sequence motif  was also detected 
by  Shell in  the Mtb reference strain H37Rv of the Euro-American lineage (Shell, 
Prestwich et al. 2013) and MamA was implicated. An asymmetric m6A motif CACGCAG 
was also detected in all of the four isolates and predicted to occur 820 times in the genome. 
It was detected as being methylated >97% across the four isolates (Table 6.2). CACGCAG 
is a non-palindromic methylated Type II RM system motif (Naidu 2014). A search for this 
motif in the REBASE database for H37Rv yielded nothing. However, the motif was found 
in the REBASE database for Beijing strain with its target methyltransferase termed 
MtuBEORF5175P according to standard methyltransferase nomenclature (Roberts, 
Vincze et al. 2015). The two “non-persister” (9909_3 and 9909_4) isolates were 
sequenced at mean motif coverages of ~179X and 145X respectively. While one of them 
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(9909_4) had similar proportion of methylated motifs and IPD ratios to the “persisters” 
the other (9909_3) was different in that it had an additional unique motif . Notwithstanding 
the fact that the average motif sequencing coverage was high (~ 179X), a rare motif 
CTCCAGB was detected, predicted to occur 1738 times in the genome and detected to be 
methylated only 1194 (69%) times in 9909_3 
. This motif could not be detected in the other three isolates. Furthermore, the IPD ratio 
for this motif was a low (2.9) signifying a weak signal. This motif is similar to a type II 
H37Rv Restriction Modification motif CTCCAG but with just an extra seventh base at 
the end. Another motif similar to CTCCAGB but having the seventh base B replaced by 
an A (CTCCAGA) was detected in this isolate. It was predicted to occur in 1947 sites 
within the genome and was detected as methylated only 209 (11%) times in the genome 
of the isolate. This isolate was shown to be methylated at 64 sites (30%) compared to 
~98% methylation in the other three isolates for  motif CTCCAG. Additionally, this motif 
(CTCCAGA) had a low IPD ratio of ~2, compared to >6 in the other three isolates.  
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Table 6. 2 General genome methylation for 4 Mtb clinical isolates 
           Sequence Motif             
Sample ID                       CTGGAG  CACGCAG              
      No. of  motifsa 
% modified 
motif No. of  motifs   
% modified 
motif 
9909_1   1947  95  820   97  
9909_2   1947  97  820   98  
9909_3   1947  58   820   97   
9909_4   1947  98  820   98  
a The number of motifs only represents a single strand 
 
Across all the four isolates, an unknown motif (AGGCMGY/AKGCMSY) predicted to 
occur a variable number of times (average 0.38-0.42)  was detected (Table 6.1). No further 
analysis for this motif was conducted due to a very low IPD ratio of ~2 and unspecified 
methylation pattern. Another unknown motif ADDTRGC was detected in one “persister” 
(9909_2) and one “non-persister” (9909_3). Again due to a low IPD ratio and non-specific 
methylation pattern, no further analysis was done.  
Since the aim was to conduct a comparative analysis of the methylation patterns between 
“persisters” and “non-persisters”, the first to be investigated was methylation occurrence 
by gene strand. Some motifs occurred as methylated palindromes (CTGGAG) on both 
strands while others were found only on a single strand (CACGCAG). Occurrence of 
methylation across these strands was variable. The most highly methylated gene was 
found to be  Rv2524c with 21 sites methylated with a large number of genes having zero 
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methylation. According to Table 6.3, no significant differences could be detected between 
“persisters” and “non-persisters” in total adenine methylation within the genic (coding) 
regions by strand (χ2 test with Yates correction, p = 0.20). Strand specific adenine 
methylation ranged between 49%-51% of the genic methylation in both “persisters” and 
“non-persisters”. Genic methylation comprised an average ~80% of the total genome 
methylation in both “persisters” and “non-persisters”. Evidently there is sharing of 
methylation sites between “persisters” and “non-persisters” and only a few sites are 
uniquely methylated. 
 
Table 6. 3 Methylation within genic regions in “persisters” and “non persisters” by strand 
Χ2 test with yates correction p = 0.20 Sample ID. Positive strand Negative strand %Total   
 No. of sites (%) No. of sites (%)  
9909_1 (“Persister”)  1533 (51)  1487 (49)  81% 
9909_2 (“Persister”)  1711 (50)  1692 (50) 80% 
9909_3(“Non- 1262 (49) 1315 (50) 79% 
9909_4(“Non-  1566 (50) 1572 (50) 81% 
  
Next was the analysis of methylation patterns within the intergenic regions of the four 
isolates. Intergenic regions were defined as any non-coding region between two gene 
regions. An analysis of the intergenic methylation revealed that 19%-21% of the whole 
genome methylation occurred within the intergenic regions across the four isolates (Table 
6.4). Strand specific methylation showed that the positive strand was slightly more 
methylated at 51% compared to the negative strand at 49% across all the four isolates 
although this difference was not statistically significant across the isolates (Fisher’s exact 
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p=0.90). This difference could be as a result of some sites of the strand remaining hemi-
methylated following cell division. 
 
Table 6. 4 Methylation within intergenic regions in persisters and non  
persisters by strand  
( Fisher’s exact p = 0.90)  
 
Sample ID. Positive strand Negative strand   
 No.of sites, (%)  No. of sites, (%) 
Total Intergenic 
Methylation 
%Intergenic 
Methylation 
     9909_1(“Persister”) 350 (51) 347 (49) 697 19% 
     9909_2(“Persister”) 418 (51) 416 (49) 834 20% 
     9909_3 
(“Non-Persister”) 356 (51) 346 (49) 702 21% 
     
9909_4 
(“Non-Persister”) 372 (51) 371 (49) 743 19% 
     
 
 Promoter regions are normally regarded as regions in the genome 10bp to 35bp upstream 
of the transcription start site (TSS)(Newton-Foot, Gey van Pittius 2013). It is in the 
promoter sequence where the RNA polymerase enzyme interacts during transcription 
thereby regulating the transcription process. Promoters are variable in length and in this 
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study promoter regions were defined as the region 100bp upstream of the TSS. Mtb genes 
occur in clusters called operons and each operon is under the control of promoter of the 
head gene (Lim, Lee et al. 2011). In this study promoters were considered as part of the 
intergenic sites. Methylation within promoter regions affects gene expression and 
eventually phenotype (Wion, Casadesus 2006). Adenine methylation sites have been 
shown to overlap with promoters of some genes thereby regulating expression of such 
genes (Shell, Prestwich et al. 2013). Shell et al. found that mamA sites in promoters 
overlapped with the sigma factor -10 binding sites regulating the expression of the 
involved genes. Additionally, mamA deletion mutants did not display transcription 
changes suggesting a significant role of DNA methylation. 
The effect of gene promoter methylation specifically on Mtb persistence has not been 
previously characterized using PacBio SMRT sequencing technology or any other 
technology. The main interest was to investigate if methylation between “persisters” and 
“non-persisters” occurred differentially within promoter regions and if there was any 
differential occurrence by strand. Methylation of promoter regions was analyzed in 
proportion to overall methylation within intergenic regions (Table 6.5). The results reveal 
that promoter methylation in all the four isolates ranged between 39% to 41% of the total 
intergenic methylation and there was no differential methylation by persistence (Fishers 
exact, p= 0.8) (Table 6.5). Strand specific promoter methylation ranged between 46% and 
54% within the four isolates. This methylation again was highly variable between the 
strands and there was no overrepresentation by strand (Fishers exact, p =0.5) for 
“persisters” and (Fishers exact, p = 0.9) for “non-persisters” respectively. 
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Table 6. 5  Methylation within promoter regions by strand for persisters and non-persisters 
compared to the rest of intergenic region. 
(Fishers exact, p= 0.8) 
Sample ID. 
Positive 
strand 
Negative 
strand     
    
No. of sites   
 ( %) 
No.of sites  
 ( %) 
Total 
Promoter 
Methylation 
% Promoter 
Methylation 
9909_1 
(“Persister”) 144/276 (52) 132/276 (48) 276/690 40% 
      
9909_2 
(“Persister”) 158/323 (49) 165/323 (51) 323/828 39% 
9909_3      
(“Non-Persister”) 159/273 (51) 134/273 (49) 273/700 39% 
9909_4       
(“Non-Persister”) 164/306 (54) 142/306 (46) 306/746 41% 
 
The assumption is that methylation occurring in intergenic region has restriction 
modification function rather than a  regulatory function. Although there was no significant 
difference in overall promoter methylation between “persisters” and “non-persisters”, it 
was observed that the exact location of this methylation varied between the two classes of 
isolates. An average 67 (21%) out of 323 m6A sites within promoter regions were 
uniquely methylated to “persisters” while an average of 50 (16%) out of 306 m6A sites 
were uniquely methylated to “non-persisters”. Genes whose operon sites were uniquely 
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methylated in both “persisters” and “non-persisters” were investigated further. The study 
focuses on the persister induced genes. 
6. 2. 3 “Persister” gene and promoter methylation 
An analysis of SNPs and indels  within persister and non persister isolates revealed 6700 
variants between the genomes of the two groups. A total of 697 only were SNPS  
suggesting a large number of variants were deletions. Multiple sequence analysis of the 
selected 15 genes previously associated with persistence (Keren, Minami et al. 2011, Sala, 
Bordes et al. 2014) against the reference genome H37Rv revealed perfect match. No SNPs 
and indels were identified in either persisters or non-persisters. 
Several genes have been implicated in the entry and maintenance of persister phenotype 
within the Mtb cells (Georgiades, Raoult 2011, Sala, Bordes et al. 2014). These include 
toxin-antitoxin modules whose transcriptome was shown to be induced under persistence 
(Keren, Minami et al. 2011) and members of the dosR regulon which have shown  
upregulation during the dormant infection model (Voskuil, Schnappinger et al. 2003).   It 
has been previously reported that methylation of some motifs within the -10 Sigma factor 
binding site promoter region led to differential expression of the genes concerned in 
response to hypoxia (Shell, Prestwich et al. 2013). In this study, methylation was 
associated with long term survival of Mtb under hypoxia. Interestingly hypoxia has also 
been associated with activation of persistence genes including the dosR regulon (Voskuil, 
Schnappinger et al. 2003). Genes and pathways that have previously been implicated in 
persistence were of interest to this study. The aim was to investigate if promoter regions 
of such genes could be differentially methylated in the “persister” isolates in comparison 
to “non-persisters”. The analysis revealed that in general, promoter regions of “persister”  
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genes had low methylation (39-41%) in comparison to the rest of intergenic region (Table 
6.5). Could persistence be due to methylation within promoters of key genes in “persister” 
cells? To answer this question, it was necessary to pinpoint the specific genes whose 
operons had the promoter region methylated.   
6. 2. 4 Specific location of differentially methylated gene promoters in persisters 
Although it was found that the four isolates were proportionally equally methylated, 
further analysis revealed that this methylation was differentially distributed along the 
genomes of “persisters” and “non-persisters”. Sixty seven out of 323 promoter sites were 
found to be differentially methylated in “persisters” as opposed to “non-persisters” and it 
was important to further investigate the specific genes under the regulation of these 
promoters. The analysis revealed that all Mtb genes whose promoters were differentially 
methylated in “persisters” could be clustered into: cell wall and cell wall processes (33%), 
virulence detoxification and adaptation (22%), intermediary metabolism and respiration 
(25%), transcription and regulatory (1%), information pathways (9%), and conserved 
hypotheticals and unknown (4%) (Figure 6. 1). A gene ontology (GO) pathway 
enrichment analysis of 67 differentially methylated genes in persisters revealed that none 
of the categories were over-represented (p-value <0.05 Fishers exact with FDR multiple 
test correction). Previously an analysis of the Mtb persister transcriptome had shown a 
downshift in metabolic and biosynthetic pathway, characteristic of dormancy (Keren, 
Minami et al. 2011). In that study, Mtb cells in log phase were exposed to D-cycloserine 
and a transcriptome of the surviving cells obtained. There was a marked downshift in 
metabolic and biosynthetic pathways accompanied by induction of a characteristic set of 
genes. Could this massive downshift be as a result of promoter methylation in genes 
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regulating these pathways? It was important to investigate if methylation in these genes 
could be correlated to the characteristic metabolic downshift observed in the Mtb 
transcriptome under conditions of persistence. Analysis of promoters revealed that both 
the dosR genes and the TA modules were largely non-methylated. Out of all the genes 
induced in persistence (Keren, Minami et al. 2011, Sala, Bordes et al. 2014), hspX (the 
heat shock protein) was the only gene found to be methylated at a single site in each of  
all the four isolates while its homologue acr2 was methylated in only one non-persister 
isolate. Other genes with a single methylation were gntR (Rv1152) and Rv3290c 
possessing a site each in 9909_2 and 9909_3 respectively (Table 6. 6). Low promoter 
methylation could be indicative of unperturbed gene expression. In absence of 
corresponding transcription data, it would be impossible to determine if any of the 
methylation patterns  in the promoters may have affected gene expression in either 
persisters or non-persisters. Naidu found the promoter for operon of mymA (Rv3083-
Rv3089) to be differentially methylated in the hyper-virulent strain of Beijing strain and 
suggested it could play a key role in adaptation to acidic stress and persistence within 
macrophages (Naidu 2014). This operon was found to be unmethylated in all the four 
strains in this study. 
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Figure 6. 1 Pathways differentially methylated in persisters  
Cell wall and cell processes 22(33%),virulence detoxication and adaptation 
15(22%),intermediary metabolism 17(25%),information pathways 6(9%) conserved 
hypotheticals 3(4%), transcriptional regulatory 1(1%) and unknown 3(4%) 
 
Table 6. 6  Methylation within promoter regions of selected persister related genes 
Genes  Persisters Non-Persisters 
 9909_1 9909_2 9909_3 9909_4 
RelBE1 0 0 0 0 
RelBE2 0 0 0 0 
MazEF1 0 0 0 0 
MazEF5 0 0 0 0 
MazEF6 0 0 0 0 
hspX 1 1 1 1 
dosR 0 0 0 0 
dosS 0 0 0 0 
acr 0 0 0 0 
gntr 0 0 1 0 
Rv3290c 0 0 0 0 
pkdA 0 0 0 0 
Rv2517 0 0 0 0 
Rv3290c 0 1 0 0 
RelEB3 0 0 0 0 
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6. 2. 5 Differential methylation within persister related genes 
 Analysis of sites in gene coding regions that have previously shown to be induced during 
Mtb persistence (Sala, Bordes et al. 2014, Keren, Minami et al. 2011) revealed that a few 
genes were differentially methylated in persisters as opposed to non-persisters (Table 6.7). 
A total of 180 different sites were found to be methylated within the 15 genes under 
analysis. One hundred and twelve sites were shared between persisters and non persisters. 
RelBE1 (Rv1246c-1247c), a TA module had a single site differentially methylated in non-
persisters while two other different sites were common between persisters and non-
persisters. In RelBE2 (Rv2865-2866) another TA module, no single  site was  found to be 
differentially methylated in both persisters  and non-persisters.  Rv2517, whose product is 
a hypothetical protein with unknown function (DeJesus, Gerrick et al. 2017) had only one 
methylated site shared between persisters and non persisters.  Rv3134c, which  encodes a 
universal stress protein, acr2 which encodes a heat shock protein and dosR which encodes 
a two component regulatory protein (DeJesus, Gerrick et al. 2017) were each found to 
have a single site differentially methylated in persisters. Rv3290c which encodes a L-
lysine-epsilon aminotransferase possessed two sites which were  methylated in persisters. 
Other persister induced genes including  TA modules RelBE3,  MazF1, MazF5, MazF6 
and gntR were non-methylated in both persisters and non-persisters. 
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Table 6. 7 Sites differentially methylated within selected persister related genes  
Gene Sites methylated 
in persisters only 
Sites methylated 
in non-persisters 
only 
Sites shared 
RelBE1 0 1 2 
RelBE2 0 0 0 
MazF1 0 0 1 
MazF5 0 0 4 
MazF6 0 0 0 
hspX 
dosR 
0 
1 
0 
1 
0 
0 
dosS 0 1 2 
Rv3134c 1 0 0 
Acr2 1 0 1 
gntR 0 0 0 
bkdA 1 0 2 
Rv2517 0 0 1 
Rv3290c 
RelBE3 
2 
0                             
 
0 
0 
0 
0 
 
Total 38 30 112 
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6. 2. 6 Stability of methylation patterns in Mycobacterium tuberculosis genome under 
different growth conditions 
Since the gene expression profiles of in vitro Mtb was shown to be different from that 
found in sputum (Garcia, Loxton et al. 2016), it was hypothesized that the methylome of 
the cultured Mtb clinical isolates could as well be different to that of similar isolates during 
infection. It has been suggested that culturing Mtb cells may introduce mutations in the 
genome (Bjørn-Mortensen, Zallet et al. 2015) consequently impacting on the methylation 
patterns. In order to know for sure, an attempt was made to sequence directly from sputum 
and determine if the methylome profile of sputum Mtb would be different to that in culture. 
A PrimeXtract DNA extraction kit was used for this purpose as it has been previously 
claimed to achieve sufficient amounts of DNA for WGS (Longhorn Vaccines 2017). 
Sufficient DNA for SMRT sequencing was obtained but expert advice compelled the 
study not to proceed with sequencing due to possibility of  high host DNA contamination 
(data not shown). As an alternative, a decision was made  to interrogate if the methylation 
patterns observed within Mtb would  remain stable under different growth conditions. To 
do this, in addition to isolates 9909_1- 9909_4, a further 14 cultured clinical isolates were 
SMRT sequenced (Table 6.9). These were again selected based on the one that grew first. 
The average genome sequencing coverage for the 18 isolates being ~173X. Two of these 
(12366_10,12366_11) were cultured in a MGIT tube for up to six weeks while the rest 
were cultured on LJ slopes and harvested after eight weeks. Lineage assignment revealed 
that 12 samples belonged to lineage 4 while 3 each belonged to lineage 1 and 2 
respectively. The aim was to compare DNA methylation patterns between MGIT cultured 
isolates and those cultured on LJ slopes. It was not possible to efficiently sequence from 
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the rest of the MGIT cultured isolates as the DNA failed to pass the sequencing quality 
control stage and therefore only two were selected for analysis. Since it had been 
established in section 6.2.2 that methylation patterns within Mtb strains were largely 
similar, four isolates were selected for comparison, two MGIT cultured 
(12366_10,12366_11) and two LJ cultured (12366_1,12366_13). The selection was based 
on which one grew first and had sufficient DNA yield for SMRT sequencing. 
6. 2. 7 Comparison of MGIT and LJ cultured isolates 
Since the persister phenotype has been reported to be in part a result of the bacterial stress 
response (Balaban, Gerdes et al. 2013) and if methylation has a role in persistence then 
the hypothesis would be that methylation itself would be an environment dependent 
phenomenon. Mtb strains grown under different growth conditions would then have 
variable methylation patterns. This part of the study was aimed at establishing whether 
growth conditions would affect the Mtb genome methylation profile. It was important to 
compare methylation patterns of liquid culture isolates and those from solid culture as 
these remain the commonly used culture methods in Mtb.  Since only two MGIT grown 
isolates could be sequenced, it was decided that these be compared with two selected LJ 
samples (12366_10, 12366_11 against 12366 _1, 12366_13). Selection was based on 
those that would grow first and had sufficient yield for SMRT sequencing. Three of  the 
four isolates were lineage 4 (12366_10,12366_11 and 12366_13)  while one (12366_1) 
belonged to lineage 1 having been confirmed using LSP PCR (Chapter 5). 
The two methylated motifs CTGGAG, and CACGCAG were detected in all the four 
isolates under comparison. Although GATN4RTAC was detected in only 12366_1, it was 
excluded from the comparison as it was absent in some other LJ cultured isolates 
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signifying the difference was not growth condition associated. Furthermore this motif was 
also found to be present in some other non-LJ cultured isolates. Motif CTGGAG was 
methylated in an average of 95% in solid cultured isolates compared to an average 94% 
in liquid cultured isolates. No significant difference could be established between liquid 
and solid culture isolates for methylated motif CTGGAG (Fishers exact test p=0.76). As 
for motif CACGCAG solid cultured isolates were methylated at an average 76% while 
liquid cultures were methylated an average 97%. It was found that liquid cultured isolates 
were significantly more methylated than solid cultures (Fisher’s exact p=0.02) for motif 
CACGCAG. It was observed that this difference was as a result of sample 12366_1 being 
lowly methylated at 56% compared to the rest at >95% (Table 6.9).This has been 
comprehensively discussed in section 6.2.6. 
Methylation within the gene regions and promoter regions of genes was next investigated. 
Methylation within gene regions ranged between 49% to 51% in each strand and there 
was no over representation of methylation by strand (Chi squared test with Yates 
correction P=0.44). On the other hand, methylation within promoter region of genes 
ranged from 37% to 62% by strand of the promoter methylation. Again there were no 
significant statistical differences observed by strand (Fishers exact test P=0.19) (Table 
6.8) 
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Table 6. 8 Comparison of methylation patterns between MGIT and LJ cultured isolates  
 
 Sample 
 
Sites with genic methylation (%) 
 
Sites with promoter methylation 
 Positive Strand  
 
Negative 
strand 
Positive 
Strand  
Negative strand 
12366_1 (LJ) 
 
1632/3210(51) 
 
1578/3210(49) 
 
188/302(62) 
 
114/302(37) 
 12366_13 (LJ) 
 
1223/2438(50) 
 
1215/2438(50) 
 
120/221(54) 
 
101/221(46) 
 
12366_10 
(MGIT) 
1218/2454(50) 
 
1236/2454(50) 
 
105/200(53) 
 
95/200(47) 
 
12366_11 1358/2721(50) 1363/2721(50) 138/245(56) 107/245(44) 
 
6. 2. 8 Lineage specific  methylation patterns across 18 Mtb strains 
It has been previously reported that DNA methylation in Mtb occurs in a strain specific 
manner (Phelan, de Sessions et al. 2018, Zhu, Zhong et al. 2015, Shell, Prestwich et al. 
2013) although the power of such studies remains suboptimal. In the current study, it was 
decided that this finding be investigated further. A sum total of 18 Mtb clinical isolates 
were therefore sequenced for this purpose including the four from section 6.2.1. 
In addition to the two motifs detected in the first four isolates sequenced (CTGGAG, and 
CACGCAG) 5’ to 3’ direction, detection was made of a characteristic type I palindromic 
motif GATN4RTAC (Table 6.9). Similar to the first four isolates sequenced, a few other 
motifs could be detected in these isolates. Again these either had a non-specific 
methylation pattern or very low IPD ratios <5 signifying they could have been as a result 
of sequencing errors. They were excluded from further downstream analysis.  
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Motif CTGGAG was detected as methylated in  the 15/18 isolates in various proportions 
ranging from 34-98% although methylation was mostly close to 100%. The target Mtase 
for this motif, MamA has been predicted to be active in all Mtb complex strains (Zhu, 
Zhong et al. 2015). Motif CACGCAG was detected as methylated in 16/18 isolates 
although in one isolate it was methylated at 56% with  most of them  being close to 100%. 
Methylation for this motif ranged from 56-98% across all the genomes. Motif 
GATN4RTAC was methylated in only 6/18 isolates with a range of 49-94% with 
methylation mostly below 90%.There was a strong association between presence or 
absence of methylation and  strain lineage (Table 6.9). Strain lineage of each of the isolates 
had previously been assigned using RD-PCR and confirmed using phylogenetic analysis  
of SMRT sequenced genomes of  the 18 isolates. 
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  Table 6. 9 Genome-wide methylation patterns among the 18 sequenced Mtb isolates 
Sequence motifs  
 
            
Sample ID(*) CTGGAGa  CACGCAG GATN4RTAC/GTAYN4ATCa 
  
 No.of  
motifs 
  
%modified 
motif   
 No of 
motifs 
  
  
 %modified 
motif 
No.of  
motifs  
  
%modified 
motif 
9909_1 (4) 1947  95  820  97  363 0 
9909_2 (4) 1947  97  820  98  363 0 
9909_3  (4) 1947  58   820  97   363 0 
9909_4  (4) 1947  98  820  98  363 0 
12366_1 (1) 1947  97  820  56  363 94 
12366_2 (4) 1947  94  820  97  363 0 
12366_3 (4) 1947  69  820  74  363 0 
12366_7 (4) 1947  95  820  97  363 0 
12366_8 (4) 1947  95  820  97  363 0 
12366_9 (1) 1947  43  820  0  282 51 
12366_10 (4) 1947  92  820  96  363 0 
12366_11(4) 1947  96  820  97  363 0 
12366_12(4) 1947  95  820  97  363 90 
12366_13(4) 1947  93  820  95  363 0 
10 (2) 1947  0  820  96  363 87 
11 (2) 1947  0  820  96  363 88 
12 (1) 1947  34  820  0  363 0 
15460_8 (2) 1947  0  820  65  363 49 
                        
a Represents methylation in only a single DNA strand 
(*) Represents strain lineage 
Loss of at least a single methyltransferase was found to be common across all the isolates. 
Out of the 18 isolates 16 had lost at least a single methylation type with only two isolates  
retaining a complete set of methylation. There was great variability in methylation across 
the isolates with some being either close to 100% or zero with a few in between. It was 
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important to investigate this variability in methylation including  the cause of loss of 
methylation. Multiple sequence alignment revealed that absence of mamA methylation 
(motif CTGGAG)  in three isolates (10,11 and 15460_8) could be associated with a point 
mutation A809C (E270A) in the mamA gene (Rv3263) as previously documented (Shell, 
Prestwich et al. 2013). This mutation was found in all these three isolates belonging to 
lineage 2 (Figure 6. 2). Additionally one lineage 4 isolate (9909_3) possessed a previously 
uncharacterized missense mutation G454A (G152S). This was again  revealed via multiple 
sequence alignment with the mamA gene using the laboratory strain H37Rv as a reference.  
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Figure 6. 2 Occurrence of mutations within the gene Rv3263 encoding the 
methyltransferase MamA and targeting the motif CTGGAG leading to partial and 
complete loss of methylation in three isolates 
(A) Nucleotide sequence: Missense mutations A809C in samples 10, 11 and 15460_8 
(B) Amino acid sequence: Amino acid changes resulting from mutations (A) in samples 
10, 11 and 15460_8 respectively, leading to complete loss of methyltransferase in those 
samples. mamA_Rv3263 (H37Rv) was used as the reference sequence. 
 
Similarly, partial or total loss of mamB methyltransferase activity (motif CACGAG)  in 
12366_1,12366_9 and 12,  could be ascribed to a novel missense mutation C758T 
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resulting in amino acid change S253L  in the mamB gene (Rv2420c) (Figure 6. 3A and 
B). This mutation has recently been characterized as being present only in lineage 1 Mtb 
isolates (Phelan, de Sessions et al. 2018). Surprisingly, this missense mutation was 
observed in all three isolates sample 12366_1 had 56% methylation with the other two 
(12366_9 and 12) being methylated at 0%. This is the first time this mutation has been  
reported as leading to complete loss of methylation in lineage 1. A previously 
characterized (Zhu, Zhong et al. 2015) synonymous  mutation C696T was also detected 
in all three lineage 2 isolates in the mamB gene. Additionally, sample 12366_1 possessed 
a 5bp frameshift deletion at position 1512, sample 12366_12 had a 3bp frameshift deletion 
at position 1509 and there were two 2bp frameshift deletions at position 1509 in isolates 
9909_1 and 9909_3 
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           A                                              B 
 
Figure 6. 3 Occurrence of mutations within the gene Rv2024c encoding the 
methyltransferase MamB and targeting the motif CACGCAG leading to partial and 
complete loss of methylation.  
(A) Nucleotide sequence: Missense mutations C758T in samples 12366_1 and 12366_9 
and 12 (B) Amino acid sequence: Amino acid changes resulting from mutations and 
deletions Ser253Lue in samples 12366_1 and 12366_9, led to partial loss of 
methyltransferase in 12366_1 and complete loss in 12366_9 and 12. mamB_Rv2024c was 
the reference sequence. 
 
Further analysis revealed that 12 isolates had completely lost HsdM methylation (motif 
GATN4RTAC) and possessed the missense mutation C917T leading to amino acid change 
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Pro306Leu (Figure 6.4A and B). Eleven out of the 12 isolates belonged to lineage 4. 
(Table 6.8). Interestingly, one lineage 1 isolate (12) that had lost HsdM methylation did 
not have the Pro306Leu mutation and also belonged to lineage 1 (Figure 6.4). Further 
analysis revealed that the hsdM gene in this isolate did not possess any other mutation.The 
reference sequence H37Rv used in the analysis belongs to the Euro-American (L4) and 
most Euro-American strains possess this mutation.Conversely all isolates without this 
mutation possessed a methylated GATN4RTAC motif in various proportions (Table 6. 8). 
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Figure 6. 4 Occurrence of mutations within the gene Rv2756c encoding the 
methyltransferase HsdM which  is known to methylate the GATN4RTAC motif leading 
to loss of methyltransferase activity. 
Occurrence of mutations within the gene Rv2756c encoding the methyltransferase HsdM 
which is known to methylate the GATN4RTAC motif. (A) Nucleotide sequence: Missense 
mutation C917T in samples 12366_2 and 12366_3, 12366_7, 12366_8, 12366_10, 
12366_11, and 12366_13, 9909_1, 9909_2, 9909_3, 9909_4 that resulted in amino acid 
change. (B) Amino acid sequence: Amino acid change at Pro306Leu in the same samples 
resulting from the mutation C917T leading to loss methyltransferase activity for HsdM. 
The laboratory strain H37Rv (NC_000962.3:c3070083-3068461) was used as a reference 
sequence. 
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6. 2. 9 Comparative analysis of Malawian isolates against a global sample 
A comparison was conducted of the 18 sequences from the current study against a global 
sample of 16 SMRT sequences downloaded from  
https://www.ebi.ac.uk/ena/data/view/PRJEB21888 of which a subset was used in  a 
published study (Phelan, de Sessions et al. 2018). These samples originated from the 
Europe, South Africa, west Africa and Asia. After aligning all the 34 genomes to the 
reference H37Rv, a total of 60,477variant sites were identified with one sample having 
51746 variants not found in any other sample. A maximum likelihood tree (Figure 6. 5) 
constructed using the variants revealed that the samples clustered by lineage as expected. 
The three lineage 1 isolates from the present study (green in figure 6.5) clustered 
separately from the others. Two samples from the comparative study (yellow in figure 
6.5) clustered separately as lineage 6. These were additionally identified by a lineage 
specific synonymous SNP C/G at position 1816587  (Rv1617) as previously described 
(Coll, McNerney et al. 2014). Eight clustered as lineage 5 (red) and were further identified 
using a lineage specific synonymous SNP C/A at position 1799921 in Rv1599 (Coll, 
McNerney et al. 2014). All the lineage 5 isolates also possessed a synonymous mutation 
G1374T in the mamA gene. Three lineage 2 isolates (blue) from the current study clustered 
with two isolates from the comparative study whereas 12 lineage 4 isolates clustered 
correctly with 4 samples from the comparative study. 
The base modifications and motif analysis of the global sample of 16 genomes revealed 
three confidently identified motifs CTCCAG, and CACGCAG, GATN4RTAC in 
complete concordance with the isolates from Malawi. All these had an IPD ratio of >5. 
Three samples (A03, A20 and A25) lacked the MamA methyltransferase. Multiple 
151 
 
sequence alignment against the reference H37Rv revealed that consistent with the three 
Malawian lineage samples, these possessed the E270A mutation in the mamA gene. Two 
of these (A03 and A20) clustered correctly as lineage 2 together with Malawian lineage 2 
isolates while one (A25) clustered as lineage 6. Sample A25 did not possess the E270A 
mutation but possessed a mutation G1378A (A460T) only in the mamA gene. The rest of 
the samples (13) were methylated in the CTCCAG motif at proportions of the range 96-
98%. All the 16 samples possessed the MamB Mtase  the motif in proportions ranging 
63%-99% with most of them close to 100%. Four samples (A05,A06,A07 and A17) lacked 
the hsdM Mtase whereas the rest were methylated in the range 84%-98%. While three 
(A05,A06 and A07) possessed the C917T  (P306L) mutation A17 did not. Intriguingly 
A17 did not possess any other mutation in the hsdM gene. 
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Figure 6.5 Comparative  phylogenetic analysis of  Malawian isolates against a global 
sample 
Phylogenetic analysis of 34 Mtb genomes run in MAFFT software. A phylogenetic  tree 
was constructed for the sequences using  RAxML (Randomized Axelerated Maximum 
Likelihood) a program for phylogenetic analysis in GTRCAT model. Three lineage one 
isolates (green) from the present study clustered separately from the others. Two 
samples from the comparative study (yellow) clustered separately as lineage 6 whereas  
eight clustered as lineage 5 (red). Three lineage 2 isolates (blue) from the current study 
clustered with two from the previous study whereas 12 lineage 4 isolates (black) 
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clustered correctly with 4 samples from the reference study. All samples from the 
present study are underlined. 
 
6. 3 Discussion 
6. 3. 1 Detection of methylated motifs in Mycobacterium tuberculosis strains 
PacBio’s SMRT sequencing offers accurate consensus long reads and is especially 
capable of resolving repetitive regions like the PE/PPE genes. In this study 18 new Mtb 
genomes were completed, the largest number to be completed using PacBio sequencing 
within a single study and had their methylome profiles analyzed. Although all these strains 
belonged to lineages 1-4 and originated from Malawi, this is  the first time that strains 
from this region have undergone methylome profile analysis.  It is of  interest to compare 
these new data to Mtb  genomes and methylomes from other regions. 
Three confidently identified motifs (CTGGAG, CACGCAG and GATN4RTAC) were 
detected across the 18 genomes and were detected as methylated (6mA) to varying 
degrees. Evidently this is not the first study to demonstrate this pattern as others have 
described these same motifs although with variability in occurrence within similar strains 
(Zhu, Zhong et al. 2015). A high IPD ratio of >5 in all cases is evidence of the strength of 
a 6mA signal within the genome. Additionally an average genome sequencing coverage 
of ~173X is evidence of the confidence in the accuracy of the sequencing process. The 
presence of m4C in Mtb is an area requiring further investigation as in this study  weak 
m4C signals were detected. So far these results seem to suggest presence of this 
methylation pattern, but with a relatively  low IPD ratio and non-specificity of methylation 
type. This is not the first study to report presence of m4C in Mtb as others (Naidu 2014) 
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have previously reported it suggesting that it could have a role to play in gene regulation. 
The methylation type m5C has not been detected in Mtb using SMRT sequencing 
technology. It has been suggested that m5C has a weak signal owing to the fact that it is 
located on the major groove of the DNA strand and is therefore  less sensitive to 
polymerase kinetics (Flusberg, Webster et al. 2010). The methylation m5C was previously 
detected however  in the virulent strain of H37Rv using methyl labelling and thin layer 
chromatography (Srivastava, Gopinathan et al. 1981). In this chapter no overall 
compelling correlation between methylation pattern and persistence phenotype has been 
established. To a certain extent this may reflect the fact  that isolation of true persister Mtb 
cells remains a challenge even in vitro. The phenotype of the  isolates used in this study 
was defined by clinical treatment failure (despite being drug susceptible) and high lipid 
body content, putative biomarkers of persistence. However, it is unknown as to whether 
at the time of DNA isolation, these isolates were indeed still in persistent state as 
persistence has been reported to be reversible. Improvements in single cell technologies 
should make it possible to isolate true persister cells in future studies. Although it has been 
demonstrated in this study that MGIT culturing had some effect  on methylation, this has 
been attributed to the lineage of the concerned isolate (see section 6.3.3). Under the current 
experimental conditions, it was not practically possible to confirm  if the isolates tested in 
this study were in a true persister state. Several attempts were made to obtain pure Mtb 
DNA directly from sputum for SMRT sequencing. This was based on the assumption that 
persister-like Mtb organisms have previously been detected in sputum (Garton, Waddell 
et al. 2008, Honeyborne, McHugh et al. 2016). An attempt to sequence directly from 
sputum was largely unsuccessful due to low DNA yields and  host DNA contamination. 
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A few methods were attempted  to extract pure high molecular weight DNA. One method 
employed was the CTAB method with which one study claimed  to achieve high yields of 
DNA for WGS (Amita, Vandana et al. 2002). In a separate study, researchers at the 
University Warwick were able to sequence directly from Mtb sputum on an illumina 
Miseq platform (Doughty, Sergeant et al. 2014) albeit at a low coverage. In that study a 
method known as metagenomics was applied. Unfortunately this method remains 
unsuitable for PacBio’s SMRT sequencing as it has limitations of sequencing all  
organisms within a sample  and will include organisms other than Mtb. Sequencing 
coverage was overall rather low as a result of probable host DNA contamination. 
Researchers at the University of Oxford  recently devised a DNA clean-up method that 
greatly reduces host DNA contamination in a MGIT culture for WGS (Votintseva, 
Pankhurst et al. 2015). In the study a saline wash step of DNA clean-up achieved 83% 
successful extractions resulting in >90% sequencing coverage. A few attempts were made 
to apply this method to Mtb sputum in the present study.While the clean-up step was 
efficient in removing host DNA and other non-tuberculous organisms, it greatly affected 
the Mtb DNA yield. It is evident that this method is not currently feasible for DNA 
extraction from sputum especially for SMRT sequencing. Additionally an attempt was 
made to generate in-vitro persister Mtb isolates via NO exposures. In vitro, NO has been 
shown to inhibit Mtb growth in a dose-dependent manner and induce the 48-gene dosR 
regulon  (Voskuil, Schnappinger et al. 2003). Additionally, higher levels of NO led to 
dose dependent bacteriostasis with little apparent killing (Voskuil, Bartek et al. 2011).  
DNA was isolated from the resulting cells and  submitted for sequencing. Unfortunately, 
samples were unable to pass the PacBio quality control stage due to high degradation of 
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DNA. This experiment was not repeated owing to time and resource constraints. With 
advances in host DNA clean-up methods future studies should focus on sequencing 
directly from sputum and possibly from in vitro generated persisters. 
6. 3. 2 Methylation within promoters and genes of persister Mtb strains 
It has been long proposed that persistence might be as a result of toxin-antitoxin modules  
that may contribute to Mtb pathogenesis (Georgiades, Raoult 2011). It has further been 
revealed that pathway metabolic shutdown during Mtb persistence is accompanied by 
upregulation of at least 10 TA systems (Sala, Bordes et al. 2014). In Ecoli it was shown 
that demobilization of the RelB antitoxin led to overexpression of the toxin RelE leading 
to a delayed relaxed stringent response in a starvation model (Christensen, Gerdes 2004). 
Two RelBE systems have been characterized in Mtb, namely RelBE1(Rv1947c-Rv1246c) 
and RelBE2 (Rv2865-Rv2866) and RelBE2 was one of the 10 most upregulated TA 
modules in the Mtb persister transcriptome (Keren, Minami et al. 2011). These two 
modules were found to impact growth, protein function and morphology in Mtb cells 
(Korch, Malhotra et al. 2015).These TA systems were of interest to this study. However, 
this module was not found to be differentially methylated in the “persister” isolates 
suggesting methylation did not have a role in the expression of this modules (RelBE1 and 
RelBE2) and hence in persistence. 
Similarly, overexpression of MazF1 (Rv2801c), MazF5 (Rv1942c) or MazF6 (Rv1102c) 
has been reported to increase “persister” formation in Mtb, while deletion of either of them 
decreased “persister” formation (Sala, Bordes et al. 2014). MazF1, MazF5 and MazF6 are 
members of the MazEF TA system. Results from the current study indicate that none of 
these three MazEF TA system members were uniquely methylated in “persisters”. Since 
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no other TA modules were methylated in “persisters”, it could be concluded that 
methylation was in no way related to TA mediated “persister” formation.   
 The dosR regulon has consistently been associated with dormant infection where bacilli 
are in a non-replicating persistence state (Voskuil, Schlesinger 2015, Voskuil, 
Schnappinger et al. 2003, Parish, Smith et al. 2003). A previous analysis of the “persister” 
Mtb transcriptome revealed that only eight of dosR genes were upregulated suggesting 
that the dosR regulon was not involved in persistence (Keren, Minami et al. 2011). 
However, hspX (acr1), a member of the dosR regulon, is one of the most upregulated 
genes in the hypoxic dormancy model. It was of interest to interrogate the methylation 
status of hspX as this might have gene expression implications. Results revealed that the 
promoter of hspX was methylated at only a single site across all the four isolates. It was 
found that Rv0251c (acr2), a homologue of hspX, was unmethylated in the four  isolates. 
Rv0251c encodes a heat shock protein and was found to be overexpressed in all “persister” 
models (Keren, Minami et al. 2011, Torrey, Keren et al. 2016). Interestingly, acr2 was the 
only one of the five genes overexpressed in all models (persister, starvation, enduring 
hypoxic response (EHR) and non-replicating persistence) whose promoter was found to 
be differentially methylated in persisters. In addition to acr2, the other four genes 
upregulated in all models were Rv1152 (gntR), Rv2497 (bkdA), Rv2517c and Rv3290c 
(Keren, Minami et al. 2011). Consistently apart from gntR and Rv3290c possessing a 
single methylation in the promoter of a non-persister and a persister respectively, no 
differential methylation within “persisters” for promoters of all these genes was observed. 
If dormancy is consistent with downshift of some metabolic pathways (Keren, Minami et 
al. 2011), it was hypothesized that methylation sites may overlap with TSS of the 
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concerned genes thereby inhibiting transcription and  regulating expression of such genes.  
The results revealed that while other members of the dosR regulon remained unmethylated 
in all the four isolates. The researcher felt that the methylation in dosR regulon  did not 
warrant further investigation as any methylation observed was insignificant  and was most 
likely a random event. It is not possible to speculate with certainty in the absence of 
transcriptomic data whether the of presence or absence of  methylation impacted on gene 
expression. Future studies integrating transcriptome and methylome data may need to 
probe this finding further.The gene regions of  Rv2517, which codes for a conserved 
hypothetical protein were the most highly methylated although specific reasons for this 
are unclear. Furthermore, although methylation within gene regions (Furuta, Namba-
Fukuyo et al. 2014) has been reported to affect gene expression specific mechanisms 
remain to be elucidated. 
 6. 3. 3 Lineage specific methylation in Mtb strains from Malawi 
Several lines of evidence have suggested that methylation in Mtb occurs in a lineage 
specific manner (Shell, Prestwich et al. 2013, Phelan, de Sessions et al. 2018). In one study 
mamA was found to influence gene expression in Mtb and to play a critical role in the 
strain specific survival of the pathogen during hypoxia. In another study, the presence or 
absence of methylation in the genomes of 16 Mtb isolates  were correlated to mutations 
that occurred within specific lineages. Studies of Mtb DNA methylation using SMRT 
sequencing have focused on strains originating from the United States of America (Shell, 
Prestwich et al. 2013), Asia (Zhu, Zhong et al. 2015) and more recently a global sample 
that included Europe, West Africa and South Africa and Asia (Phelan, de Sessions et al. 
2018). To date, no Mtb samples from Malawi and the surrounding region have been 
159 
 
subjected to either PacBio SMRT sequencing technology or DNA methylation analysis. 
To this end, a decision was made to investigate methylation patterns within the commonly 
occurring lineages in Malawi and determine whether methylation could have a role in 
lineage propensity to cause disease within this geographical region. In this study, SMRT 
sequencing of 18 Mtb clinical isolates revealed three methyltransferases (MamA, MamB 
and Hsdm) across the three lineages under study. The activity of these methyltransferases 
was inactivated by three different mutations in a lineage specific manner. MamA was 
found to be active in all isolates except three lineage 2 (Beijing) isolates putatively due to 
a point mutation A809C (E270A). This point mutation has been previously characterized 
(Shell, Prestwich et al. 2013). This mutation was also implicated in the failure of Beijing 
strains to survive during hypoxia, a condition in which lineage 4 (H37Rv) isolates were 
able to survive. Interestingly, lineage 2 (Beijing) strains are the most virulent and have 
been associated with increasing drug resistance in some areas (Cowley, Govender et al. 
2008, Tsolaki, Gagneux et al. 2005, Ribeiro, Gomes et al. 2014).  A recent study however 
failed to establish a possible role of methylation in virulence of Beijing strains (Naidu 
2014). MamA was shown to a play key role in the long term survival of H37Rv Mtb strain 
during hypoxia (Shell, Prestwich et al. 2013), a condition under which the dosR regulon 
is also known to be induced (Leistikow, Morton et al. 2010, Voskuil, Schnappinger et al. 
2003). The dosR regulon is also induced in Beijing strains and whether these two 
conditions are related is an area requiring further investigation (Phelan, de Sessions et al. 
2018). However, the novel mutation G454A (G152S) in mamA was found to be 
dispensable in impacting methylation. Similarly, the mamB methyltransferase (motif 
CACGCAG) was absent in two lineage 1 isolates. This was attributed to a novel missense 
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mutation C758T (S253L), recently characterized elsewhere (Phelan, de Sessions et al. 
2018) and confirmed in this study. Additionally, while this mutation appeared to lead to 
partial methylation (50-60%) this study found that it could also lead to complete loss of 
methyltransferase activity as two of the lineage 2 isolates had 0% methylation. This is the 
first time the mutation C758T (S253L) has been reported as resulting in complete loss of 
MamB methylation. This mutation is present only in the EAI6 family of lineage 1 which 
have been shown to be responsible for recent TB outbreaks globally (Duarte, Nery et al. 
2017). The occurrence of the EAI6 family of lineage 1 in Malawi is not surprising as it 
has previously been reported in Malawi, South Africa, Germany, the Republic of Congo, 
Zambia, Zimbabwe and and French Guiana (Duarte, Nery et al. 2017). One study from 
Karonga reported occurrence of  variety in the lineage 1 (EAI) spoligotype families 
(Glynn, Alghamdi et al. 2010). It is still unknown whether this global prevalence could be 
correlated with fitness advantages associated with the S253L mutation. Although other 
frameshift deletions were detected in the mamB gene in some samples (5bp deletion at 
1512 in 12366_1), these were found not to lead to functional inactivation of the gene. 
Other studies have reported a truncated of the mamB gene (positions 1520-48210) in some 
Euro-American lineage strains (H37Rv and H37Ra) which has been suspected to lead to 
loss of methyltransferase activity (Zhu, Zhong et al. 2015, Phelan, de Sessions et al. 2018). 
No reference strains (H37Rv and H37Ra) were sequenced in the current study and no such 
deletion in the mamB gene was  identified in any of the 18 clinical isolates sequenced.This 
suggests that a truncated mamB gene is dispensable in terms of loss of methyltransferase 
activity at least in these clinical isolates (L1,2 and 4).This is consistent with previous 
studies (Zhu, Zhong et al. 2015, Phelan, de Sessions et al. 2018) as this deletion was not 
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reported in any of the clinical isolates. As for HsdM, 11/12 lineage 4 clinical isolates 
lacked this methyltransferase which could be attributed to the C917T (P306L) mutation 
present in all the 11 isolates. Similarly, these results are consistent with previous studies 
which seem to suggest that the P306L mutation is very common in lineage 4 strains 
(Phelan, de Sessions et al. 2018, Zhu, Zhong et al. 2015). In one study, the mutation was 
found to be present in 35 out of 37 lineage 4 clinical isolates (Zhu, Zhong et al. 2015). No 
cognate restriction enzyme for HsdM has been identified suggesting it could be an orphan 
methyltransferase (Zhu, Zhong et al. 2015). Its main function could therefore be more 
related to gene regulation as opposed to restriction modification. Lineage 4 isolates have 
a higher global prevalence than any other lineage and more studies will be required to 
establish whether loss of HsdM methylation could be associated with this global success. 
One lineage 1 isolate that was found to lack the HsdM methylation did not have the 
Pro306Leu mutation. Lack of methylation therefore could not be attributed to the mutation 
in all lineage 4 isolates. However, it is suspected that failure to detect HsdM methylation 
in this isolate could be attributed to the low average genome sequencing coverage of ~ 
27X compared to the overall average genome coverage of ~173X as no methylation 
disrupting mutation was identified elsewhere in the genome of the strain. Elsewhere, 
lineage 3 (East African/Indian) clinical isolates were found to be associated with reduced 
transmissibility compared to other lineages (Albanna, Reed et al. 2011, Reed, Pichler et 
al. 2009) although evidence supporting this phenotype is very limited. In animal studies 
Indian lineage 1 isolates were associated with reduced virulence (Narayanan, Gagneux et 
al. 2008). The conviction in this study is that  DNA methylation could help provide clues 
to some of these phenotypes which have been associated with lineage variation. The fact 
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that mutations leading to loss of methylation were so common (16/18) in these isolates 
may seem to suggest that Mtb uses loss of methylation as a form of achieving fitness 
advantage such as immune evasion or persistence in the hostile host environment.  
In addition, this study has revealed the importance of using lineage specific references to 
identify these mutations. For example, in the identification of the mutation C917T which 
is common in the Euro-American strain, a reference H37Rv belonging to Euro-American 
lineage was used.This particular strain is a mutant at position 917 in this gene. This created 
problems in identifying the mutation as the reference strain was supposed to be the wild 
type for this locus. Similarly, all Euro-American strains possess a 7bp deletion in the 
pks15/1 gene. Consequently during identification of all lineage 4 strains a reference 
belonging to lineage 1(Indo-Oceanic) was used as lineage 1 strains have an intact pks15/1 
gene as opposed to H37Rv. 
Comparison of isolates from this study against a global sample of isolates doubles the 
number of isolates available for analysis and expands the representation of lineages 
prevalent globally.While access to the twenty six genomes from 
https://www.ebi.ac.uk/ena/data/view/PRJEB21888 was granted, the identities of the 
samples that had been used in the (Phelan, de Sessions et al. 2018) study could not be 
provided. Consequently, the 16 samples that were used for comparison in this study were 
selected based on read quality of the genome and might not have been congruent with 
those in the study. This analysis revealed that Mtases are highly conserved in all Mtb 
complex isolates and that loss of Mtase may be used as a means to increase fitness 
advantage. While methylation disrupting mutations have been identified and appear to be 
highly lineage specific, some unresolved issues remain regarding correlation of genotype 
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with loss of methylation. For instance, it is not currently possible to explain why some 
lineage 1 isolates lose activity of HsdM Mtase in the absence of the C917T mutation or 
any other mutation in the hsdM gene. This has been demonstrated in both Malawi isolates 
and the global sample. This may suggest that there could be some other currently unknown 
additional mechanism that is responsible for disrupting Mtase activity. While the 
comparative study had three EAI6 lineage 1 isolates, these were not found during the 
comparison due to differences in the choice of the 16 samples used. It was not possible to 
definitively identify the samples in absence of sample identities. It is likely that the three 
lineage one isolates used in the Phelan et al. study were not included in the comparison 
analysis. 
Overall, the data presented in this chapter shows the potential of SMRT sequencing to 
help in better understanding the complete biology of Mycobacterium tuberculosis and its 
relationship to epidemiology and clinical phenotype.       
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CHAPTER SEVEN: FINAL DISCUSSIONS AND CONCLUSIONS  
7. 1 Introduction  
The thesis started by evaluating different DNA extraction methods that can be used for 
Mtb DNA extraction compatible with  SMRT sequencing. The advent of WGS has offered 
an opportunity to characterize the entire genome of Mtb. Pacific Biosciences SMRT 
sequencing offers additional benefits of being able to completely characterize the entire 
methylome of Mtb in addition to the genome. Although a few extraction methods have 
been applied for other WGS platforms, SMRT sequencing poses additional challenges. 
SMRT sequencing has more stringent DNA requirements than those required in other 
WGS platforms. One of the barriers to extracting high molecular weight DNA from Mtb 
is the tough cell wall made of numerous lipids and polysaccharides. It was important to 
find a DNA extraction method that would effectively lyse the Mtb cell wall and also 
efficiently separate the DNA from the rest of the impurities. 
This DNA would be subjected to SMRT sequencing to determine base sequences and 
compare methylation patterns in various Mtb clinical isolates. Additionally the clinical 
isolates were subjected to molecular characterization and their specific lineages assigned 
using an alternative approach. 
The main aims of the study have been restated hereunder in advance of the final 
discussion: 
Primary aim: To identify genetic and epigenetic factors that could be responsible for Mtb 
persistence. 
Secondary aims: 
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i. To validate genomic DNA extraction methods compatible with DNA methylation 
analysis in Mtb 
ii. To analyze DNA methylation patterns in persistent Mtb 
iii. To assess stability of DNA methylation patterns in passage/strains 
iv. To evaluate occurrence of methylation within different Mtb strains and factors that lead 
to loss of methylation 
7. 2 Isolation of persisters and DNA extraction 
The definition of a true persister Mtb cell has not been completely elucidated. In this study 
persister cell selection was based on putative markers of persistence. These are lipid body 
formation, increased time to positivity and poor treatment outcomes (Sloan, Mwandumba 
et al. 2015). The cells used in this study were cultured in LJ and MGIT. It has been 
suggested that persistence is a transient phenotype and that persisters may switch back 
into a non-persistent state if a stressful environmental condition is removed (Balaban, 
Gerdes et al. 2013). One of the limitations in this study may have been to confirm whether 
the cells were indeed in true a persister state when they were isolated. Culturing may have 
exposed them to a different environmental condition that may affect this phenotype. The 
study attempted to generate in vitro persister Mtb cells via NO exposure of the laboratory 
strain H37Rv. DNA obtained could not be successfully sequenced at it failed to pass the 
quality control stage. This assay could not be repeated owing to time and resource 
constraints. Future studies should explore interrogating persisters generated via this 
method as it would guarantee a characteristic in vitro persister phenotype. The alternative 
was to use cells directly from sputum as persisters have been demonstrated in respiratory 
samples (Garton, Waddell et al. 2008, Honeyborne, McHugh et al. 2016).The main  
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challenge with sputum was to find a method of separating non-tuberculous and host cells 
from Mtb. A few methods were attempted including one  that employed use of a saline 
wash step as previously documented (Votintseva, Pankhurst et al. 2015). Although this 
method has successfully been demonstrated to work with other WGS platforms, it was 
found to be incompatible with SMRT sequencing. The saline wash step, while improving 
the purity, was found to significantly affect the DNA yield. Extraction of Mtb DNA has 
always been problematic. Successful extraction of Mtb DNA was dependent on finding 
the optimum extraction method that would be compatible with SMRT sequencing. This 
study has explored a number of DNA extraction methods both in culture and sputum in 
Chapters 3 and 4. The first to be explored in culture was the CTAB based chloroform-
phenol method (Warren, de Kock et al. 2006). This method may or may not employ a bead 
beating step to lyse the tough mycobacterial cell wall. In this study, bead beating was 
found not to significantly affect DNA yield. Bead beating was therefore abandoned as it 
only poses an additional safety risk in the laboratory due to aerosols from the beating 
process. Overall the phenol/chroloform CTAB method has a long turna-round time and 
was therefore dismissed. 
 The alternative CTAB method without phenol (Somerville, Thibert et al. 2005) was 
preferred and was successfully used for SMRT sequencing. While it has been 
demonstrated in this study that the CTAB method of DNA extraction from culture is 
amenable to SMRT sequencing future studies should focus on developing DNA a clean-
up method for extraction of Mtb DNA from sputum. The DNA clean-up method attempted 
in this study was found to be incompatible with SMRT sequencing as it could not generate 
significantly sufficient quantities of DNA. One method that offers hope has used 
167 
 
biotinylated RNA baits to capture Mtb genomes from sputum (Brown, Bryant et al. 2015). 
In this study, 20 smear positive sputa achieved > 20X sequencing depth and >90% genome 
coverage on an Illumina sequencing following targeted oligonucleotide enrichment. 
Whether this method can be successfully applied to SMRT sequencing should be a 
question answered in future studies. 
7. 3 Lineage assignment and SMRT sequencing 
Limited data on Mtb molecular epidemiology in Malawi compelled this study to 
investigate this area. Currently the only available data on Mtb strains circulating in Malawi 
comes from Karonga in the Northern Region (Glynn, Crampin et al. 2005, Glynn, 
Alghamdi et al. 2010). Although Malawi is a relatively small country the two areas (north 
Malawi and Blantyre) are geographically distinct. This may suggest that distinct Mtb 
strains may be circulating in these areas. Chapter 4 covers the molecular characterization 
of 64 Mtb clinical isolates obtained from patients presenting with bacteriologically 
confirmed pulmonary TB at the main referral hospital in Blantyre, Malawi. Results from 
this study show that the diversity of Mtb lineages in Malawi may follow a similar pattern. 
The sample size in this study was relatively small, more larger studies are required to 
confirm results obtained in this study. This study has for the first time compared 
phylogenies and base modifications of SMRT sequences between Malawian isolates and 
a global sample. This is the first time that such an analysis has included SMRT sequences 
of lineages 5 and 6 which are restricted to west Africa. This will aid in increasing 
understanding the methylome diversity of Mtb complex. 
The principal  objective of this study was to  establish a correlation between DNA 
methylation and Mtb persistence using SMRT sequencing. SMRT sequencing is capable 
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of providing the link between a particular change at single base pair resolution to  genes 
and ultimately to biological function (Chen, Jeannotte et al. 2014). Since the Mtases in 
Mtb have so far not been shown to have cognate restriction enzymes, the restriction 
function is therefore dispensable. It is logical to suggest that DNA methylation indeed has 
gene regulation function in Mtb (Shell, Prestwich et al. 2013). While the role of MamA 
during Mtb hypoxia has been established (Shell, Prestwich et al. 2013), studies should 
now focus on finding the role of other Mtases such as MamB and HsdM in gene 
expression. A comparison of two persisters and non persisters in the current study failed 
to establish a compelling correlation. While a few sites were found to be differentially 
methylated in persisters as opposed to non-persisters, these were considered not to be 
significant. A further attempt to interrogate differences in methylation within persister 
specific genes was not informative. The dosR regulon among many other genes has been 
widely associated with the persister phenotype (Voskuil, Schnappinger et al. 2003) and 
was specifically targeted in this study. In the absence of any gene expression data, it is not 
possible to determine whether any of these small differences in methylation may have had 
an impact. Future studies should combine methylation data with transcriptomic data to put 
this question to rest. Additionally, an enrichment analysis of genes and pathways 
differentially methylated found none of the categories were over-represented in persisters. 
7. 4 Key findings of the study 
The study has established that four principal Mtb strains (L1-4) circulate in Blantyre and 
that lineage 4 is predominant. These results are consistent with previous studies from 
Karonga (Glynn, Crampin et al. 2005, Glynn, Alghamdi et al. 2010). Studies with larger 
sample sizes will be required in Blantyre to confirm the proportion of these strains. 
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Lineage assignments obtained by LSP-PCR were consistent with those from SMRT 
sequencing for the 18 Mtb isolates. SMRT sequencing has also confirmed three 
confidently detected motifs (CTGGAG, CACGCAG and GATN4RTAC) in Mtb as 
previously documented (Zhu, Zhong et al. 2015, Phelan, de Sessions et al. 2018). Three 
methylation disrupting mutations (A809C, C758T and C917T) were detected in which a 
novel mutation (C758T) recently characterized (Phelan, de Sessions et al. 2018) was 
confirmed. Additionally, for the first time, mutation C758T was found to cause complete 
loss of methylation in lineage 1 strains and not only partial loss as previously believed. 
These mutations occur in a lineage specific manner. While methylation plays a role in 
gene regulation, complete loss of one or more Mtases has been shown to be a common 
phenomenon of Mtb. This may suggest that loss of methylation could play a critical role 
in the fitness advantage of different strains of the pathogen, perhaps in key characteristics 
such as transmissibility, immune evasion and persistence in vivo. It is possible that 
different strains adapt to different environments through loss of specific Mtases. While 
MamA was shown to play a key role in survival of H37Rv (L4) during hypoxia, it is 
possible that it could have a completely different role in a different strain in the presence 
or absence of other Mtases. Future studies should explore the link between loss of Mtase 
and pathogen survival in vivo in different lineages. This study has completed the largest 
number of Mtb clinical isolates (18) from a single study in a single location using SMRT 
sequencing. This study also completed the largest number of Euro-American strains (12) 
and has confirmed the methylation profile of this lineage with much greater confidence.   
All lineage 2 clinical isolates to be completed using SMRT sequencing (Zhu, Zhong et al. 
2015, Phelan, de Sessions et al. 2018) in the present study have shown the  presence of 
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the A809C mutation in the mamA  gene and the mutation could be used as an alternative 
means of  lineage assignment. As for lineage 1 although all clinical isolates sequenced 
using SMRT sequencing (Phelan, de Sessions et al. 2018) and the present study possess 
the  C758T mutation in the mamB gene, others have suggested that this mutation is only 
present in the EAI6 family of lineage 1 globally  (Duarte, Nery et al. 2017). Whether this 
methylation disrupting mutation can be used for lineage assignment of all lineage 1 
isolates will require more studies. At present however, it can be used to classify EAI6 
family.While the C917T mutation is the commonest occurring in the hsdM gene within 
lineage 4 isolates, and has been associated with loss of HsdM Mtase activity, some lineage 
1 isolates have been shown to lose the Mtase activity in absence of this Mtase. Future 
studies will need to investigate other possible factors responsible for such loss of Mtase 
activity such as gene silencing via small nuclear RNAs. At present this mutation may only 
be used for confirmatory purposes of lineage 4 isolates. 
Overall this work has helped to confirm the results of two key prior studies to have SMRT-
sequenced Mtb isolates and will help in increasing the power and representativeness of 
such studies. Furthermore, it has demonstrated the power of SMRT sequencing to 
completely elucidate the entire methylome of Mtb in an efficient way, enabling global 
analyses of its impact on important biological functions in representative sets of strains. 
This tool will aid in understanding the complete biology of Mtb and could assist in 
epidemiological studies and development of more efficient and ultra-short drug regimens. 
7. 5 Limitations of the study  
The study analyzed 64 Mtb clinical isolates and assigned them into 4 different lineages. 
This study was unable to design specific primers for lineage 4 and as a result all isolates 
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not belonging to three lineages (L1-3) were assumed to belong to lineage 4. This does not 
discount the fact that a novel strain could exist. Although the study has managed to 
sequence the largest number (18) of Mtb isolates to date using SMRT sequencing, only 
three lineages have been covered. A more diverse coverage of the seven Mtb lineages 
would have given the study more power. This however was due to the fact that these are 
the commonly circulating lineages in Malawi as the study targeted strains from this 
country alone . The study has however managed to conduct a comparative analysis of a 
global sample of isolates to compare the isolates from Malawi to those from other 
geographical areas. The study failed to successfully sequence directly from sputum 
samples in line with the objectives. There are a few methods of cleaning up DNA for 
sequencing that have come up. One such methods  makes use of biotinylated RNA baits 
to trap Mtb genomes (Brown, Bryant et al. 2015). Whether such a method would be 
compatible with SMRT sequencing is a question that needs to be answered in future 
studies.  Recently SMRT sequencing has become an area of active research and similar 
studies will add and increase the power of these studies. 
7. 6 Future direction 
Future work should explore the possibility of SMRT sequencing directly from sputum 
without culture by using more efficient extraction methods such as capturing Mtb genomes 
using biotinylated RNA baits (Brown, Bryant et al. 2015). Further work comparing 
methylation patterns under stress conditions in vitro and in clinical isolates may be helpful 
in understanding the role of methylation profiles in determining the persistence phenotype. 
Finally, methods that can directly isolate persister cells from clinical samples for 
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characterization of their methylome would help to overcome many of the limitations 
encountered in this study. 
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